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A B S T R A C T
Background
Mefloquine is one of four antimalarial agents commonly recommended for preventing malaria in travellers to malaria-endemic areas.
Despite its high efficacy, there is controversy about its psychological side effects.
Objectives
To summarize the efficacy and safety of mefloquine used as prophylaxis for malaria in travellers.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials
(CENTRAL), published on the Cochrane Library; MEDLINE; Embase (OVID); TOXLINE (https://toxnet.nlm.nih.gov/newtoxnet/
toxline.htm); and LILACS. We also searched the World Health Organization (WHO) International Clinical Trials Registry Platform
(ICTRP; http://www.who.int/ictrp/en/) and ClinicalTrials.gov (https://clinicaltrials.gov/ct2/home) for trials in progress, using ’meflo-
quine’, ’Lariam’, and ’malaria’ as search terms. The search date was 22 June 2017.
Selection criteria
We included randomized controlled trials (for efficacy and safety) and non-randomized cohort studies (for safety). We compared
prophylacticmefloquine with placebo, no treatment, or an alternative recommended antimalarial agent.Our study populations included
all adults and children, including pregnant women.
Data collection and analysis
Two review authors independently assessed the eligibility and risk of bias of trials, extracted and analysed data.We compareddichotomous
outcomes using risk ratios (RR) with 95% confidence intervals (CI). Prespecified adverse outcomes are included in ’Summary of
findings’ tables, with the best available estimate of the absolute frequency of each outcome in short-term international travellers. We
assessed the certainty of the evidence using the GRADE approach.
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Main results
We included 20 RCTs (11,470 participants); 35 cohort studies (198,493 participants); and four large retrospective analyses of health
records (800,652 participants). Nine RCTs explicitly excluded participants with a psychiatric history, and 25 cohort studies stated that
the choice of antimalarial agent was based on medical history and personal preference. Most RCTs and cohort studies collected data
on self-reported or clinician-assessed symptoms, rather than formal medical diagnoses.
Mefloquine efficacy
Of 12 trials comparing mefloquine and placebo, none were performed in short-term international travellers, and most populations had
a degree of immunity to malaria. The percentage of people developing a malaria episode in the control arm varied from 1% to 82%
(median 22%) and 0% to 13% in the mefloquine group (median 1%).
In four RCTs that directly compared mefloquine, atovaquone-proguanil and doxycycline in non-immune, short-term international
travellers, only one clinical case of malaria occurred (4 trials, 1822 participants).
Mefloquine safety versus atovaquone-proguanil
Participants receiving mefloquine were more likely to discontinue their medication due to adverse effects than atovaquone-proguanil
users (RR 2.86, 95% CI 1.53 to 5.31; 3 RCTs, 1438 participants; high-certainty evidence). There were few serious adverse effects
reported with mefloquine (15/2651 travellers) and none with atovaquone-proguanil (940 travellers).
One RCT and six cohort studies reported on our prespecified adverse effects. In the RCT with short-term travellers, mefloquine users
were more likely to report abnormal dreams (RR 2.04, 95% CI 1.37 to 3.04, moderate-certainty evidence), insomnia (RR 4.42, 95%
CI 2.56 to 7.64, moderate-certainty evidence), anxiety (RR 6.12, 95% CI 1.82 to 20.66, moderate-certainty evidence), and depressed
mood during travel (RR 5.78, 95% CI 1.71 to 19.61, moderate-certainty evidence). The cohort studies in longer-term travellers were
consistent with this finding but most had larger effect sizes. Mefloquine users were also more likely to report nausea (high-certainty
evidence) and dizziness (high-certainty evidence).
Based on the available evidence, our best estimates of absolute effect sizes for mefloquine versus atovaquone-proguanil are 6% versus
2% for discontinuation of the drug, 13% versus 3% for insomnia, 14% versus 7% for abnormal dreams, 6% versus 1% for anxiety,
and 6% versus 1% for depressed mood.
Mefloquine safety versus doxycycline
No difference was found in numbers of serious adverse effects with mefloquine and doxycycline (low-certainty evidence) or numbers of
discontinuations due to adverse effects (RR 1.08, 95% CI 0.41 to 2.87; 4 RCTs, 763 participants; low-certainty evidence).
Six cohort studies in longer-term occupational travellers reported our prespecified adverse effects; one RCT in military personnel and
one cohort study in short-term travellers reported adverse events. Mefloquine users were more likely to report abnormal dreams (RR
10.49, 95% CI 3.79 to 29.10; 4 cohort studies, 2588 participants, very low-certainty evidence), insomnia (RR 4.14, 95% CI 1.19 to
14.44; 4 cohort studies, 3212 participants, very low-certainty evidence), anxiety (RR 18.04, 95%CI 9.32 to 34.93; 3 cohort studies, 2559
participants, very low-certainty evidence), and depressed mood (RR 11.43, 95% CI 5.21 to 25.07; 2 cohort studies, 2445 participants,
very low-certainty evidence). The findings of the single cohort study reporting adverse events in short-term international travellers were
consistent with this finding but the single RCT in military personnel did not demonstrate a difference between groups in frequencies
of abnormal dreams or insomnia.
Mefloquine users were less likely to report dyspepsia (RR 0.26, 95% CI 0.09 to 0.74; 5 cohort studies, 5104 participants, low certainty-
evidence), photosensitivity (RR 0.08, 95% CI 0.05 to 0.11; 2 cohort studies, 1875 participants, very low-certainty evidence), vomiting
(RR 0.18, 95% CI 0.12 to 0.27; 4 cohort studies, 5071 participants, very low-certainty evidence), and vaginal thrush (RR 0.10, 95%
CI 0.06 to 0.16; 1 cohort study, 1761 participants, very low-certainty evidence).
Based on the available evidence, our best estimates of absolute effect for mefloquine versus doxycyline were: 2% versus 2% for
discontinuation, 12% versus 3% for insomnia, 31% versus 3% for abnormal dreams, 18% versus 1% for anxiety, 11% versus 1% for
depressed mood, 4% versus 14% for dyspepsia, 2% versus 19% for photosensitivity, 1% versus 5% for vomiting, and 2% versus 16%
for vaginal thrush.
Additional analyses, including comparisons of mefloquine with chloroquine, added no new information. Subgroup analysis by study
design, duration of travel, and military versus non-military participants, provided no conclusive findings.
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Authors’ conclusions
The absolute risk of malaria during short-term travel appears low with all three established antimalarial agents (mefloquine, doxycycline,
and atovaquone-proguanil).
The choice of antimalarial agent depends on how individual travellers assess the importance of specific adverse effects, pill burden, and
cost. Some travellers will prefer mefloquine for its once-weekly regimen, but this should be balanced against the increased frequency of
abnormal dreams, anxiety, insomnia, and depressed mood.
P L A I N L A N G U A G E S U M M A R Y
Can mefloquine prevent malaria during travel to areas where the disease is widespread?
We summarized trials that evaluated the effectiveness and safety of mefloquine when used to prevent malaria in people travelling to
areas where the disease is widespread. We searched for relevant studies up to 22 June 2017 and included 20 randomized trials that
involved 11,470 participants, 35 cohort studies (198,493 participants) and four large retrospective analyses of health records (800,652
participants).
What are the concerns about mefloquine and what are the alternatives?
Mefloquine is often prescribed to prevent malaria during travel to areas where the disease is widespread. However, there is controversy
about the safety of mefloquine, especially when prescribed for military personnel in stressful situations, and there have been reports of
depression and suicide.
The only commonly-used alternative drugs are doxycycline (which can cause skin problems and indigestion) and atovaquone-proguanil
(which is often more expensive).
What the research says
Mefloquine appears to be a highly effective drug to reduce the risk of malaria (low-certainty evidence), however, evidence did not come
from short-term international travellers.
Mefloquine has not been shown to have more frequent serious side effects than either atovaquone-proguanil (low-certainty evidence) or
doxycycline (very low-certainty evidence).
People who take mefloquine are more likely to stop taking the drug due to side effects than people who take atovaquone-proguanil
(high-certainty evidence), but may be equally as likely to stop as people who take doxycyline (low-certainty evidence).
People taking mefloquine are more likely to have abnormal dreams, insomnia, anxiety and depressed mood during travel than people
who take atovaquone-proguanil (moderate-certainty evidence) or doxycyline (very low-certainty evidence). Doxycycline users are more
likely to have dyspepsia, photosensitivity, vomiting, and vaginal thrush (very low-certainty evidence).
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Mefloquine compared with atovaquone-proguanil for preventing malaria in travellers
Population: non-immune adults and children travelling to or living in malaria-endemic sett ings
Intervention: mef loquine 250 mg weekly
Comparison: atovaquone-proguanil (250 mg atovaquone and 100 mg proguanil hydrochloride) daily
Outcome data collection: physicians performed blinded assessment of whether reported symptoms could be related to the study drug
Outcomes Anticipated absolute effects∗
(95% CI)
Relative effect
(95% CI)
Studies contributing to
effect estimate
(participants)
Additional studies con-
sidered in GRADE as-
sessment
(participants)
Certainty of the evi-
dence
(GRADE)
Atovoquone-proguanil Mefloquine
Clinical malaria - - - 2 RCTs
(1293)
- ⊕⊕©©
low1,2,3
Serious adverse ef-
fects
0 per 100 1 in 100
(0 to 12)
RR 1.40
(0.08 to 23.22)
4 cohort studies
(3693)
1 RCT
(976)
⊕⊕©©
low1,2,4,5
Discontinuation
of drug due to adverse
effects
2 per 100 6 per 100
(3 to 11)
RR 2.86
(1.53 to 5.31)
3 RCTs
(1438)
7 cohort studies
(4498)
⊕⊕⊕⊕
high1,2,4,6
Abnormal dreams 7 per 100 14 per 100
(10 to 21)
RR 2.04
(1.37 to 3.04)
1 RCT
(976)
7 cohort studies
(3848)
⊕⊕⊕⊕
high1,2,4,6
Insomnia 3 per 100 13 per 100
(8 to 23)
RR 4.42
(2.56 to 7.64)
1 RCT
(976)
8 cohort studies
(3986)
⊕⊕⊕⊕
high1,2,4,6
Anxiety 1 per 100 6 per 100
(2 to 21)
RR 6.12
(1.82 to 20.66)
1 RCT
(976)
4 cohort studies
(2664)
⊕⊕⊕©
moderate1,2,4,7
Depressed mood 1 per 100 6 per 100
(2 to 20)
RR 5.78
(1.71 to 19.61)
1 RCT
(976)
6 cohort studies
(3624)
⊕⊕⊕©
moderate1,2,4,7
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Abnormal thoughts or
perceptions
0 per 100 1 per 100
(0 to 4)
RR 1.50
(0.30 to 7.42)
3 cohort studies
(2433)
- ⊕©©©
very low1,2,8
Nausea 3 per 100 8 per 100
(5 to 15)
RR 2.72
(1.52 to 4.86)
1 RCT
(976)
7 cohort studies
(3509)
⊕⊕⊕⊕
high1,2,4,6
Vomiting 1 per 100 1 per 100
(0 to 4)
RR 1.31 (0.49 to 3.50) 1 RCT
(976)
3 cohort studies
(2180)
⊕⊕⊕©
moderate1,2,4,7
Abdominal pain 5 per 100 5 per 100
(3 to 8)
RR 0.90
(0.52 to 1.56)
1 RCT
(976)
7 cohort studies
(3509)
⊕⊕©©
moderate1,2,4,8
Diarrhoea 8 per 100 8 per 100
(5 to 12)
RR 0.94
(0.60 to 1.47)
1 RCT
(976)
7 cohort studies
(3509)
⊕⊕⊕©
moderate1,2,4,8
Headache 4 per 100 7 per 100
(4 to 12)
RR 1.72
(0.99 to 2.99)
1 RCT
(976)
8 cohort studies
(4163)
⊕⊕⊕©
moderate1,2,4,8
Dizziness 2 per 100 8 per 100
(4 to 15)
RR 3.99
(2.08 to 7.64)
1 RCT
(976)
8 cohort studies
(3986)
⊕⊕⊕⊕
high1,2,4,6
Pruritis 2 per 100 3 per 100
(1 to 5)
RR 1.28
(0.60 to 2.70)
1 RCT
(976)
3 cohort studies
(1824)
⊕⊕⊕©
moderate1,2,4,8
Visual impairment 2 per 100 4 per 100
(2 to 9)
RR 2.04
(0.88 to 4.73)
1 RCT
(976)
2 cohort studies
(1956)
⊕⊕⊕©
moderate1,2,4,8
Mouth ulcers 2 per 100 3 per 100
(1 to 6)
RR 1.45 (0.70 to 3.00) 1 RCT
(976)
2 cohort studies
(783)
⊕⊕⊕©
moderate1,2,4,8
* The assumed risk is the median control group risk across studies unless stated in footnotes. The corresponding risk (and its 95% conf idence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). Where the control group risk was 0, we used a value of 0.5 to calculate the
corresponding risk in the intervent ion group. Data f rom cohort studies were used when data f rom RCTs were unavailable.
Abbreviations: CI: conf idence interval; RR: risk rat io
’Summary of f indings’ tables are usually lim ited to seven outcomes. For adverse ef fects this problematic, as there are many, and to include some and not others risks select ive
report ing. We have therefore included all prespecif ied outcomes in the table
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GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: the RCTs were generally at low risk of bias but two of three were sponsored by the manufacturer
of one of the study drugs. All cohort studies had methodological problems which could introduce confounding or bias.
However, as the GRADE approach automatically downgrades certainty by two levels for non-randomized studies, we did
not downgrade further.
2No serious indirectness: the RCTs were conducted in short-term internat ional travellers to malaria-endemic areas in Af rica
or South America for less than 28 days. The cohort studies were f rom a variety of populat ions including short-term travellers
(8 studies), longer-term occupat ional travellers (3 studies) and military personnel (1 study).
3Downgraded by two levels for serious imprecision: no episodes of malaria were recorded in either trial.
4No serious inconsistency: the f indings of the cohort studies were consistent with the ef fects seen in the RCTs.
5No serious imprecision: serious adverse ef fects were rare in all studies.
6No serious imprecision. The ef fect was stat ist ically signif icant and the overall data (RCTs and cohort studies) were
adequately powered to detect this ef fect.
7Downgraded by one level for serious imprecision: although the direct ion of the ef fect was consistent across all t rials, there
was substant ial heterogeneity in the size of the ef fect.
8Downgraded by one level for serious imprecision: the 95% CI is wide and includes important ef fects and no ef fect.
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B A C K G R O U N D
Description of the condition
Malaria is a parasitic protozoal infection which is usually trans-
mitted through the bite of female Anopheles mosquitoes (Warrell
2002). It is most common in tropical and subtropical regions.
Clinical disease is caused by infection of red blood cells by
one of four Plasmodium species: P. falciparum, P. vivax,P. ovale,
andP. malariae (WHO 2017). Humans can also become in-
fected by forms of malaria that usually infect animals, such asP.
knowlesi (WHO 2017). Clinical presentation is nonspecific and
varied; symptoms include fever, chills, headache, diarrhoea, mus-
cle cramps, and abdominal pain (WHO 2015). Severe disease is
usually caused by infection with P. falciparum, but can also occur
following infection with P. vivax and P. knowlesi. Host factors de-
termining severity include genetics, host immune status, and age
(WHO 2015).
The true global incidence and prevalence of malaria is difficult to
determine; the highest disease burden occurs in sub-SaharanAfrica
where vital registration and disease notification systems are weak
(Murray 2014). However, the latest World Health Organization
(WHO) figures estimate 212 million new cases of malaria in 2015
leading to 429,000 deaths (WHO 2016). Around 125 million
travellers visit malaria-endemic areas annually, and all need to take
steps to prevent infection with malaria (Croft 2005). Each year
there are between 10,000 and 30,000 known cases of malaria in
returned travellers, but the real figure is likely to be higher due to
under-reporting (WHO 2017).
The individual risk of acquiring malaria is determined by the host
immune status, the area travelled to, the duration of travel and sea-
son, and the use of prevention measures. Pregnant women, young
children and non-immune travellers are particularly vulnerable to
severe disease if they become infected (WHO 2015). In Europe,
the incidence of malaria is higher in people who travel to their
country of origin to visit friends and relatives than in tourists
(Behrens 2015). However, mortality is higher in tourists (Behrens
2015).
The natural life cycle of malaria involves the consecutive infection
of two hosts: female Anopheles mosquitoes and humans (CDC
2015a). The female mosquito acquires the disease when taking
a blood meal from an infected human host. It will then become
infectious over a period of 10 to 14 days depending on the region.
Sporozoites are injected into the human host the next time the
mosquito feeds. These travel via the blood stream to the liver and
develop into schizonts which then rupture releasing merozoites.
Merozoites invade erythrocytes and undergo asexual replication.
Some of these develop through ring stage trophozoites into sch-
izonts which rupture releasing further merozoites and thus per-
petuate the infection. Others will develop into female and male
gametocytes which are ingested by Anophelesmosquitoes during a
blood meal leading to the spread of disease.
Description of the intervention
Mefloquine has been available for use in Europe since 1985 and
the USA since 1990 (Schlagenhauf 1999). Alongside atovaquone-
proguanil and doxycycline, it is considered standard chemopro-
phylaxis by many international health guidelines (CDC 2015b;
PHAC 2014; PHE 2015; WHO 2017).
Mefloquine belongs to the aryl amino acid group of antimalarial
agents. Mefloquine has a long half life and is given as a weekly
dose of 250 mg when used for prophylaxis in adults (Schlagenhauf
2010). Mefloquine is effective against all five strains of malaria
known to affect humans. Although guidelines vary,many state that
mefloquine should be taken for two to three weeks before travel
and continued for four weeks following return (WHO 2017).
There are several situations in which mefloquine is potentially ad-
vantageous. All guidelines recommend that where avoidable preg-
nant women should not travel to areas where malaria is endemic
(WHO 2017). However, where travel is essential, mefloquine is
often the preferred option. Mefloquine is widely considered to
be safe within the second and third trimesters of pregnancy and
guidelines increasingly recommend its use in the first trimester
(CDC2015b; Schlagenhauf 2010).Mefloquine is suitable for both
children who weigh more than 5 kg and breastfeeding mothers
(Schlagenhauf 2010).
Doxycycline has restrictions on its use during pregnancy due to
effects on skeletal development found in animal studies. The use
of atovaquone-proguanil is limited by a lack of evidence for sa-
fety (PHE 2015). Chloroquine-proguanil is considered safe for
pregnant women, but its use is limited by widespread resistance
(PHAC 2014).
Themain side effects of mefloquine are gastrointestinal, neurolog-
ical and psychological. Psychological side effects vary from those
considered to be very common (including insomnia and abnormal
dreaming) to those with unknown frequency (including psychosis
and suicidal ideation) (eMC 2015a). Existing drug labels suggest
that these side effects are both prodromal and dose related (eMC
2015a).
How the intervention might work
Malaria chemoprophylaxis is defined as the use of antimalar-
ial medication to prevent the clinical symptoms of malaria
(Schlagenhauf 2010). This is because no drugs are able to pre-
vent the introduction of infection by destroying the sporozoites
injected by the female Anopheles mosquito. Chemoprophylaxis is
one of several tools used to prevent malaria; other recommended
measures include sleepingunder insecticide-treated bednets, wear-
ing insecticide-treated clothing, and applying chemical repellent
sprays to the skin surface (WHO 2017). None of these methods
provide complete protection and a combination of approaches is
advised.
Chemoprophylaxis works by blocking the development or repro-
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duction of the malaria parasite at various stages in its life cycle:
• doxycycline and mefloquine are examples of suppressive
prophylactics and act in the blood stream as the schizonts invade
erythrocytes. Doxycycline therefore needs to be taken for at least
one month after returning from endemic areas (Shanks 2005);
• atovaquone-proguanil and primaquine have effects on the
early liver stages of Plasmodium spp and prevent the progression
to blood stage parasites which cause clinical illness. These agents
therefore only need to be taken for one week after leaving the
malaria-endemic area (Shanks 2005).
Currently, the baseline efficacy of doxycycline, atovaquone-
proguanil and mefloquine when used as prophylaxis to prevent
malaria is thought to be similar. Most guidelines therefore rec-
ommend selecting appropriate antimalarial prophylaxis based on
individual choice, pre-existing conditions, side effect profile, and
drug resistance patterns in the destination country (CDC 2015b;
PHE2015;WHO2017).Drug resistance to all antimalarial agents
is a growing concern, and mefloquine resistance has been reported
in some areas of north-western Thailand (Treiber 2010; Treiber
2011).
In addition, the efficacy of all forms of malaria prevention is
impeded by adherence. Nearly all cases of fatal malaria in trav-
ellers occur due to non-adherence with prophylactic measures
(Schlagenhauf 2010). However, this needs to be balanced against
the tolerability and safety of chemoprophylaxis; the frequency of
mild to moderate adverse drug reactions varies from 32% to 45%
(Schlagenhauf 2003). Both policymakers and individual travellers
need to balance carefully the risk benefit profile of contracting
malaria against using chemoprophylaxis.
Why it is important to do this review
Mefloquine has long been associated with neurological and psy-
chological side effects which range frommild headaches and dizzi-
ness to reports of suicide and psychosis. The frequency and severity
of these outcomes has been debated. In 2013 the USA Food and
Drug Administration (FDA) released a safety communication re-
garding potential long-term and significant neurological and psy-
chiatric side effects of mefloquine (FDA 2013). This included the
addition of a boxed warning to the drug label, the most serious
form of warning that can be issued. Similarly in Europe in 2014
the European Medicine Agency (EMA) Pharmacovigilance Risk
Assessment Committee (PRAC) required a change to the sum-
mary of product characteristics noting that “...in a small number
of patients it has been reported that neuropsychiatric reactions
(for example, depression, dizziness or vertigo and loss of balance)
may persist for months or longer, even after discontinuation of the
drug” (EMA 2014). This has been incorporated into summaries
of product characteristics throughout Europe. Most recently the
UKDefence Committee has suggested mefloquine should only be
used as a drug of last resort (UK Parliament 2016).
Previous reviews on this topic have limited analyses to random-
ized controlled trials (RCTs) (Jacquerioz 2009; Jacquerioz 2015).
However, RCTs are not always the optimal study design to deter-
mine the type, prevalence or nature of adverse events and adverse
effects, and many set inclusion criteria which exclude groups of
people who are likely to be affected (Loke 2007). In addition, ad-
verse effects are often the primary outcome measure of non-ran-
domized trials, meaning that researchers may attempt to capture
and define adverse events in a more rigorous manner than when
they are a tertiary measure (Loke 2011).
This Cochrane Review update broadened study inclusion criteria
to include non-randomized studies that provide useful informa-
tion regarding the side effect profile of mefloquine.
This review did not address:
• the efficacy or safety of alternative forms of malaria
chemoprophylaxis;
• the use by pregnant women of mefloquine as intermittent
presumptive treatment of malaria, or;
• the use by travellers of emergency standby malaria
treatment.
This new edition replaces the Cochrane Review on mefloquine
for preventing malaria in non-immune adult travellers (Jacquerioz
2015). Malaria prophylaxis in children living in endemic ar-
eas, chemoprophylaxis in pregnant women, and malaria pre-
vention in people with sickle cell disease have been assessed in
other Cochrane Reviews (Meremikwu 2008; Oniyangi 2006;
Radeva-Petrova 2014).
O B J E C T I V E S
To summarize the efficacy and safety of mefloquine used as pro-
phylaxis for malaria in travellers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For efficacy we included randomized and quasi-randomized con-
trolled trials, including cluster-randomized trials.
For safety we also included non-randomized controlled trials/co-
hort studies. We included both prospective and retrospective co-
hort studies, but excluded studies where recruitment was linked
to the occurrence of specific adverse events.
A list of study design features for all included studies is included
in Appendix 1.
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Types of participants
Adults and children, including pregnant women.
Types of interventions
Intervention
Mefloquine at a prophylactic dose (for example, 250 mg once
weekly in adults and equivalent dosing for children).
Control
Placebo, no intervention or an alternative malaria chemoprophy-
laxis agent in current use.
Types of outcome measures
Efficacy
Clinical cases of malaria.
Safety
• Adverse effects of any severity: defined as “an adverse event
for which the causal relation between the intervention and the
event is at least a reasonable possibility” (Loke 2011);
• serious adverse effects are those “leading to death, [which]
are life threatening, require inpatient hospitalization or
prolongation of existing hospitalization, or result in persistent or
significant disability or incapacity, or is a congenital anomaly/
birth defect” (ICH 1994);
• adverse events of any severity: defined as “any untoward
medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a
causal relationship with this treatment” (WHO-ART 2008);
• serious adverse events are those “leading to death, [which]
are life threatening, require inpatient hospitalization or
prolongation of existing hospitalization, or result in persistent or
significant disability or incapacity, or is a congenital anomaly/
birth defect.” (ICH 1994);
• discontinuations of study drug due to adverse effects;
• measures of adherence to the drug regimen.
Pregnancy-related outcomes:
• adverse pregnancy outcomes: spontaneous abortions,
stillbirths, congenital malformations.
Study authors often use the terms ’adverse event’, ’adverse effect’
or ’side effect’ interchangeably and loosely. Where possible, we
used the definitions described above to distinguish adverse events
and adverse effects. Adverse effects encompasses reporting by study
authors of ’adverse effects’, ’side effects’, ’adverse events attributed
to the study drug’, ’adverse reactions’, and ’symptoms related to
the study drugs’.
Search methods for identification of studies
We attempted to find all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 2:
• Cochrane Infectious Diseases Group Specialized Register to
22 June 2017;
• Central Register of Controlled Trials (CENTRAL),
published on the Cochrane Library to 22 June 2017;
• MEDLINE (PubMed) from 1966 to 22 June 2017;
• Embase (Ovid) from 1974 to 22 June 2017; and
• LILACS (Bireme) from 1982 to 22 June 2017.
We also searched the WHO International Clinical Trials Reg-
istry Platform (WHO ICTRP) and ClinicalTrials.gov (https://
clinicaltrials.gov/) for trials in progress, using ’mefloquine’, ’Lar-
iam’, and ’malaria’ as search terms (22 June 2017).
For the safety analysis we also searched MEDLINE (PubMed)
(1966 to 22 June 2017), Embase (Ovid) (1974 to 22
June 2017), and TOXLINE (1980 to 22 June 2017) (
https://toxnet.nlm.nih.gov/newtoxnet/toxline.htm). The follow-
ing MEDLINE terms were adapted as needed: (“Mefloquine/
adverse effects”[Mesh] OR “Mefloquine/poisoning”[Mesh] OR
“Mefloquine/toxicity”[Mesh] ); Mefloquine ti, ab AND (safety
OR tolerability OR death*OR suicid* OR adverse OR reaction*
OR “side effect*”) ti, ab.
Searching other resources
Wechecked the reference lists of included studies for any references
not identified by our searches.
Data collection and analysis
Selection of studies
Two review authors independently screened the results of the liter-
ature search for potentially relevant trials usingCovidence software
(Covidence 2017), and looked for multiple publications from the
same data set. Full text copies were retrieved for all trials deemed
potentially relevant for inclusion.
Two review authors then independently assessed all identified trials
for inclusion in the review using the prespecified inclusion criteria.
Any disagreements were resolved through discussion.
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Data extraction and management
Two review authors independently extracted data using a stan-
dardized and pre-piloted data collection form. When available we
extracted data on:
• details of study: start and end dates, setting (country of
recruitment and country of malaria exposure), study design,
method of participant recruitment and selection, number of
participants enrolled, number of participants for whom data was
available, mean duration of exposure to malaria, antimalarial
resistance pattern of mefloquine and the comparator;
• study participants: inclusion and exclusion criteria, age,
gender, body mass index (BMI), pregnancy status, risk factors
(for malaria and for adverse outcomes), immune or non-immune
participants, military or non military;
• details of the intervention: drug dose during prophylaxis,
use of a loading dose, duration of drug therapy before and after
travel, frequency of drug administration and use of any co-
interventions;
• outcomes measured and reported including definition,
method of detection, timing in relation to treatment, duration
and frequency of monitoring.
We resolved any disagreements through discussion, and where
necessary we consulted a third review author. If clarification was
necessary, we attempted to contact the trial authors for further
information.
For dichotomous data, we recorded the number of participants
experiencing the event and the number analysed in each group.
For continuous outcome data, we extracted arithmetic means and
standard deviations for each group together with the numbers
analysed in each group. We also extract medians and ranges where
provided.
We extracted details of all serious adverse events and effects. For
non-serious adverse events and effects we sought information on
the following specific symptoms and groups of symptoms which
are frequently associated with mefloquine, doxycycline or ato-
vaquone-proguanil:
• ear and labyrinth disorders: vertigo;
• eye disorders: visual impairment;
• gastrointestinal disorders: nausea, vomiting, abdominal
pain, diarrhoea, dyspepsia;
• nervous system disorders: dizziness and headaches;
• psychiatric disorders: abnormal dreams, insomnia, anxiety,
depression, psychosis; and
• skin and subcutaneous tissue disorders: pruritis,
photosensitivity, vaginal candida.
We also reported data on all other very common (> 1/10) and
common (> 1/100 to < 1/10) adverse events and adverse effects, as
defined by the electronic Medicines Compendium (eMC 2015b).
Where possible we attempted to derive absolute estimates of ad-
verse outcomes (events or effects). For all adverse outcomes, we
included only the denominator trials that actively reported the
presence or absence of each specific adverse event or effect.
Most RCTs and cohort studies collected data on self-reported or
clinician-assessed symptoms rather than formalmedical diagnoses.
Therefore, we reported outcomes as symptoms. For example, we
reported on ’depressed mood’ rather than ’depression’.
When deciding which relative effect measure to present in ’Sum-
mary of findings’ tables, we considered which meta-analysis most
closely answered our PICO (population, intervention, compara-
tor, outcome/s) question. We created a decision tree in advance to
assess the directness of a group of studies in relation to: the pop-
ulation studied (short-term international travellers versus other
populations), outcomes measured (adverse effects versus adverse
events), and study design (RCTs versus cohort studies). The inter-
vention and comparator were fixed in each drug-pair comparison.
Other less direct meta-analyses were used in our appraisal of the
certainty of the evidence. The decision tree used is provided in
Appendix 3.
Conventionally, ’Summary of findings’ tables include up to seven
outcomes. However, the key questions for clinical decisionmaking
relate to adverse effects, and therefore limiting the number of out-
comes a priori was problematic, as we could not know in advance
which adverse effects mefloquine would have. To constrain the
number of outcomes in the ’Summary of findings’ tables to seven
would mean only reporting outcomes where effects were shown,
which would lead to selective reporting.
We included ’Summary of findings’ tables for comparisons of
mefloquine with doxycycline and atovaquone-proguanil. This de-
cision was made because chloroquine is used less frequently than
mefloquine, doxycyline and atovaquone-proguanil. As reported in
Results, the adverse effect profile of mefloquine in comparison
to chloroquine was consistent with comparisons with doxycycline
and atovaquone-proguanil.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included study. For randomized and quasi-randomized controlled
trials we used Cochrane’s ’Risk of bias’ tool (Higgins 2011). We
followed the guidance for making judgements on the risk of bias in
five domains: sequence generation; allocation concealment; blind-
ing (of participants, personnel and outcome assessors); incomplete
outcome data; selective outcome reporting and other risk of bias.
We categorized these judgements as low risk of bias, high risk of
bias, or unclear risk of bias.
For non-randomized (cohort) studies we assessed the risk of bias
using the Cochrane Risk of Bias Assessment Tool for Non-Ran-
domized Studies of Interventions (now referred to as ROBINS-I)
(ACROBAT-NSRI tool). We followed the guidance for making
judgements on the risk of bias in eight domains: confounding,
selection of participants into the study, measurement of interven-
tions, departures from intended interventions, missing data, selec-
tion of the reported result and other risk of bias. We categorized
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these judgements as low risk of bias, moderate risk of bias, serious
risk of bias and critical risk of bias. Where no information was
provided on a category, this was stated. The criteria we used to
make specific judgements are provided in Table 1.
For adverse events and adverse effects, we assessed the risk of bias
in the conduct of the study by examining whether harms were pre-
defined using standardized or precise definitions, ascertainment
methods were adequately described, monitoring was active or pas-
sive and data collection was prospective or retrospective (Table 2).
For laboratory tests and other investigations we assessed whether
the number and timing of the tests was adequate.
We resolved any disagreement through discussion, and where nec-
essary, we consulted a third review author.
Measures of treatment effect
We analysed data using Review Manager 5 (RevMan 5) (RevMan
2014) and combined dichotomous data using risk ratios (RR). For
continuous data summarized by arithmetic means and standard
deviations, we combined data using mean differences (MD). We
present RRs and MD with 95% confidence intervals (CI) and
report medians and ranges in tables for non-RCTs.
Unit of analysis issues
When trials included more than two comparison groups, we split
the trial for analysis as individual pair-wise comparisons. If more
than one comparison group was included in a meta-analysis, we
ensured that participants were only counted once by dividing the
cases and participants evenly between the comparisons.
For clinical cases of malaria, we included participants as the unit
of analysis, such that each participant was counted once in the
intervention or placebo arm. Where study reporting was unclear
regarding the unit of analysis (that is, total clinical cases of malaria
rather than clinical cases in each participant) we noted this in foot-
notes and performed a sensitivity analysis excluding these results.
Dealing with missing data
If data from trial reports were insufficient, unclear, or missing, we
attempted to contact the trial authors for additional information.
Our primary analysis was a complete-case analysis which excluded
all participants without treatment outcomes. No imputation mea-
sures for missing data were applied.
Where studies had grouped symptoms together by body system
when reporting safety outcomes, we contacted authors to ob-
tain disaggregated data. We obtained two additional full data sets
(Cunningham 2014; Korhonen 2007) and received further clari-
fication from two study authors (Kato 2013; Sonmez 2005). The
full details of subsequent analyses are provided in the characteris-
tics of included studies tables.
Assessment of heterogeneity
We assessed heterogeneity among trials by inspecting forest plots
for overlapping CIs, applying the Chi² test with a 10% level of
statistical significance, and using the I² statistic with a value of
50% to denote moderate levels of heterogeneity.
Assessment of reporting biases
We were unable to assess publication bias using funnel plots be-
cause there were too few trials reporting the same outcomes.
Data synthesis
We carried out statistical analyses using RevMan 5 (RevMan
2014).We analysed randomized controlled trials (RCTs) and non-
RCTs separately, and compared interventions as individual pair-
wise comparisons.
In the absence of heterogeneity, we used a fixed-effect model.
Where we identified moderate heterogeneity, and it was appropri-
ate to combine data, we used the random-effects model. When it
was not appropriate to combine data in a meta-analysis, we tabu-
lated data and reported outcomes as a narrative.
We report the term used for each adverse event in each trial.Where
trials used different terminology for similar adverse events and ad-
verse effects, we coded them using the preferred term based on
Medical Dictionary for Regulatory Activities (MedDRA) termi-
nology (for example, sleepiness, somnolence) and analysed these
together (MedDRA 2016).
Subgroup analysis and investigation of heterogeneity
We explored possible sources of heterogeneity using subgroup
analyses (study design, military versus non-military participants,
short- versus long-duration of travel).
Sensitivity analysis
We conducted sensitivity analyses to evaluate the robustness of the
results to the risk of bias components, by excluding studies at high
or unclear risk of bias.
R E S U L T S
Description of studies
Results of the search
Searches (conducted 22 June 2017) identified 2155 records; we
screened seven additional studies after reviewing reference lists.
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Of these, we excluded 1953 after assessing titles and abstracts. We
retrieved 209 full text publications to assess for inclusion.
Included studies
We included 20 randomized controlled trials (RCTs) (11,470 par-
ticipants), 35 cohort studies (190,286 participants) and four large
retrospective analyses of health records (800,652 participants).
Efficacy outcomes were reported in 14 RCTs conducted between
1977 and2003 inThailand (four trials), Brazil, Cambodia,Ghana,
Indonesia, Ivory Coast, Malawi, Nigeria, Kenya and two studies
which included travellers to various destinations (10,710 partici-
pants). Two were conducted in short-term international travellers
(Overbosch 2001; Schlagenhauf 2003); nine involved general pop-
ulations living in endemic areas who are likely to have some im-
munity to malaria (Boudreau 1991; Bunnag 1992; Hale 2003;
Nosten 1994; Pearlman 1980; Salako 1992; Sossouhounto 1995;
Steketee 1996; Weiss 1995), two recruited non-immune military
personnel (Arthur 1990; Ohrt 1997), and one recruited a mixed
military and civilian semi-immune population (Santos 1993).
All 20 included RCTs and 35 cohort studies reported safety out-
comes. Nine RCTs explicitly excluded participants with a psychi-
atric history, and 25 cohort studies stated that the choice of an-
timalarial agent was based on medical history and personal pref-
erence. Most RCTs and cohort studies collected data on self-re-
ported or clinician-assessed ’symptoms’, rather than formal medi-
cal diagnoses. Consequently, when describing these data we used
non-medical descriptions such as ’depressed mood’ rather than
’depression’, even where the trial authors described the symptom
as depression. However, four retrospective cohort studies analysed
healthcare records (Eick-Cost 2017;Meier 2004; Schneider 2013;
Wells 2006) and looked for people with formalmental health diag-
noses. Where outcomes were presented grouped by organ system,
we approached study authors for additional data and received full
data sets for two studies (Cunningham 2014; Korhonen 2007) and
additional information from another two (Kato 2013; Sonmez
2005).
Three RCTs (1827 participants) and 24 cohort studies (170,487
participants) included short-term international travellers. Five co-
hort studies included long-term occupational travellers (UK For-
eign and CommonwealthOffice Staff and PeaceCorps volunteers)
(13,211 participants); four RCTs (961 participants) and six co-
hort studies (6588 participants) included military personnel (in-
cluding 1 study with a mixed military and civilian population).
Thirteen RCTs included local residents who did not travel outside
their home countries: Australia (Davis 1996), Ghana (Hale 2003),
Israel (Potasman 2002), Ivory Coast (Sossouhounto 1995), Kenya
(Weiss 1995),Malawi (Steketee 1996), theNetherlands (Vuurman
1996), Nigeria (Salako 1992), Switzerland (Schlagenhauf 1997)
and Thailand (Boudreau 1991, Bunnag 1992, Nosten 1994,
Pearlman 1980).
Seven RCTs and three cohort studies were sponsored by Roche
(manufacturer of mefloquine), three RCTs and one cohort
study were sponsored by GlaxoSmithKline (manufacturer of ato-
vaquone-proguanil), one RCT was sponsored by Pfizer (manufac-
turer of doxycycline), and one by Mepha Ltd (manufacturer of a
film-coated form of mefloquine). Only one RCT and one cohort
study reported whether the study sponsor had any influence over
collecting, analysis or interpretation of study results or the deci-
sion to publish.
Excluded studies
We excluded 141 studies after full-text screening (Figure 1). We
excluded 37 studies because they were not research studies; 29
studies reported no relevant outcomes; 23 studies were single arm
cohort studies and did not meet our inclusion criteria; 17 studies
compared mefloquine with a regime which is not routinely used;
11 studies were not a randomized or cohort study (for example,
case report or case-control study); in seven studies mefloquine
was not used at a prophylactic dose, for example, treatment dose;
seven studies were multiple publications from the same data set as
included studies; four cohort studies the population was identified
on the basis of having experienced adverse effects and we excluded
6 studies for other reasons. We have provided full details in the
’Characteristics of excluded studies’ tables.
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Figure 1. Study flow diagram.
Risk of bias in included studies
We performed ’Risk of bias’ assessments for the included RCTs
using the Cochrane ’Risk of bias’ assessment tool. We assessed the
risk of bias in the cohort studies using the ACROBAT-NSRI tool
(now referred to as ROBINS-I). For a summary of the ’Risk of
bias’ assessments for RCTs see Figure 2.
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Figure 2. ’Risk of bias’ summary for RCTs: review authors’ judgements about each ’Risk of bias’ item for
each included study.
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Allocation
Three trials were at low risk of selection bias, with adequate de-
scriptions of generation of the random sequence and allocation
concealment (Davis 1996;Overbosch 2001; vanRiemsdijk 2002).
A further 16 trials were at unclear risk of selection bias due to
providing insufficient information regarding their methodology.
One trial described sequential allocation of unblinded participants
(Steketee 1996).
Blinding
Seven trials adequately described blinding of study personnel, in-
cluding blinding of pathology technicians when detectingmalaria,
and blinding of outcome assessors when assessing safety outcomes
(Nosten 1994; Ohrt 1997; Overbosch 2001; Potasman 2002;
Schlagenhauf 2003; van Riemsdijk 2002; Weiss 1995). The re-
maining 13 trials did not adequately describe how outcome asses-
sors were blinded.
Incomplete outcome data
Six trials had low and balanced losses to follow-up rates for effi-
cacy outcomes (Hale 2003;Nosten 1994;Overbosch 2001; Salako
1992; Sossouhounto 1995; Weiss 1995). One trial was at high
risk of bias because investigators did not follow up participants
beyond the active phase of treatment for relapses (Santos 1993).
Two studies did not make the method of detection of malaria, fre-
quency or duration of follow up clear (Arthur 1990; Schlagenhauf
2003).
Seven trials had low losses to follow-up rates for adverse outcomes
(Arthur 1990; Davis 1996; Hale 2003; Pearlman 1980; Salako
1992; Sossouhounto 1995; Weiss 1995). We judged four of the
trials to be at high risk of bias because investigators did not provide
numbers of participants lost to follow up across groups (Nosten
1994; Steketee 1996); did not assess all participants who received
the study drug in the final analysis (Ohrt 1997); and because
the proportion of participants who did not complete the study
due to adverse outcomes varied significantly between groups (van
Riemsdijk 2002).
Selective reporting
Fourteen trials reported on efficacy outcomes, and twelve of these
appropriately reported all outcomes.
However, 21 trials reported on our safety outcomes and only
nine of these appropriately reported on all pre-specified out-
comes. Three of these trials only reported on statistically signifi-
cant differences between groups (Boudreau 1993; Pearlman 1980;
Schlagenhauf 1997), and another four did not report data from all
time points (Bunnag 1992; Nosten 1994; Ohrt 1997; Overbosch
2001). Two trials reported aggregate data across multiple time
points (Schlagenhauf 2003; Steketee 1996), one trial only reports
symptoms which occurred in > 10% of participants in each study
arm (Davis 1996). Vuurman 1996 only reported events which oc-
curred more than once and Hale 2003 reports the total number of
serious adverse events does not allocate them to a drug regimen.
Other potential sources of bias
Seven trials were sponsored by Roche (manufacturer of meflo-
quine) (Bunnag 1992; Davis 1996; Ohrt 1997; Santos 1993;
Schlagenhauf 1997; Schlagenhauf 2003; Vuurman 1996), three
were sponsored by GlaxoSmithKline (manufacturer of ato-
vaquone-proguanil) (Hale 2003; Overbosch 2001; Schlagenhauf
2003), one by Pfizer (manufacturer of doxycycline) (Ohrt 1997),
and one by Mepha Ltd (manufacturer of a film-coated form of
mefloquine) (Potasman 2002). Only one made the role of the
study sponsor clear (Ohrt 1997).
We have presented details of the risk of bias of cohort studies in
the ’Effects of interventions’ section.
Effects of interventions
See: Summary of findings for the main comparisonMefloquine
versus atovaquone-proguanil for preventing malaria in travellers;
Summary of findings 2 Mefloquine versus doxycycline for
preventing malaria in travellers
Comparison 1: Mefloquine versus placebo or no
treatment
Description of studies
RCTs
Nine RCTs comparing prophylactic mefloquine with placebo re-
ported efficacy (4032 participants, Table 3), and 13 reported sa-
fety outcomes (4293 participants, Table 4). The trials were con-
ducted between 1977 and 2003, and none included participants
travelling outside their home country. One trial conducted among
soldiers in Indonesia described participants as non-immune (Ohrt
1997), but immunity is likely to be low in other trials from Asia
(Bunnag 1992;Nosten 1994; Pearlman 1980). The participants in
four trials fromAfricawere described as semi-immune (Hale 2003;
Salako 1992; Sossouhounto 1995; Weiss 1995). Santos 1993 was
conducted in an area of Brazil in which endemic transmission oc-
curs.
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Seven trials used mefloquine at a dose of 250 mg weekly (or equiv-
alent doses for children), four at 250 mg weekly for the first four
weeks and then 125 mg weekly for the remainder of the study,
and one trial used mefloquine doses of 500 mg every four weeks
and 250 mg every two weeks (Santos 1993). Pearlman 1980 used
mefloquine doses of 180 mg weekly, 360 mg weekly and 360 mg
fortnightly. Trial duration varied from 48 hours to 26 weeks.
For safety, nine trials used interviews with study personnel to elicit
adverse events (Bunnag 1992; Hale 2003; Nosten 1994; Ohrt
1997; Salako 1992; Santos 1993; Schlagenhauf 1997; Vuurman
1996; Weiss 1995). Of these, six trials questioned participants
about symptoms at least weekly (Hale 2003; Nosten 1994; Ohrt
1997; Salako 1992; Vuurman 1996; Weiss 1995). Two trials used
participant self-reported diaries to record any adverse events (Davis
1996, Potasman 2002). Pearlman 1980 used a weekly ’sick call’ by
study personnel and Sossouhounto 1995 provided ’access to the
village health centre’. Only two trials used explicit definitions for
adverse events and effects that allow for reproducible ascertain-
ment (Davis 1996, Vuurman 1996). For safety outcomes, nine
of the 13 trials adequately described how adverse events were as-
certained. Eleven trials actively sought adverse events, and all 13
collected data prospectively (Table 5).
Eleven of thirteenwhich assessed safety outcomes trials did not ad-
equately describe random sequence generation or allocation con-
cealment, and eight did not adequately describe how outcome as-
sessors and study personnel were blinded. We judged eight trials
to be at high risk of selective outcome reporting with regard to
safety outcomes. In two trials, this was because the overall number
of adverse events in each study arm was reported, but not the type
or severity (Bunnag 1992; Potasman 2002). Davis 1996 reported
only adverse events that occurred inmore than 10%of participants
in both study arms; Vuurman 1996 reported only adverse events
that occurred more than once; and Nosten 1994 only reported on
adverse events in the second phase of the trial.
Five trials were funded by Roche (manufacturer of mefloquine)
(Bunnag 1992; Davis 1996; Santos 1993; Schlagenhauf 1997;
Vuurman 1996) and one by GlaxoSmithKline (manufacturer of
atovaquone-proguanil) (Hale 2003) and one byMepha Ltd (man-
ufacturer of a film-coated form of mefloquine) (Potasman 2002).
Cohort studies
Five cohort studies compared mefloquine users with participants
who travelled but did not take antimalarial prophylaxis at all (
Hoebe 1997; Petersen 2000; Rietz 2002; van Riemsdijk 1997;
Wells 2006). Four of these were conducted in travellers, and one
in military personnel (Table 4).
Two cohort studies included travellers who were prescribed an
antimalarial agent but did not commence using (Hoebe 1997;
Petersen 2000) and two asked travellers about an extensive list of
general complaints which could have occurred during their jour-
ney (Rietz 2002; van Riemsdijk 1997). Wells 2006 was a retro-
spective healthcare record analysis looking at hospitalizations in
active-duty USA military personnel (397, 442 participants).
Two cohort studies had non-response rates of over 20%. Wells
2006 was at serious risk for selection of participants and mea-
surement of outcomes because start of follow up began after par-
ticipants had finished taking mefloquine, authors used surrogate
measures for mefloquine exposure and there was a possibility that
some participants in the reference groups took mefloquine. Four
cohort studies actively sought information fromparticipants about
adverse events and only one (van Riemsdijk 1997) obtained infor-
mation prospectively (see Figure 3).
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Figure 3. ’Risk of bias’ summary in cohort studies: mefloquine versus placebo/no treatment1Assesses
whether our pre-defined confounders were measured and balanced across groups.2Assesses the non-response
rate of prospective participants.3Assesses the risk that participants labelled as taking mefloquine (or another
antimalarial) actually took something else.4Assesses the risk that participants whose adverse effects are
attributed to mefloquine (or another antimalarial) actually took another drug as well.5Assesses whether
outcome data reasonably complete for most participants and whether intervention status reasonably
complete for those in whom it was sought.6Assesses whether the outcome measure was subjective, and
whether participants and outcome assessors were blinded.7Assesses whether it is clear that all information
collected within the study has been reported.8Assess the risk of bias due to influence by a corporate study
sponsor.
Efficacy
Mefloquine is highly efficacious in reducing clinical cases of
malaria compared to placebo, although there were important dif-
ferences among trials, particularly regarding the dose of meflo-
quine used, populations studied and the risk of malaria in the
control group (Analysis 1.1). The risk of malaria was highest in
the trial in military personnel travelling to Indonesia, described as
“largely non-immune”, where 53/65 (81%) of those in the placebo
group had an episode of malaria compared to 0/67 (0%) with
mefloquine (RR 0.01, 95% CI 0.00 to 0.16; Ohrt 1997, 126 par-
ticipants). In the remaining trials the risk of malaria with placebo
ranged from 1% to 59% (Bunnag 1992;Hale 2003; Nosten 1994;
Pearlman 1980; Salako 1992; Santos 1993; Sossouhounto 1995;
Weiss 1995).
Although quantitative heterogeneity was high, the direction of the
effect was consistent across all trials. We performed a series of
subgroup analyses by dose and immune status of participants, but
this did not explain the heterogeneity or provide a reliable point
estimate of efficacy with subgroups.
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Five trials also reported the effect on parasitaemia (which was
much more common than clinical malaria) (Hale 2003; Nosten
1994; Salako 1992; Sossouhounto 1995; Weiss 1995). Overall,
mefloquine reduced numbers of participants who developed par-
asitaemia by around 80% (RR 0.18, 95% CI 0.06 to 0.55; 3 tri-
als, 414 participants, Analysis 1.2), and substantially reduced the
number of episodes of parasitaemia (RR 0.05, 95% CI 0.00 to
5.25; 2 trials, 510 participants, Analysis 1.2).
Safety
Serious adverse events or effects
Only three serious adverse events were reported from six RCTs,
none of which were attributed to the drug regimen (1/592 meflo-
quine users versus 2/629 placebo; 6 trials; 1221 participants, Anal-
ysis 1.3). The serious event in the mefloquine user was the death
of a pregnant woman who received mefloquine (septic shock after
an emergency caesarean section for obstructed labour) (Nosten
1994). For serious pregnancy-related outcomes, Nosten 1994 re-
ported four congenital malformations in the mefloquine group:
limb dysplasia (1 case), ventricular septal defect (2 cases), amniotic
bands (1 case) and one in the placebo group: anencephaly. All were
considered unrelated to the drug regimen (Table 6).
By comparison in cohort studies, seven serious adverse effects (all
attributed by study authors to the drug regimen) were reported
among 913 mefloquine users, compared to none in 254 travellers
who did not use antimalarials (RR 3.08, 95% CI 0.39 to 24.11;
2 studies, 1167 participants; Analysis 1.3; Table 7). Five of these
were psychological (depression) and two were neurological adverse
effects (dizziness).
Wells 2006 was a retrospective healthcare record analysis that re-
ported adverse events. It compared numbers of hospitalizations in
military personnel who had been prescribed mefloquine and were
deployed to active duty in malarial areas, with those who had been
deployed to non-malarial areas, and with military personnel with
duty zip codes for Europe or Japan, who had not been deployed
to active duty. Mefloquine users were less likely to be hospitalized
(after deployment) with mood disorders (RR 0.38, 95% CI 0.17
to 0.86; 241,239 participants) or for any cause (RR 0.60, 95% CI
0.51 to 0.71; 241,239 participants) than military personnel who
did not receive any antimalarial agents (but who were deployed to
a war zone).
Discontinuations due to adverse effects
Within RCTs the number of people who discontinued the study
drug due to adverse effects was low in both groups: 6/541 (1.1%)
with mefloquine versus 4/583 (0.7%) with placebo (RR 1.64,
95% CI 0.55 to 4.88; 7 trials, 1124 participants, Analysis 1.4).
No comparative data were available on this outcome from cohort
studies because the comparison was with no treatment.
Prespecified adverse events or effects
None of the RCTs or cohort studies for this comparison reported
on adverse effects (symptoms attributed by researchers or partic-
ipants to the drug regimen). All comparisons were for adverse
events (all symptoms that occurred while taking the study drug).
Gastrointestinal symptoms
Within RCTs, participants who received mefloquine were more
likely to experience nausea than those who took placebo (RR 1.35,
95% CI 1.05 to 1.73; 2 trials, 244 participants, Analysis 1.5), but
there was no difference between groups for vomiting, abdominal
pain or diarrhoea (Analysis 1.6; Analysis 1.7; Analysis 1.8). The
results from cohort studies were consistent with this finding, with
more mefloquine users experiencing nausea (RR 1.85, 95% CI
1.42 to 2.43; 3 studies, 1901 participants, Analysis 1.5).
One RCT in pregnant women (Nosten 1994) reported on both
upper and lower abdominal pain. Inclusion of both groups of
results in sensitivity analyses had no impact on the results.
Neurological symptoms
Mefloquine users in RCTs were no more likely that recipients
who took placebo to experience headache (RR 0.84, 95% CI 0.71
to 0.99; 5 trials, 791 participants, Analysis 1.9) or dizziness (RR
1.03, 95% CI 0.90 to 1.17; 3 trials, 452 participants, Analysis
1.10). This is in contrast to cohort studies, in which participants
who took mefloquine were significantly more likely to experience
dizziness than participants who travelled but took no prophylaxis
(RR 1.80, 95% CI 1.29 to 2.49; 3 studies, 1901 participants,
Analysis 1.10).
Psychological symptoms
None of the RCTs included in the analysis reported on any of our
prespecified psychological symptoms. Participants in cohort stud-
ies who received mefloquine were more likely than participants
who did not take prophylaxis to experience abnormal dreams (RR
2.35, 95% CI 1.15 to 4.80; 2 cohort studies, 931 participants,
Analysis 1.11), and insomnia (RR 1.46, 95% CI 1.06 to 2.02; 2
cohort studies, 931 participants, Analysis 1.12). Effects on anxiety
(RR1.21, 95%CI 0.67 to 2.21; 2 cohort studies, 931 participants;
I² statistic = 48%; Analysis 1.13), depressed mood (RR 2.43, 95%
CI 0.65 to 9.07; 3 cohort studies, 1901 participants, I² statistic =
72%, Analysis 1.14) and abnormal thoughts or perceptions (RR
5.77, 95% CI 0.79 to 42.06; 1 cohort study, 970 participants,
Analysis 1.15), were not consistent across studies, and overall, did
not reach standard levels of statistical significance.
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Other symptoms
Mefloquine users in cohort studies were more likely to experience
pruritis (RR 6.71, 95% CI 1.58 to 28.55; 1 cohort study, 197 par-
ticipants, Analysis 1.16). However, this finding was not replicated
in RCTs (RR 0.86, 95% CI 0.60 to 1.24; 3 RCTs, 609 partici-
pants, Analysis 1.16). There was no difference between groups for
visual impairment and vertigo in either RCTs nor cohort studies
(Analysis 1.17; Analysis 1.18).
Other adverse events reported in more than 1% of study partic-
ipants (in either study arm) in RCTs and cohort studies are pre-
sented in Analysis 1.19 and Analysis 1.20. Only respiratory tract
infection reached statistical significance between groups; data were
from a single trial with few events (RR 2.63, 95% CI 1.04 to 6.61;
1 trial, 140 participants).
Studies reporting groups of symptoms or other outcomes which
could be used as proxy markers of psychological or neurological
adverse effects are reported in Appendix 4.
Pregnancy outcomes
Nosten 1994 conducted an RCT in pregnant women over 20
weeks gestation. There was no reported difference between meflo-
quine and placebo for spontaneous abortions (RR 0.48, 95% CI
0.04 to 5.22; 311 participants), still births (RR 2.63, 95%CI 0.86
to 8.08; 311 participants) or congenital malformations (RR 3.82,
95% CI 0.43 to 33.83; 311 pregnant women). However, the trial
was significantly underpowered to evaluate these outcomes.
Adherence
In their RCT, Davis 1996 reported on any measure of adherence
to the drug regimen assessed by pill count and direct questioning.
Reported adherence was 100% in both arms.
Comparison 2: Mefloquine versus doxycycline
Description of studies
RCTs
Four RCTs, enrolling 1317 participants, reported on both effi-
cacy and safety (Table 8). One was conducted in short-term trav-
ellers (Schlagenhauf 2003), two in military personnel (Arthur
1990; Ohrt 1997) and one in Kenyan children (Weiss 1995).
The populations were described as non-immune (Arthur 1990;
Schlagenhauf 2003), “largely” non-immune (Ohrt 1997) and
semi-immune (Weiss 1995). Trial duration varied from four weeks
to four months. The method for detecting malaria was unclear in
two trials (Arthur 1990; Schlagenhauf 2003). Three studies con-
ducted daily interviews with participants to monitor for adverse
events (Arthur 1990; Ohrt 1997; Weiss 1995) and one used a par-
ticipant self-reporting questionnaire (Schlagenhauf 2003).
None of the RCTs adequately described allocation concealment.
Blinding of participants was adequately described in all but Weiss
1995; two trials did not adequately describe how outcome asses-
sors were blinded (Arthur 1990; Schlagenhauf 2003).We also con-
sidered Ohrt 1997 and Schlagenhauf 2003 to be at high risk of se-
lective outcome reporting because they did not report all collected
data: Ohrt 1997 completed an exit questionnaire within the last
month of the study, but did not report all results; Schlagenhauf
2003 collected data at baseline, twice before travel and once on
return, but only presented data for participants “who completed
questionnaires at recruitment and at least one of the follow up pe-
riods”. All four studies collected information on adverse events ac-
tively and prospectively (Table 9). Schlagenhauf 2003 was funded
byGlaxoSmithKline (manufacturer of atovaquone-proguanil) and
Roche (manufacturer of mefloquine) and Ohrt 1997 was funded
by Roche and Pfizer (manufacturers of doxycycline) but specified
that “neither of the pharmaceutical companies that provided sup-
port played any role in the gathering, analysing or interpreting the
data”.
Cohort studies
We included 20 cohort studies that assessed and reported sa-
fety outcomes, in a total of 435,209 participants. Of these, 10
were conducted in short-term travellers (Goodyer 2011; Laver
2001; Lobel 2001; Meier 2004; Napoletano 2007; Philips 1996;
Schwartz 1999; Sharafeldin 2010; Stoney 2016; Waner 1999),
four in longer-term occupational travellers (Cunningham 2014;
Korhonen 2007; Landman 2015; Tan 2017) and six in mili-
tary personnel (Eick-Cost 2017; Saunders 2015; Shamiss 1996;
Sonmez 2005; Terrell 2015; Tuck 2016); none included pregnant
women. Most (17 cohort studies) used participant self-reported
questionnaires to monitor adverse events.
Ten cohort studies had non-response rates of over 20% (
Cunningham 2014;Korhonen2007; Landman 2015; Lobel 2001;
Philips 1996; Sharafeldin 2010; Tan 2017; Terrell 2015; Tuck
2016; Waner 1999), (Figure 4). We judged two to be at high
risk of missing data; Goodyer 2011 included pre- and post-travel
questionnaires, with an interim loss to follow-up rate of 27%,
and Terrell 2015 excluded participants from the analysis if they
reported an adverse effect but did not record its impact on their
ability to work. None of these studies blinded participants or men-
tioned outcome assessors being blinded to intervention status.
Seven studies collected data retrospectively, and eight collected
information at an unclear or variable time point during treat-
ment (Table 9). One study (Goodyer 2011) was funded by Glaxo-
SmithKline (manufacturer of atovaquone-proguanil), one (Meier
2004) by Roche (manufacturer of mefloquine), and one (Philips
1996) by Roche and Pfizer (manufacturers of doxycycline) (see
Figure 4).
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Figure 4. ’Risk of bias’ summary in cohort studies: mefloquine versus doxycycline1Assesses whether our
pre-defined confounders are measured and balanced across groups.2Assesses the non-response rate of
prospective participants.3Assesses the risk that participants labelled as taking mefloquine (or another
antimalarial) actually took something else.4Assesses the risk that participants whose adverse effects are
attributed to mefloquine (or another antimalarial) actually took another drug as well.5Assesses whether
outcome data reasonably complete for most participants and whether intervention status reasonably
complete for those in whom it was sought.6Assesses whether the outcome measure was subjective, and
whether participants and outcome assessors were blinded.7Assesses whether it is clear that all information
collected within the study has been reported.8Assesses the risk of bias due to influence by a corporate study
sponsor.
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Efficacy
Only seven episodes of malaria were reported while participants
were receiving prophylaxis; similar numbers of participants were
infected in both arms (4 episodes in 378 mefloquine users versus
3 episodes in 366 doxycycline users: RR 1.35, 95% CI 0.35 to
5.19; 4 trials, 744 participants, Analysis 2.1).
Weiss 1995 reported on episodes of parasitaemia in the semi-im-
mune population. There was no clear difference between groups
(RR 1.47, 95% CI 0.68 to 3.14; 62 participants).
Safety
Serious adverse events or effects
Only Ohrt 1997 described an adverse event as “serious” (acute
hysteria) in a doxycycline user, but did not provide sufficient detail
to meet our definition. No other serious adverse outcomes were
described in RCTs including 348 mefloquine users and 334 doxy-
cycline users (Analysis 2.2; Table 6).
In comparison, three cohort studies reported a total of 29 serious
adverse effects (attributed to the study drug by users): 19 in 2125
mefloquine users, and10 in1597doxycycline users (RR1.53, 95%
CI 0.23 to 10.24; 3 cohort studies, 3722 participants; Analysis
2.2, Table 7).
Serious adverse effects in mefloquine users were psychological (4
cases) or due to dizziness (3), heart palpitations (2), limb numb-
ness (1), abdominal pain (1), visual disturbance (1), yeast infection
(1), passing out (2), seizure (1) and three hospitalizations with “ei-
ther gastrointestinal or neurologic symptoms”. In contrast, serious
adverse effects in doxycycline users were due to gastrointestinal
disturbance (6), anaemia (1), photosensitivity (1), oesophagitis (1)
and cough (1).
In addition, a cohort study (Lobel 2001) reported on hospital-
izations in users of mefloquine and doxycycline which were not
necessarily attributed to the drug regimen (adverse events). There
were eight hospitalizations in 3703 mefloquine users, and none
in 69 doxycycline users, with no statistically significant difference
between groups (RR 0.32, 95% CI 0.02 to 5.51; 3772 partici-
pants, Table 6).
Discontinuations due to adverse effects
There were no overall differences between groups in numbers of
discontinuations due to adverse effects in the RCTs (8/391 meflo-
quine users, 8/382 doxycycline users, RR 1.08, 95% CI 0.41 to
2.87; 4 RCTs, 773 participants, Analysis 2.3) or cohort stud-
ies (852/6116 mefloquine users, 378/4049 doxycycline users, RR
0.92, 95%CI 0.54 to 1.55; 10 cohort studies, 10,165 participants,
Analysis 2.3). However, heterogeneity among cohort studies was
high (I² statistic = 85%).
Prespecified adverse outcomes
Prespecified adverse effects (attributed to the study drug) were only
reported by cohort studies conducted in long-term occupational
travellers (3 studies) andmilitary personnel (3 studies). These form
our primary analysis (see Appendix 3 for decision tree).
OneRCT inmilitary personnel (Ohrt 1997) and one cohort study
in short-term international travellers (Philips 1996) reported on
all symptoms experienced by participants while taking the study
drug (adverse events). Two large retrospective analyses of health
records in general practice (Meier 2004) andUSAmilitary person-
nel (Eick-Cost 2017) databases compared rates of incident neuro-
logical or psychological diagnoses in participants who had received
a prescription for mefloquine or doxycycline (adverse events).
Gastrointestinal symptoms
Across the cohort studies reporting adverse effects, mefloquine
users were less likely to report nausea (RR 0.37, 95% CI 0.30 to
0.45; 5 cohort studies, 2683 participants, Analysis 2.4), vomiting
(RR 0.18, 95% CI 0.12 to 0.27; 4 cohort studies, 5071 partici-
pants, Analysis 2.5), abdominal pain (RR 0.30, 95% CI 0.09 to
1.07; 4 cohort studies, 2569 participants, Analysis 2.6) and di-
arrhoea (RR 0.28, 95% CI 0.11 to 0.73; 5 cohort studies, 5104
participants, Analysis 2.7).
However, this finding was not consistent across study types. In the
single RCT in military personnel that reported adverse events, no
differences were demonstrated for nausea, vomiting, abdominal
pain or diarrhoea. In the single cohort study in short-term inter-
national travellers reporting adverse events, mefloquine users were
more likely to report nausea and diarrhoea; there was no difference
between groups for abdominal pain (Analysis 2.4; Analysis 2.5;
Analysis 2.6; Analysis 2.7).
Dyspepsia was consistently more common in doxycycline users
but there was substantial heterogeneity in the size of this effect (RR
0.26, 95% CI 0.09 to 0.74; 5 cohort studies, 5104 participants,
I² statistic = 77%, Analysis 2.8)
Neurological symptoms
In the cohort studies reporting adverse effects, no difference was
demonstrated for headache (RR 1.21, 95% CI 0.50 to 2.92; 5
cohort studies, 3322 participants, Analysis 2.9) or dizziness (RR
3.49, 95% CI 0.88 to 13.75; 5 cohort studies, 2633 participants,
Analysis 2.10).
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In the RCT in military personnel (Ohrt 1997) and a cohort study
in short-term international travellers (Philips 1996) both headache
and dizziness were more common inmefloquine users. However, a
large retrospective analysis of health records in military personnel
(Eick-Cost 2017) found higher rates of dizziness in doxycycline
users (Analysis 2.9; Analysis 2.10).
Psychological symptoms
In the cohort studies reporting adverse effects, mefloquine users
were more likely to report abnormal dreams (RR 10.49, 95% CI
3.79 to 29.10; 4 cohort studies, 2588 participants, Analysis 2.11),
insomnia (RR 4.14, 95% CI 1.19 to 14.44; 4 cohort studies,
3212 participants, Analysis 2.12), anxiety (RR 18.04, 95% CI
9.32 to 34.93; 3 cohort studies, 2559 participants, Analysis 2.13)
and depressed mood (RR 11.43, 95% CI 5.21 to 25.07; 2 cohort
studies, 2445 participants, Analysis 2.14). There were 15 episodes
of abnormal thoughts and perceptions with mefloquine and none
with doxycyline in cohort studies reporting adverse effects (RR
6.60, 95% CI 0.92 to 47.20; 2 cohort studies, 2445 participants,
Analysis 2.15).
The findings of the single cohort study in short-term international
travellers reporting adverse events (Philips 1996) were consistent
with this. However in the single RCT (Ohrt 1997) and the large
retrospective healthcare record analyses, there were either no dif-
ferences between groups, or doxycycline users were more likely to
experience psychological symptoms (Analysis 2.11; Analysis 2.12;
Analysis 2.13; Analysis 2.14; Analysis 2.15).
Other prespecified symptoms
Pruritis was more common in doxycycline users in cohort studies
reporting adverse effects (RR 0.52, 95% CI 0.30 to 0.91; 2 cohort
studies, 1794 participants, Analysis 2.16), but more commonwith
mefloquine in the single cohort in short-term travellers reporting
adverse events (RR 2.69, 95% CI 0.93 to 7.78; 1 cohort study,
668 participants).
In cohort studies reporting adverse effects, photosensitivity was
more common in doxycycline users (RR 0.08, 95% CI 0.05 to
0.11; 2 cohort studies, 1875 participants, Analysis 2.17), as was
vaginal yeast infection in female participants (RR 0.10, 95% CI
0.06 to 0.16; 1 cohort study, 1761 participants, Analysis 2.18).
The findings of the single cohort study in short-term travellers
reporting adverse events were consistent with this finding (Analysis
2.17; Analysis 2.18).
Visual impairment was more commonly reported among meflo-
quine users (RR 2.37, 95% CI 1.41 to 3.99; 2 cohort studies,
1875 participants; Analysis 2.19).
Other adverse events and effects
A range of other adverse effects were reported by the cohort stud-
ies. These included alopecia (hair loss), asthenia (physical weak-
ness), balance disorder, decreased appetite, fatigue, hypoaesthe-
sia (numbness), malaise, mouth ulcers, palpitations and tinnitus
(Analysis 2.20). Mefloquine users were more likely to report alope-
cia (RR 3.44, 95% CI 1.96 to 6.03; 2 cohort studies, 1875 par-
ticipants), unsteadiness (RR 2.87, 95% CI 1.48 to 5.59; 1 cohort
study, 1761 participants) and limb numbness (RR 11.48, 95% CI
3.01 to 43.70; 2 cohort studies, 2445 participants), but were less
likely to report malaise (RR 0.28, 95% CI 0.11 to 0.71; 1 cohort
study, 734 participants).
Additional adverse events reported in the RCT and cohort studies
are presented in Analysis 2.21 and Analysis 2.22 respectively. In
Eick-Cost 2017, a large retrospective healthcare record analysis in
USA military personnel that reported adverse events, mefloquine
users were less likely than doxycycline users to receive formal med-
ical diagnoses of adjustment disorder (RR 0.43, 95% CI 0.40 to
0.45; 354,959 participants), convulsions (RR 0.58, 95% CI 0.45
to 0.75), hallucinations (RR 0.18, 95% CI 0.08 to 0.45), post-
traumatic stress disorder (PTSD) (RR 0.58, 95%CI 0.53 to 0.64),
suicidal ideation (RR 0.38, 95% CI 0.31 to 0.47), and tinnitus
(RR 0.65, 95% CI 0.61 to 0.71). There were no differences in
overall rates of suicide in the large retrospective healthcare record
analyses (4/53,029 mefloquine users and 15/322,995 doxycycline
users; RR 1.21, 95% CI 0.32 to 4.56, Analysis 2.22).
Studies reporting groups of symptoms or other outcomes that
could be used as proxy markers of psychological or neurological
adverse effects are reported in Appendix 5.
Adherence
Arthur 1990, an RCT, performed serological assays to assess ad-
herence. Arthur 1990 reported measurable serum drug levels at
the end of the trial in 87% of 119 military personnel prescribed
doxycycline and 92% of 134 who were prescribed mefloquine.
However, medication was administered under the supervision of
each participant’s squad leader.
Thirteen cohort studies compared the proportion of participants
with 100% self-reported adherence and found higher rates of ad-
herence during travel in mefloquine users (RR 1.15, 95% CI 1.12
to 1.18; 13 cohort studies, 15,583 participants, Analysis 2.23), but
no differences between groups in the post-travel period (RR 1.08,
95% CI 0.95 to 1.22; 4 cohort studies, 840 participants, Analysis
2.23). Most (77%) mefloquine users described themselves as ad-
herent during travel (range 24% to 100%), compared to 63% of
doxycycline users (range 37% to 92%). In the post-travel period
this dropped to 55% of mefloquine users (range 50% to 87%)
and 51% of doxycycline users (range 27% to 75%). There was no
difference in the results when the analysis was limited to short-
term international travellers (RR 1.11, 95% CI 1.06 to 1.17; 4
cohort studies; 8390 participants).
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Comparison 3: Mefloquine versus atovaquone-
proguanil
Description of studies
RCTs
Two RCTs in non-immune travellers reported efficacy, with most
participants visiting sub-Saharan Africa for fewer than three weeks
(Overbosch 2001; Schlagenhauf 2003). Efficacy was assessed by
testing for antibodies to a circumsporozoite protein four weeks
after travel in the study by Overbosch 2001, and the method was
unclear in Schlagenhauf 2003.
Three RCTs (Overbosch 2001; Schlagenhauf 2003; van Riemsdijk
2002), and 16 cohort studies (Andersson 2008; Belderok 2013;
Cunningham 2014; Eick-Cost 2017; Goodyer 2011; Kato 2013;
Korhonen 2007; Kuhner 2005; Landman 2015; Laverone 2006;
Napoletano 2007; Schneider 2013; Sharafeldin 2010; Stoney
2016; Tan 2017; Tuck 2016) assessed and reported safety out-
comes (Table 10).
TwoRCTs included adults and children aged≥ 3years (Overbosch
2001; van Riemsdijk 2002); all other studies were restricted
to adults. The RCTs described participants as non-immune
travellers, and most participants visited sub-Saharan Africa for
fewer than three weeks. The cohort studies included short-
term travellers (Belderok 2013; Goodyer 2011; Kato 2013;
Kuhner 2005; Laverone 2006; Napoletano 2007; Schneider 2013;
Sharafeldin 2010; Stoney 2016), longer-term occupational trav-
ellers (Cunningham 2014; Korhonen 2007; Landman 2015; Tan
2017) and military personnel (Andersson 2008; Eick-Cost 2017;
Tuck 2016).
All three RCTs that assessed and reported safety outcomes col-
lected information on adverse events actively and prospectively,
and predefined harms using standardized and precise definitions
(Overbosch 2001; Schlagenhauf 2003; van Riemsdijk 2002; Table
11). Only Overbosch 2001 performed a blinded assessment of
whether there was a reasonable possibility that each adverse event
was caused by the study drug (adverse effects). Overbosch 2001
was funded by GlaxoSmithKline (manufacturer of atovaquone-
proguanil) and Schlagenhauf 2003 received funding from both
GlaxoSmithKline and Roche (manufacturers of mefloquine).
Cohort studies
In the cohort studies, safety was assessed by self-reported ques-
tionnaires (Andersson 2008; Belderok 2013; Cunningham 2014;
Goodyer 2011; Kato 2013; Korhonen 2007; Kuhner 2005;
Landman 2015; Laverone 2006; Sharafeldin 2010; Stoney 2016;
Tan 2017; Tuck 2016), telephone interview (Napoletano 2007),
and retrospective analysis of a healthcare records (Eick-Cost 2017;
Schneider 2013). Seven studies collected adverse event data retro-
spectively and six collected these data at an unclear or variable time
point during treatment (Table 11). One study (Goodyer 2011)
was funded by GlaxoSmithKline (manufacturer of atovaquone-
proguanil) and one (Schneider 2013) was funded by Roche (man-
ufacturer of mefloquine) (Figure 5).
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Figure 5. ’Risk of bias’ summary in cohort studies: mefloquine versus atovaquone-proguanil1Assesses
whether our pre-defined confounders are measured and balanced across groups.2Assesses the non-response
rate of prospective participants.3Assesses the risk that participants labelled as taking mefloquine (or another
antimalarial) actually took something else.4Assesses the risk that participants whose adverse effects are
attributed to mefloquine (or another antimalarial) actually took another drug as well.5Assesses whether
outcome data reasonably complete for most participants and whether intervention status reasonably
complete for those in whom it was sought.6Assesses whether the outcome measure was subjective, and
whether participants and outcome assessors were blinded.7Assesses whether it is clear that all information
collected within the study has been reported.8Assesses the risk of bias due to influence by a corporate study
sponsor.
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Efficacy
No clinical cases of malaria were recorded (2 RCTs, 636 meflo-
quine users; 657 atovaquone-proguanil users).
Safety
Serious adverse events or effects
Overbosch 2001, an RCT, reported 10 serious adverse events in
483 participants who received mefloquine and four in 493 partic-
ipants who received atovaquone-proguanil. None were considered
attributable to the drug regimen (Table 6).
Three cohort studies reported a total of 15 serious adverse effects
(attributed by participants to the study drug) in 2651 mefloquine
users (Table 7). There were no serious adverse effects reported
in participants who received atovaquone-proguanil (940 users).
The difference between groups was not statistically significant (RR
1.40, 95% CI 0.08 to 23.22; 3 cohort studies, 3591 participants,
Analysis 3.2).
The serious adverse effects in mefloquine users were: psychological
(4 cases), dizziness (3), heart palpitations (2), limb numbness (1),
abdominal pain (1), visual disturbance (1), yeast infection (1), and
passing out (2).
Discontinuations due to adverse effects
In the RCTs, participants who received mefloquine were more
likely to discontinue their medication due to adverse effects than
participants who took atovaquone-proguanil (39/714 mefloquine
versus 13/724 atovaquone-proguanil; RR 2.86, 95% CI 1.53 to
5.31; 3 RCTs, 1438 participants, Analysis 3.3).
The overall effect size was similar in the cohort studies (RR 2.73,
95%CI 1.83 to 4.08; 9 cohort studies, 7785 participants, Analysis
3.3).
Prespecified adverse effects
Gastrointestinal symptoms
Mefloquine users were more likely to report nausea than ato-
vaquone-proguanil users with similar effect sizes in the RCT (RR
2.72, 95% CI 1.52 to 4.86; 976 participants) and overall in the
cohort studies (RR 2.50, 95% CI 1.54 to 4.06; 7 cohort studies,
3509 participants, Analysis 3.4). There were no consistent differ-
ences in the frequency of reported vomiting (Analysis 3.5), ab-
dominal pain (Analysis 3.6) or diarrhoea (Analysis 3.7). Mouth
ulcers were less commonly reported with mefloquine in cohort
studies (RR 0.12, 95% CI 0.04 to 0.37; 2 cohort studies, 783
participants), but not in the RCT (RR 1.45, 95%CI 0.70 to 3.00;
976 participants; Analysis 3.8).
Neurological symptoms
Mefloquine users were more likely to report headache although
this did not reach standard levels of statistical significance in the
RCT (RR1.72, 95%CI 0.99 to 2.99; 976 participants). The effect
was larger and consistent across the cohort studies (RR 3.42, 95%
CI 1.71 to 6.82; 8 cohort studies, 4163 participants, I² statistic
= 0%, Analysis 3.9). Similarly, dizziness was more common in
mefloquine users in the RCT (RR 3.99, 95% CI 2.08 to 7.64)
and consistently more common in the cohort studies (RR 3.83,
95%CI 2.23 to 6.58; 8 cohort studies, 3986 participants, Analysis
3.10). The same trend was seen in the retrospective healthcare
record analyses, although the effect size was smaller (RR1.23, 95%
CI 1.04 to 1.46; 49,419 participants).
Psychological symptoms
In the RCT, mefloquine users were more likely than atovaquone-
proguanil users to report abnormal dreams (RR 2.04, 95% CI
1.37 to 3.04), insomnia (RR 4.42, 95% CI 2.56 to 7.64), anxiety
(RR 6.12, 95% CI 1.82 to 20.66) and depressed mood (RR 5.78,
95%CI 1.71 to 19.61; 976 participants) (Overbosch 2001). Con-
sistent, larger effects were seen in the cohort studies: abnormal
dreams (RR 6.81, 95% CI 1.65 to 28.15; 7 cohort studies, 3848
participants, Analysis 3.11), insomnia (RR 7.29, 95% CI 4.37 to
12.16; 8 cohort studies, 3986 participants, Analysis 3.12), anxiety
(RR 10.10, 95% CI 3.48 to 29.32; 4 cohort studies, 2664 partici-
pants, Analysis 3.13) and depressed mood (RR 8.02, 95%CI 3.56
to 18.07; 6 cohort studies, 3624 participants, Analysis 3.14). In
addition, 21 mefloquine users and no atovaquone-proguanil users
reported abnormal thoughts or perceptions, but the difference be-
tween groups was not statistically significant (RR 1.50, 95% CI
0.30 to 7.42; 3 cohort studies, 2441 participants, Analysis 3.15).
Consistent effects were seen in the retrospective healthcare record
analysis (adverse events, Eick-Cost 2017) although the effect size
was smaller.
Other prespecified adverse symptoms
No differences were demonstrated for pruritis (1 RCT, 3 cohort
studies; Analysis 3.16); or visual impairment (1 RCT, 2 cohort
studies; Analysis 3.17).
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Other adverse outcomes
Other adverse effects reported in more than 1% of study partici-
pants in cohort studies (in either study arm) included: allergic re-
action, alopecia (hair loss), asthenia (weakness), balance disorder,
cough, disturbance in attention, dyspepsia, fatigue, hypoaesthe-
sia, loss of appetite, muscle pain, palpitation, photosensitization,
pyrexia, rash, restlessness, slight illness, somnolence, tinnitus and
circulatory disorders (Analysis 3.18). Mefloquine users were more
likely to report concentration difficulties (RR 4.45, 95% CI 1.84
to 10.77; 3 cohort studies, 1363 participants).
In the large retrospective healthcare record analyses which reported
adverse events, mefloquine users weremore likely to receive formal
medical diagnoses of adjustment disorder (RR 1.76, 95% CI 1.54
to 2.02; 49,419 participants, Analysis 3.19), PTSD (RR 2.51,
95% CI 1.93 to 3.26; Analysis 3.19), suicidal ideation (RR 1.69,
95% CI 1.03 to 2.77; Analysis 3.19) and tinnitus (RR 1.42, 95%
CI 1.21 to 1.68; Analysis 3.19). However, users were less likely to
experience hallucinations (RR0.25, 95%CI 0.08 to 0.79; Analysis
3.19).
Studies reporting groups of symptoms, or other outcomes which
could be used as proxy markers of psychological or neurological
adverse effects, are reported in Appendix 6.
Adherence
van Riemsdijk 2002 monitored adherence through reference to
the participants’ diary cards and counts of returned study medica-
tion. It was found that 93% of mefloquine users were completely
adherent, compared to 98.3% of atovaquone-proguanil users (RR
0.95, 95% CI 0.88 to 1.02; 1 RCT, 119 participants, Analysis
3.20).
Overbosch 2001 defined participants as adherent if they took at
least 80% of prescribed doses. Overbosch 2001 also found no
difference between the groups during travel (RR 0.98, 95% CI
0.95 to 1.01; 966 participants; Analysis 3.20). However, analysis
in the post-travel period found that mefloquine users were less
likely to complete the regimen (RR 0.80, 95% CI 0.74 to 0.85;
966 participants); 93% of mefloquine users were adherent during
travel, dropping to 70% in the post-travel period, compared to
95% and 88% for atovaquone-proguanil.
Six cohort studies compared the proportion of participants with
100% self-reported adherence and found no difference during
travel (RR 1.08, 95% CI 0.86 to 1.34; 6 cohort studies, 5577
participants, Analysis 3.21) or in the post-travel period (RR 0.89,
95% CI 0.64 to 1.23; 2 cohort studies, 422 participants, Analysis
3.21). In these studies, 60% of mefloquine users described them-
selves as adherent during travel, dropping to 51% in the post-
travel period, compared to 53% and 62% respectively for people
who took atovaquone-proguanil.
Belderok 2013 categorized travellers as adherent if they took at
least 75% of prescribed doses. Belderok 2013 reported higher rates
of adherence in participants who took mefloquine both during
and after travel. Meta-analysis of these results did not result in
a significant difference (during travel: RR 1.04, 95% CI 0.77 to
1.40; 5 cohort studies, 2810 participants, post-travel: RR 1.07,
95% CI 0.72 to 1.59; 3 cohort studies, 941 participants).
Pregnancy outcomes
One cohort study included respondents who were pregnant
(Cunningham 2014) but did not report which prophylaxis the
women took or on any outcomes related to pregnancy.
Mefloquine versus chloroquine
Description
RCTs
We included five RCTs comparing mefloquine with chloroquine
that reported on efficacy and six on safety (Table 12). Trials were
conducted in immune or semi-immune adult populations in the
Ivory Coast (Sossouhounto 1995), Malawi (Steketee 1996), Nige-
ria (Salako 1992) Thailand (Boudreau 1991; Bunnag 1992) and
theUSA. (Boudreau 1993). TheMalawi trial by Steketee 1996 was
limited to pregnant women. None included non-immune trav-
ellers or children. All six trials used interview with study person-
nel to obtain information about adverse events. Boudreau 1993
excluded participants with a history of psychiatric or neurological
problems.
None of the trials adequately described random sequence gen-
eration or allocation concealment. Participants were adequately
blinded in four trials (Boudreau 1993; Bunnag 1992; Salako 1992;
Sossouhounto 1995), the trial in pregnant women did not blind
participants or outcome assessors (Steketee 1996).We judged three
of the trials to be at high risk of selective reporting of safety
outcomes. Bunnag 1992 was funded by Roche (manufacturer of
mefloquine). Five trials actively sought information on adverse
events (Boudreau 1991; Boudreau 1993; Bunnag 1992; Salako
1992; Steketee 1996) and all collected information prospectively
(Table 13).
Cohort studies
We included 15 cohort studies in this comparison; 12 included
short-term travellers (Albright 2002; Corominas 1997; Hill 2000;
Laver 2001; Laverone 2006; Lobel 2001; Napoletano 2007;
Petersen 2000; Rietz 2002; Steffen 1993; Stoney 2016; Waner
1999) and three longer-termoccupational travellers (Cunningham
2014; Korhonen 2007; Tan 2017) (Table 12). Albright 2002 in-
cluded only children. Twelve studies used participant-self reported
questionnaires to collect information about adverse events; three
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of these, including the largest study (Steffen 1993, 145,003 par-
ticipants), collected information from travellers flying back to Eu-
rope from Africa. The remaining three studies collected informa-
tion through interviews with study personnel (Albright 2002; Hill
2000; Napoletano 2007)
Eight of the cohort studies had non-response rates of over 20%
(Figure 6).We judged 14 cohort studies to be at low risk of missing
data, the largest study (Steffen 1993) was at moderate risk due to a
15% loss to follow-up between the first and second questionnaire
in the second phase of the study. Steffen 1993 did not report
on non-serious adverse effects from the first phase of the study
(44,677 participants) and was funded by Roche (manufacturer
of mefloquine). Six studies collected information about adverse
events at set time points (Corominas 1997; Hill 2000; Napoletano
2007; Petersen 2000; Rietz 2002; Stoney 2016; Tan 2017), and
one collected information prospectively (Stoney 2016) (Table 13;
Figure 6).
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Figure 6. ’Risk of bias’ summary in cohort studies: mefloquine versus chloroquine1Assesses whether our
pre-defined confounders are measured and balanced across groups.2Assesses the non-response rate of
prospective participants.3Assesses the risk that participants labelled as taking mefloquine (or another
antimalarial) actually took something else.4Assesses the risk that participants whose adverse effects are
attributed to mefloquine (or another antimalarial) actually took another drug as well.5Assesses whether
outcome data reasonably complete for most participants and whether intervention status reasonably
complete for those in whom it was sought.6Assesses whether the outcome measure was subjective, and
whether participants and outcome assessors were blinded.7Assesses whether it is clear that all information
collected within the study has been reported.8Assesses the risk of bias due to influence by a corporate study
sponsor.
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Efficacy
Participants who took mefloquine were less likely to experience
malaria than participants who took chloroquine (RR 0.38, 95%
CI 0.28 to 0.52; 4RCTs, 877 participants, Analysis 4.1).However,
two RCTs were conducted in settings with known chloroquine
resistance at the study sites, and the other two reported no episodes
of malaria in either study arm. All RCTs included semi-immune
populations, and were conducted over 20 years ago.
Safety
Serious adverse events or effects
Across four RCTs, two serious adverse events were reported in
529 mefloquine users and none in 471 chloroquine users; the
difference between groups was not significant (RR 2.77, 95% CI
0.32 to 23.85; 5 RCTs, 1000 participants, Analysis 4.2, Table 6).
Both events were psychiatric admissions due to depression and
suicidal thoughts; both study participants had previous psychiatric
histories. In one case, the participant’s psychiatrist did not think
the event was drug-related, and in the other “felt this individual’s
current depression was not drug related, unless it was aggravated
by inability to sleep”. Additionally, Steketee 1996 described one
withdrawal due to a “neuropsychiatric side effect” (disorientation
to time and place) but did not provide enough detail to meet our
definition of serious adverse event or effect.
Four cohort studies reported a total of 29 serious adverse effects
(attributed by users to the study drug) in 56,674 mefloquine users,
and 13 serious adverse effects in 22,583 chloroquine users. The
difference between groups was not statistically significant (RR
1.14, 95% CI 0.62 to 2.07; 6 cohort studies; 79,257 participants;
Analysis 4.2). Serious side effects in mefloquine users were psy-
chological (11 cases), dizziness (5), seizures (3), heart palpitations
(2), abdominal pain (1), blackout (2), visual disturbance (1), limb
numbness (1), yeast infection (1), and two which were not de-
scribed (Table 7). Those in chloroquine users were psychological
(4 cases), seizures (3), abdominal pain (1) and visual disturbance
(1).
Discontinuations of the study drug due to adverse effects
There was no differences between groups in the number of dis-
continuations due to adverse effects in the RCTs (RR 1.60, 95%
CI 0.61 to 4.18; 3 RCTs, 815 participants, Analysis 4.3) or cohort
studies in short-term international travellers (RR 0.99, 95% CI
0.78 to 1.26; 6 cohort studies, 55,397 participants, Analysis 4.3).
However, in the two cohort studies in longer-term occupational
travellers, mefloquine users were significantly more likely to stop
taking medication (RR 2.97, 95% CI 2.41 to 3.66; 2 cohort stud-
ies; 6085 participants; Analysis 4.3).
Prespecified adverse effects
The RCTs only reported adverse events (all symptoms without
assessing whether they might be related to the study drug). Our
primary analysis was therefore taken from the six cohort studies
reporting adverse effects.
Gastrointestinal symptoms
There were no consistent differences between groups for nausea
(RR1.23, 95%CI0.89 to 1.68; I² statistic = 78%, 6 cohort studies,
58,984 participants, Analysis 4.4), vomiting (RR 1.05, 95% CI
0.78 to 1.40; 5 cohort studies, 5577 participants, Analysis 4.5) or
abdominal pain (RR 0.99, 95% CI 0.80 to 1.22; 4 cohort studies,
5440 participants; Analysis 4.6). This was consistent with adverse
events reported by RCTs (Analysis 4.4; Analysis 4.5; Analysis 4.6)
Overall, mefloquine users were less likely to report diarrhoea but
this finding was from a single cohort study with over 90% of the
weight in the meta-analysis (RR 0.84, 95% CI 0.74 to 0.95; 5
cohort studies, 5577 participants; Analysis 4.7). No difference was
seen in the RCTs (Analysis 4.7).
Neurological symptoms
In the cohort studies, there was no substantial difference between
groups in the proportion of participants reporting headache (RR
0.84, 95% CI 0.53 to 1.34; 6 cohort studies, 56,998 participants,
Analysis 4.8), but mefloquine users reported more dizziness (RR
1.51, 95% CI 1.34 to 1.70; 5 cohort studies, 56,710 participants;
Analysis 4.9). The RCTs reporting adverse events did not demon-
strate a difference between groups (Analysis 4.8; Analysis 4.9).
Psychological symptoms
Across the cohort studies, mefloquine users were more likely to
report abnormal dreams (RR 1.21, 95% CI 1.10 to 1.33; 4 co-
hort studies, 2845 participants, Analysis 4.10), anxiety (RR 6.30,
95%CI 4.37 to 9.09; 3 cohort studies, 3408 participants, Analysis
4.12), depressed mood (RR 3.14, 95% CI 1.15 to 8.57; I² statistic
= 90%; 5 cohort studies, 58,855 participants, Analysis 4.13) and
abnormal thoughts or behaviour (RR 5.49, 95%CI 2.65 to 11.35;
4 cohort studies, 4831 participants, Analysis 4.14). Of these out-
comes only abnormal dreams was reported by RCTs and the result
was consistent with the cohort studies (Analysis 4.10). Insomnia
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was reported by five cohort studies (RR 1.81, 95% CI 0.73 to
4.51; 5 cohort studies, 56952 participants) and two RCTs (RR
1.19, 95% CI 0.76 to 1.84; 2 RCTs, 359 participants), and no
consistent differences were seen between groups (Analysis 4.11).
Other prespecified adverse symptoms
There were no consistent differences demonstrated in reported
pruritis between groups in cohort studies (RR 1.13, 95% CI 0.92
to 1.40; 2 cohort studies; 55,544 participants) or RCTs (RR 0.28,
95% CI 0.03 to 2.93; 2 RCTs, 413 participants; Analysis 4.15).
There were no differences in visual impairment in cohort studies
(RR 1.10, 95% CI 0.50 to 2.44; I² statistic = 90%, 5 cohort
studies, 58,847 participants), or in the single RCT (RR 0.14, 95%
CI 0.01 to 2.63; 210 participants, Analysis 4.16).
Prespecified adverse symptoms restricted to cohort studies in
short-term travellers
Analysis 4.18 presents the pre-specified adverse symptoms re-
stricted to the cohort studies in short-term travellers.
Other adverse outcomes
Other adverse effects reported by cohort studies were alopecia (hair
loss), asthenia, altered spatial perception, balance disorder, confu-
sion, decreased appetite, fatigue, hypoaesthesia, irritability, mouth
ulcers, paraesthesia, palpitation, photosensitization, restlessness,
slight illness, somnolence and yeast infection (Analysis 4.19). Of
note, single cohort studies found that mefloquine users were more
likely to report altered spatial perception (RR 3.16, 95% CI 1.55
to 6.45; 2032 participants), unsteadiness (RR 3.59, 95% CI 2.15
to 6.00; 2137 participants), alopecia (RR 1.69, 95% CI 1.27 to
2.25; 2137 participants), limbnumbness (RR 20.26, 95%CI 1.23
to 333.93; 2137 participants) and tingling (RR2.22, 95%CI 1.27
to 3.89; 2 cohort studies, 2778 participants).
Other adverse events reported by RCTs were abdominal disten-
sion, anger, disturbance in attention, irritability, loss of appetite,
malaise and altered mood (Analysis 4.20). No statistically signifi-
cant differences were noted.
Pregnancy-related outcomes
One quasi-randomized trial (Steketee 1996) was conducted in
pregnant Malawian women and reported no difference between
mefloquine and chloroquine for spontaneous abortions (RR 0.80,
95% CI 0.36 to 1.79; 2334 participants), still births (RR 1.01,
95% CI 0.67 to 1.52; 2334 participants) or congenital malfor-
mations (0 events in either study arm, 2334 participants, Analysis
4.21). Steketee 1996 sequentially allocated participants to each
drug regimen, and did not blind participants or study personnel.
Adherence
Three cohort studies in short-term travellers (Hill 2000; Laver
2001; Rietz 2002) compared the proportion of participants with
100% self-reported adherence and found no difference overall (RR
1.00, 95% CI 0.90 to 1.13; 3 cohort studies, 852 participants,
Analysis 4.22). Among participants in these studies, 84%ofmeflo-
quine users described themselves as adherent during travel (range
71% to 88%) compared to 82% of chloroquine users (range 82%
to 85%). In the two studies in longer-term occupational travellers,
self-reported adherence was higher in mefloquine users (RR 2.02,
95% CI 1.80 to 2.26; 2 cohort studies, 5777 participants).
One study (Stoney 2016) measured adherence in the post-travel
period and found no difference (RR 1.00, 95% CI 0.54 to 1.87;
46 participants, Analysis 4.22). However, rates of completion were
low in both groups (56% in mefloquine users and 54% in chloro-
quine users).
Subgroup analyses
Given the similarity in adverse effect profiles for mefloquine com-
pared to the two main alternatives (doxycycline and atovaquone-
proguanil), we combined findings from the two comparisons and
performed a series of subgroup analyses to explore the effects of
study design, duration of travel, and military versus non-military
participants.
Prespecified adverse effects
Study design
Only one RCT performed a blinded assessment of whether there
was a reasonable possibility that any reported symptoms could be
related to the study drug (Overbosch 2001). We compared this
with participants self-reporting of adverse effects in cohort stud-
ies. The findings were largely consistent across study designs with
mefloquine users experiencing higher rates of headache (Analysis
5.4), dizziness (Analysis 5.5), abnormal dreams (Analysis 5.6), in-
somnia (Analysis 5.7), anxiety (Analysis 5.8) and depressed mood
(Analysis 5.9). Although the relative risk of psychiatric side effects
was consistently slightly higher in cohort studies, in only one case
was the test for subgroup differences statistically significant (ab-
normal dreams: RCT: RR 2.04, 95% CI 1.37 to 3.04; 976 partic-
ipants, cohort studies: RR 7.30, 95% CI 2.51 to 21.18; 7 cohort
studies, 4543 participants, test for subgroup differences P = 0.03).
Duration of travel
The relative risk of all psychological adverse effects was higher with
longer-term travel than in short-term travel; insomnia (short-term
RR 3.09 versus longer-term RR 8.67), anxiety (short-term RR
3.26 versus longer-term RR 18.05), depressed mood (short-term
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RR 2.52 versus longer-term RR 12.59) and abnormal thoughts
and perceptions (short-termRR 1.29 versus longer-term RR 7.78)
(Table 14).However, in only one case was the test for subgroup dif-
ferences statistically significant (P range 0.02 to 0.40). This same
effect was not observed with gastrointestinal symptoms (nausea,
abdominal pain, diarrhoea) or neurological symptoms (headache,
dizziness).
Military versus non-military participants
There were no significant differences in the relative risk of adverse
effects between military and non-military participants (Table 15).
Very few cohort studies in military personnel reported on our
prespecified symptoms. In one of these inwhichmilitary personnel
who took mefloquine for 6 months or longer (Andersson 2008),
the rates of psychological side effects were significantly higher than
in short-term travellers, but not significantly different from other
trials in longer-term travellers.
Adherence
Study design
Across cohort studies, self-reported complete adherence was
slightly higher in participants who took mefloquine than in users
of other antimalarial agents (RR 1.16, 95% CI 1.03 to 1.30; 11
cohort studies, 12131 participants, Analysis 5.13). However, there
was no difference in self-reported completion of the treatment af-
ter return (RR 1.04, 95% CI 0.92 to 1.17; 4 cohort studies, 1221
participants, Analysis 5.14).
Duration of travel
Self-reported complete adherence was slightly higher in short-term
travellers who took mefloquine than users of other antimalarial
agents (RR 1.10, 95% CI 1.03 to 1.18; 7 cohort studies, 7241
participants). However, the same effect was not seen in longer-
term travellers (RR 1.20, 95% CI 0.88 to 1.62; 4 cohort studies,
4890 participants, test for subgroup differences P = 0.61, Table
14).
There was no overall difference in rates of completing the treat-
ment regimen after return in short-term travellers who tookmeflo-
quine than in those who received other antimalarial agents (RR
1.04, 95% CI 0.92 to 1.17; 4 cohort studies, 1221 participants).
No studies in longer-term travellers monitored adherence after re-
turn.
Military versus non-military participants
There were no differences in self-reported complete adherence
when comparing military versus non-military participants, either
during travel or after return (Table 15).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Mefloquine compared with doxycycline for preventing malaria in travellers
Population: Non-immune adults and children travelling to malaria-endemic sett ings
Intervention: Mef loquine 250 mg weekly
Comparison: Doxycycline 100 mg daily
Outcome data collection: Self -reported symptoms experienced whilst taking prophylaxis (adverse events)
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
Studies contributing to
effect estimate
(participants)
Additional studies con-
sidered in GRADE as-
sessment
(participants)
Certainty of the evi-
dence
(GRADE)
Doxycycline Mefloquine
Clinical malaria 1 per 100 1 per 100
(0 to 5)
RR 1.35
(0.35 to 5.19)
4 RCTs
(744)
- ⊕⊕©©
low1,2,3,4
Serious adverse ef-
fects
6 per 10005 9 per 1000
(1 to 61)
RR 1.53
(0.23 to 10.24)
3 cohort studies
(3722)
3 RCTs, 1 cohort study
(682; 3772)
⊕©©©
very low2,3,6,7
Discontinuations
due to adverse effects
2 per 100 2 per 100
(1 to 6)
RR 1.08
(0.41 to 2.87)
4 RCTs
(763)
10 cohort studies
(10,165)
⊕⊕©©
low1,3,7,8
Abnormal dreams 3 per 100 31 per 100
(11 to 87)
RR 10.49
(3.79 to 29.10)
4 cohort studies
(2588)
1 RCT, 1 cohort study
(123; 688)
⊕©©©
very low2,6,9,10
Insomnia 3 per 100 12 per 100
(4 to 43)
RR 4.14 (1.19 to 14.44) 4 cohort studies
(3212)
1 RCT, 2 cohort studies
(123; 355,627)
⊕©©©
very low6,9,10,11
Anxiety 1 per 100 18 per 100
(9 to 35)
RR 18.04
(9.32 to 34.93)
3 cohort studies
(2559)
2 cohort studies
(355,627)
⊕©©©
very low6,9,10,11
Depressed mood 1 per 100 11 per 100
(5 to 25)
RR 11.43
(5.21 to 25.07)
2 cohort studies
(2445)
3 cohort studies
(430,006)
⊕©©©
very low6,9,10,11
Abnormal thoughts or
perceptions
0 per 100 3 per 100
(0 to 24)
RR 6.60
(0.92 to 47.20)
2 cohort studies
(2445)
2 cohort studies
(376,024)
⊕©©©
very low6,9,10,113
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Nausea 8 per 100 3 per 100
(2 to 4)
RR 0.37
(0.30 to 0.45)
5 cohort studies
(2683)
1 RCT, 1 cohort study
(123; 668)
⊕©©©
very low3,6,10,11
Vomiting 5 per 100 1 per 100
(1 to 1)
RR 0.18
(0.12 to 0.27)
4 cohort studies
(5071)
1 RCT
(123)
⊕©©©
very low3,6,10,11
Abdominal pain 15 per 100 5 per 100
(1 to 16)
RR 0.30
(0.09 to 1.07)
3 cohort studies
(2536)
1 RCT, 1 cohort
(123; 668)
⊕©©©
very low6,7,9,11
Diarrhoea 5 per 100 1 per 100
(1 to 4)
RR 0.28
(0.11 to 0.73)
5 cohort studies
(5104)
2 RCTs; 1 cohort study
(376; 668)
⊕©©©
very low3,6,10,11
Dyspepsia 14 per 100 4 per 100
(1 to 10)
RR 0.26
(0.09 to 0.74)
5 cohort studies
(5104)
- ⊕©©©
low2,3,6,10
Headache 2 per 100 2 per 100
(1 to 6)
RR 1.21
(0.50 to 2.92)
5 cohort studies
(3320)
1 RCT, 1 cohort study
(123; 688)
⊕©©©
very low3,6,7,11
Dizziness 1 per 100 3 per 100
(1 to 14)
RR 3.49
(0.88 to 13.75)
5 cohort studies
(2633)
1 RCT, 2 cohort studies
(123; 355,627)
⊕©©©
very low3,6,7,11
Visual impairment 3 per 100 7 per 100
(4 to 12)
RR 2.37
(1.41 to 3.99)
2 cohort studies
(1875)
- ⊕©©©
very low2,6,7,9
Pruritis 3 per 100 2 per 100
(1 to 3)
RR 0.52
(0.30 to 0.91)
2 cohort studies
(1794)
1 cohort study
(688)
⊕©©©
very low6,9,10,11
Photosensitivity 19 per 100 2 per 100
(1 to 2)
RR 0.08
(0.05 to 0.11)
2 cohort studies
(1875)
1 cohort study
(688)
⊕©©©
very low2,6,9,10
Vaginal thrush 16 per 100 2 per 100
(1 to 3)
RR 0.10
(0.06 to 0.16)
1 cohort study
(1761)
1 cohort study
(354)
⊕©©©
very low2,6,9,10
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* The assumed risk is the median control group risk across cohort studies unless stated in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI). Where the control group risk was 0, we used a value of 0.5 to calculate
the corresponding risk in the intervent ion group. Where no RCTs including short-term travellers reported on our prespecif ied adverse outcomes, we included information f rom
cohort studies as our primary analysis
’Summary of f indings’ tables are usually lim ited to seven outcomes. For adverse ef fects this problematic, as there are many, and to include some and not others risks select ive
report ing. We have therefore included all prespecif ied outcomes in the table
GRADE Working Group grades of evidence
High certainty: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate certainty: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low certainty: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low certainty: we are very uncertain about the est imate.
1No serious risk of bias: none of the RCTs adequately described methods of random sequence generat ion or allocat ion
concealment, However, given that so few events occurred in these trials, it is unlikely to have introduced bias.
2No serious inconsistency: the direct ion of the ef fect is consistent across study designs, or there in consistency in the f inding
of no ef fect.
3No serious indirectness: the primary analysis included studies in short-term internat ional travellers, longer-term occupat ional
travellers, and military personnel.
4Downgraded by two levels for imprecision: only seven episodes of clinical malaria occurred in the four trials, and consequent ly,
the analysis was substant ially underpowered to exclude important dif f erences.
5For serious adverse outcomes we expressed the control group risk as the overall risk in the control group.
6No serious risk of bias: all cohort studies had methodological problems which could introduce confounding or bias. However,
as the GRADE approach automatically downgrades certainty by two levels for non-randomized studies, we did not downgrade
further.
7Downgraded by one level for serious imprecision: the 95% conf idence interval includes both clinically important ef fects and
no ef fect.
8Downgrade by one level for serious inconsistency: although there was no substant ial dif f erence between drugs in the cohort
studies, the proport ion of discont inuat ions was higher with both drugs: 14% for mef loquine and 9% for doxycycline.
9Downgraded by one level for indirectness: the primary analysis included only cohort studies in longer-term occupat ion
travellers (USA Peace Corps volunteers) and military personnel. Adverse ef fects in shorter-term internat ional travellers may
be lower.
10No serious imprecision: the ef fect was stat ist ically signif icant and the overall data (RCTs and cohort studies) were
adequately powered to detect this ef fect.
11Downgraded by one level for serious inconsistency: there was heterogeneity between trials in the direct ion of ef fect.
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D I S C U S S I O N
Summary of main results
Mefloquine efficacy
We included 12 randomized controlled trials (RCTs) that com-
pared mefloquine with placebo; none were performed in short-
term international travellers, and most populations had a degree
of immunity to malaria. The percentage of people developing a
malaria episode in the control arm varied from 1% to 82% (me-
dian 22%) and in themefloquine group 0% to 13% (median 1%).
In four other RCTs that directly compared mefloquine, ato-
vaquone-proguanil and doxycycline in non-immune, short-term
international travellers, only one clinical case of malaria occurred
(low certainty evidence).
Mefloquine safety versus currently used alternatives
Serious adverse effects have been reported for mefloquine and
doxycyline, but not for atovaquone-proguanil. Serious adverse ef-
fects are uncommon, and on statistical testing, no difference was
detected between mefloquine and atovaquone-proguanil (low-cer-
tainty evidence), or betweenmefloquine and doxycycline (very low-
certainty evidence).
Participants who received mefloquine were more likely to discon-
tinue their medication due to adverse effects than participants who
received atovaquone-proguanil (high-certainty evidence), but there
was no difference in comparisons with doxycycline (low-certainty
evidence).
We included one RCT and six cohort studies that reported our
prespecified adverse effects that compared mefloquine and ato-
vaquone-proguanil. In the RCT in short-term travellers, meflo-
quine users were more likely to report abnormal dreams (moderate-
certainty evidence), insomnia (moderate-certainty evidence), anxiety
(moderate-certainty evidence), and depressed mood during travel
(moderate-certainty evidence). The cohort studies in longer-term
travellers were consistent with these findings but most had larger
effect sizes. Mefloquine users were also more likely to report nau-
sea (high-certainty evidence) and dizziness (high-certainty evidence).
We included six cohort studies in longer-term occupational trav-
ellers that compared mefloquine with doxycycline which reported
our prespecified adverse effects. We also included one RCT in
military personnel and one cohort in short-term travellers that
reported adverse events. Mefloquine users were more likely to re-
port abnormal dreams (very low-certainty evidence), insomnia (very
low-certainty evidence), anxiety (very low-certainty evidence) and
depressed mood (very low-certainty evidence). The findings of the
single cohort study reporting adverse events in short-term interna-
tional travellers were consistent with these findings but the single
RCT in military personnel did not demonstrate a difference be-
tween groups in the frequency of abnormal dreams or insomnia.
Doxycycline users were more likely to report dyspepsia (very low-
certainty evidence), photosensitivity (very low-certainty evidence),
vomiting (very low-certainty evidence) and vaginal thrush (very low-
certainty evidence).
Comparisons with chloroquine showed a broadly consistent pat-
tern with these results.
Overall completeness and applicability of
evidence
Mefloquine has been licensed for prevention of malaria in trav-
ellers since the late 1980s, and as such, it is perhaps surprising
how few well-conducted RCTs were available. However, because
we were mainly interested in the adverse effect profiles of different
antimalarial agents, cohort studies (of which there are many) are
probably the most appropriate study design despite their inher-
ent limitations. Most RCTs excluded people with a previous his-
tory of mental health problems, precluding an analysis of whether
psychological side effects are more common in this group. Con-
versely, many of the cohort studies explicitly stated that the choice
of antimalarial agent was influenced by both past medical history
and personal preference.While this undoubtedly introduces some
confounding between study groups, we consider this confounding
to be appropriate and directly applicable to clinical practice. Simi-
larly, we would normally be cautious about interpreting unblinded
self-reported assessments of adverse effects and causality. In this
scenario, self-reported adverse effects provide useful and relevant
information for travellers, who would also be unblinded. It should
be noted that the reported adverse effects are largely self-reported
psychiatric symptoms and not formal psychiatric diagnoses.
Given the heterogeneity in trial design, mefloquine doses used,
and the study population, we were unable to derive a reliable es-
timate for mefloquine efficacy. However, the evidence suggests
that mefloquine is likely to be highly effective in reducing clini-
cal episodes of malaria. Comparative trials found no difference in
efficacy between mefloquine and atovaquone-proguanil or doxy-
cycline for preventing clinical malaria, but the number of malaria
episodes was very low, and consequently, much larger trials would
be needed to exclude clinically important differences. As a con-
sequence, knowledge about antimalarial resistance patterns in the
country of travel seems an appropriate approach to decision mak-
ing rather than further RCTs.
The choice between antimalarial agents will therefore depend on
how individual travellers rate the relative importance of specific
adverse effects, pill burden and cost. Prophylactic mefloquine is
widely acknowledged to cause abnormal dreams and psychological
adverse effects and we found consistent evidence for these effects
across comparisons with atovaquone-proguanil, doxycycline and
chloroquine (the most commonly used alternatives). Doxycycline
does not have the same risk of psychological adverse effects, but is
associated with increased risk of photosensitivity, dyspepsia, and
vaginal thrush, which some travellers will undoubtedly consider
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important. In line with this, participants who receivedmefloquine
were more likely to discontinue treatment due to adverse effects
than participants who received atovaquone-proguanil, but there
was no difference in comparisons with doxycycline.
We found estimating the risk of serious psychological adverse ef-
fects from the studies was not straightforward. Study authors used
the term ’serious’ loosely, and often did not provide us with the
detail required to determine whether these events met standard-
ized definitions. Furthermore, the estimates of the absolute risk
in both mefloquine and comparator arm varied considerably be-
tween trials, which may be related to data collection methods and
the cut-offs used rather than true differences among populations.
Overall, we did not identify large differences in the risk of serious
adverse effects among antimalarial agents; but what we did find
was that the nature of these serious adverse effects corresponded
with the known side effect profile of each drug.
The findings of our related systematic review which analysed
deaths and parasuicides associated with mefloquine prophylaxis,
and included case reports, had findings consistent with this
(Tickell-Painter 2017). This systematic review reports that there
were no suicides we could reliably attribute to mefloquine pro-
phylaxis, and one para-suicide with a possible causal association.
In the analysed reports, we identified two deaths with a probable
association that appeared to be idiosyncratic drug reactions; the
remaining eight deaths we categorised as “unlikely” to be related
to mefloquine, or “unclassifiable”.
We believe it is important that the large retrospective healthcare
record analyses did not demonstrate a clear quantitative association
between mefloquine use and formal mental health disorders. This
may reflect the inadequacy of the study methods to detect this
outcome, but may also reflect the transient nature of the mood
disturbance, with resolution once mefloquine is discontinued. We
were unable to comment on the severity or durationof the reported
adverse effects based on the available data.
The data on mefloquine at a prophylactic dose during pregnancy
were limited (2 RCTs; no comparative cohort studies). Both RCTs
included semi-immune populations who did not travel.
Mefloquine has an advantage as the only malaria prophylaxis with
a once weekly regimen. Many have cited this as a mechanism to
improve adherence, which is notoriously low in all users of anti-
malarial prophylaxis. However, the evidence base for this assertion
is weak, with almost all data originating from cohort studies which
reported a variety ofmeasures of self-reported complete adherence.
We were unable to perform some prespecified subgroup analyses
including children versus adults, female versus male travellers and
pregnant versus non-pregnant women. Thismeant wewere unable
to test whether women were more likely to experience adverse
effects from mefloquine use (which has been widely reported in
the literature).
We appreciate that the distinction between adverse events (all
events regardless of relationship to the study drug) and adverse
effects (events attributed by study authors or participants to the
study drug) can seem arbitrary and cause confusion. However,
we consulted extensively with methodologists who advised that
both outcomes are useful to decision makers, and there is no over-
all gold standard. For example, reporting only the adverse effects
(for example, hospitalizations, psychiatric side effects) thought to
be attributed to the drug regimen can introduce selective bias by
the study authors. For controversial or pharmaceutical company-
funded studies this can distort the outcomes. By comparing all
events across both groups any difference in the relative risk can be
compared without the potential for selective bias. However, this
does have its own limitations, such as if the two groups were not
comparable at baseline or if the sample size is not big enough to
exclude differences due to chance. We therefore chose to include
both options (events and effects) to give readers and decision mak-
ers the complete picture.
Quality of the evidence
In the ’Summary of findings’ tables we present what we consider
to be the best estimate of effect for each outcome, within each
comparison. Where possible we chose the estimate from RCTs
reporting adverse effects, but where this was not available we used
estimates from cohort studies.However, whenmaking judgements
about the certainty of evidence we considered all the evidence
available, as well as the consistency of the effect across different
population groups and study designs.
For the comparison ofmefloquine with atovaquone-proguanil, the
best estimates of effect came from a single, well-conducted RCT
in short-term travellers, recording participant-reported adverse ef-
fects. The findings of this study were supported by seven cohort
studies in long-term occupational travellers and military person-
nel. We considered the evidence of increased risk of abnormal
dreams and insomnia to be high certainty because the effects were
consistent across all population groups. However, we downgraded
the effect estimate on anxiety and depressed mood for inconsis-
tency tomoderate certainty because there was substantial variation
in the effect size across populations, with much larger effects in
long-term travellers and military personnel.
For the comparisonofmefloquinewith doxycycline, the only avail-
able RCT was very small, and reported adverse events rather than
adverse effects. Consequently, we considered the effect estimates
from cohort studies to be more reliable. Evidence from cohort
studies was automatically downgraded to low based on the inher-
ent bias in the study design. We further downgraded almost all
estimates of effect for indirectness, because most data were from
long-term travellers and military personnel, and may therefore
over estimate the effect in short-term travel. The evidence is there-
fore considered to be very low-certainty with little confidence in
the size of the effect. It is important to note however, that the
pattern of adverse effects with mefloquine in these cohort stud-
ies is entirely consistent with the pattern seen in comparisons of
mefloquine with atovaquone-proguanil and chloroquine.
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Potential biases in the review process
During the course of this review we made changes to the protocol.
Two changes weremade to shorten the overall length of the review:
• we excluded comparisons of mefloquine with primaquine
and tafenoquine because these are planned for assessment in
another Cochrane Review (Rodrigo 2016);
• we excluded single-arm cohort studies because there were
sufficient data from comparative studies to reach reasonable
conclusions. These studies have been analysed for the very rare
outcomes of death or attempted suicide in another systematic
review (Tickell-Painter 2017).
We do not think these decisions biased the review.
Agreements and disagreements with other
studies or reviews
Several recently published reviews regarding the safety of meflo-
quine have been narrative, and included little or no description
of methods applied and a lack of clearly defined and prespecified
outcomes (McCarthy 2015; Nevin 2015; Schlagenhauf 2010).
McCarthy 2015 and Nevin 2015 discuss the policy implications
of mefloquine use by the military which was beyond the scope of
this Cochrane Review.
Schlagenhauf 2010 highlighted several areas in which mefloquine
prophylaxis may be considered advantageous (during pregnancy
and while breastfeeding, in long-term travellers, travellers who are
visiting friends and relatives and families with small children). The
main disagreement with our review was in regard to safety in long-
term travellers, in whom the review authors refer to mefloquine
as “a good option if well tolerated”. This is based on a narrative
analysis of a single cohort study which comparedmefloquine users
with users of chloroquine-proguanil, which was not included in
this review (Lobel 1993).
Our review added data from several additional studies evaluating
longer-term use (Andersson 2008; Cunningham 2014; Korhonen
2007; Landman 2015), andwe found some observational evidence
that risk of adverse effects was higher than with short-term travel.
Our findings are broadly consistent with the previous version of
this Cochrane Review, which was withdrawn (Jacquerioz 2015).
Jacquerioz 2015 found higher rates of neuropsychiatric adverse
events in mefloquine users compared with users of both ato-
vaquone-proguanil and doxycycline. We expanded on this find-
ing by providing estimated risks for specific neurological and psy-
chiatric symptoms, and by including additional data from cohort
studies. Jacquerioz 2015 included a brief analysis of case reports of
deaths associated with mefloquine in theDiscussion. We excluded
this analysis from this update, but this aspect has been addressed
in a separate review of single-arm cohort studies and case reports
(Tickell-Painter 2017).
Two recent reviews included evaluations of mefloquine efficacy
and safety during pregnancy. González 2014 concluded there were
no indications that mefloquine use during pregnancy carries an
increased risk for the foetus. González 2014 included additional
studies to those we included in this Cochrane Review, includ-
ing mefloquine when used at treatment dose, or as intermittent
presumptive treatment in pregnancy. Muanda 2015 also included
mefloquine when used as intermittent presumptive treatment in
pregnancy. Muanda 2015 reported findings from two trials in
which the number of adverse events (Briand 2009), and num-
ber of serious adverse events (González 2014a) was higher in par-
ticipants who received mefloquine as intermittent presumptive
treatment in pregnancy than in those who received sulphadoxine-
pyrimethamine.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The absolute risk of malaria during short-term travel appears to be
very lowwith all three established antimalarial agents (mefloquine,
doxycycline and atovaquone-proguanil).
The choice of antimalarial agent will therefore depend on how
individual travellers rate the relative importance of specific adverse
effects, pill burden and cost. Some will prefer mefloquine for its
once-weekly regimen, but this should be balanced against the in-
creased frequency of abnormal dreams, anxiety, insomnia, and de-
pressed mood during travel.
Implications for research
Given the low absolute risk of malaria in travellers, very large
trials would be necessary to exclude clinically important differ-
ences among antimalarial agents. As a consequence, knowledge
about antimalarial resistance patterns in the country of travel seems
an appropriate approach to decision making rather than further
RCTs.
Although a large number of RCTs evaluating mefloquine pro-
phylaxis have been performed, very few could be included in our
analyses. Many RCTs chose to report proxy measures of psychi-
atric outcomes, such as Profile of Mood States questionnaires and
Environmental Symptoms Questionnaires, which are difficult for
clinicians and participants to interpret. Furthermore, many stud-
ies grouped symptoms together when reporting outcomes. ’Neu-
ropsychiatric’ or ’neuropsychologic’ were commonly used terms,
although the symptoms included varied from headaches to psy-
chosis, making them of limited value in clinical decision making.
Even thoughwe foundmoderate- and high-certainty evidence that
mefloquine use is associated with a range of psychological adverse
effects, further RCTs could increase confidence in the size of the
effect. The relative risk of psychological side effects was higher with
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long-term use of mefloquine, although this finding was only sta-
tistically significant in one comparison. An alternative explanation
is the possibility of an interaction betweenmefloquine and level of
psychological stress given the occupation of participants surveyed
(Foreign and Commonwealth Office workers, Peace Corps vol-
unteers and military personnel). Further research should examine
these potential interactions.
Furthermore, well-designed trials could test hypotheses regarding
male versus female users, whethermefloquine users with a previous
history of mental health problems are more likely to experience
psychological adverse effects, and the severity or duration of the
reported adverse effects.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Albright 2002
Methods Design: retrospective cohort study.
Study dates: November 1997 to January 2000
Malaria transmission pattern and local antimalarial drug resistance: various destinations, not specified
Adverse event monitoring: one off telephone interview with parents whose children had previously been prescribed
antimalarial prophylaxis
Participants Number enrolled: 177 fit inclusion criteria and interviewed, 190 contacted
Inclusion criteria: children aged ≤ 13 years who visited the travel clinic at the Children’s Memorial Hospital in
Chicago within the study dates. Subjects who were not on other medications
Exclusion criteria: “...data were only included if the child was living with the interviewed parent while taking the
antimalarial”. “Unwillingness to participate in the study and language barriers”
Factors influencing drug allocation: “children... instructed to take mefloquine or chloroquine for malaria prophylaxis”
Country of recruitment: USA.
Country of malaria exposure: various; Africa 58%, Central or South America 21%, India 12% or Eastern Asia 9%
Duration of exposure to malaria: various, not specified.
Type of participants: travellers
Interventions 1. Mefloquine*
2. Chloroquine*
*dosing regimen not specified
Outcomes 1. Adverse effects; any, nausea, vomiting, diarrhoea, headache, insomnia, abnormal dreams
2. Serious adverse effects
3. Discontinuations of study drug due to adverse effects
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex and destination of travel were recorded, but were
not reported across prophylactic regimens
2. Selection of participants into the study: low
Non-response rate 1.6%
3. Measurement of interventions: moderate
The prescription was provided by a travel clinic, but par-
ticipants were asked to recall if they discontinued their
medication 2.8 to 28 months after visiting
4. Departures from intended interventions: serious
Information was collected up to 2 years after taking the
drug. No information was captured on switches
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Albright 2002 (Continued)
5. Missing data: low
All information was collected at one time point, there
were no losses to follow-up
6. Measurement of outcomes: serious
The outcome measure was subjective, participants and
personnel were not blinded
7. Selection of the reported results: low
All outcomes included in the introduction were reported
in the results
8. Other: low
“The authors had no financial or other conflicts of interest
to disclose”
Andersson 2008
Methods Design: prospective cohort study
Study dates: March 2004 to November 2006
Malaria transmission pattern and local antimalarial drug resistance: malaria attack rate of 44% with P falciparum in
another similar study at the time
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 690 soldiers sent questionnaire, 609 respondents
Inclusion criteria: all Swedish soldiers deployed to Liberia within the study dates
Exclusion criteria: none stated.
Factors influencing drug allocation: “...mefloquine was prescribed to almost all soldiers in the first two contingents and
to about two-thirds in the last three contingents. The remaining soldiers were recommended atovaquone/ proguanil.
The latter group consisted mainly of those with body weight < 70 kg and those who had already experienced adverse
events with mefloquine. No other drug regimes were used”
Country of recruitment: Sweden
Country of malaria exposure: Liberia
Duration of exposure to malaria: 6 months
Type of participants: military
Interventions 1. Mefloquine*
2. Atovaquone-proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; any, nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness, abnormal dreams night-
mares, insomnia sleep disturbance, depression
2. Serious adverse events; serious
3. Adverse events; other (concentration difficulties, mouth ulcers, fever, muscle pain)
4. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
5. Clinical cases of malaria
6. Overall satisfaction with the drug
7. Whether they would take the drug again
8. Measures of adherence to the drug regimen (data provided on aggregate)
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Andersson 2008 (Continued)
Notes Funding sources: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Information on potential confounders is not provided
across prophylactic groups
2. Selection of participants into the study: moderate
609/690 (88%) response rate
3. Measurement of interventions: low
All participants were issued with the study drug.
4. Departures from intended interventions: low
Switches were recorded and reported
5. Missing data: serious
Outcomes were reported from 3 of 5 cohorts. No infor-
mation was provided for 2 remaining cohorts
6. Measurement of outcomes: serious
The outcome measure was subjective, participants and
personnel were not blinded
7. Selection of the reported results: low
All outcomes prespecified in the introduction were re-
ported.
8. Other: moderate
Study sponsor notmentioned, but 2 study authorsworked
for GlaxoSmithKline
Arthur 1990
Methods Design: RCT
Study dates: June to August 1988
Malaria transmission pattern and local drug resistance: local chloroquine resistance
Adverse event monitoring: blood taken at induction and at days 57 and 70 of treatment.
Interviews regarding side effects when sera taken. Stool sample at induction, at end of
exercise and at any time participants sought medical care
Participants Number enrolled: 270
Inclusion criteria: soldiers (aged 18 to 40 years), awaiting deployment to Thailand
Exclusion criteria: previous history of gastrointestinal illness
Country of recruitment: USA
Country of malaria exposure: Thailand
Duration of exposure to malaria: 5 weeks
Type of participants: soldiers, non-immune
Interventions 1. Mefloquine (1 x 250 mg tablet) once weekly, starting 1 week before travel and con-
tinuing throughout the period of deployment.*
2. Doxycycline (1 capsule containing doxycycline hyclate 100 mg) once daily, starting 1
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Arthur 1990 (Continued)
week before travel and continuing throughout the period of deployment*
Co-interventions: Both groups given doxycycline 100mg daily for suppression of P
falciparum and primaquine 45mg weekly for elimination of liver hypnozoites for 6 weeks
on return to the USA
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Serious adverse event
3. Adverse events; diarrhoea
4. Discontinuation of study drug due to adverse effects
5. Measures of adherence to the drug regimen
Outcomes assessed not included in the review:
6. Laboratory tests; enteric pathogens
7. Adverse events; nausea, vomiting, headache, dizziness (data provided on aggregate)
Notes Funding sources: Pfizer Inc supplied active and placebo doxycycline; Hoffman-La Roche
Inc supplied active and placebo mefloquine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Volunteers were assigned from a computer
generated random number list to receive
daily doxycycline or weekly mefloquine”
Allocation concealment (selection bias) Unclear risk Comment: Unclear how the tablets were la-
belled and whether allocation concealment
occurred
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “Soldiers receiving mefloquine also re-
ceived identical appearing doxycycline
placebo capsules daily, and those receiving
daily doxycycline received weekly meflo-
quine placebo tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no explanation of how this was achieved for
researchers and outcome assessors
Incomplete outcome data (attrition bias);
efficacy
High risk “Of the 270 volunteers whowere deployed,
253 were correctly taking the assigned
study malaria prophylaxis on arrival in Ko-
rat”
Comment: Reasons for not taking medica-
tion were not reported. Method of detec-
tion for malaria, frequency and duration of
follow-up were not reported
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Arthur 1990 (Continued)
Incomplete outcome data (attrition bias);
safety
Low risk Comment: 17 participants (6%) were not
“correctly taking the prophylaxis on arrival
to Korat” and were excluded from the anal-
ysis. Data were not stratified by time point
Selective reporting (reporting bias); efficacy Low risk “None of the soldiers developed malaria”
Selective reporting (reporting bias); safety Unclear risk Comment: data for general side effects (e.
g. headaches) were presented for the study
population but not for each group
Other bias Unclear risk Comment: study sponsor not mentioned
Belderok 2013
Methods Design: prospective cohort study
Study dates: October 2006 to October 2007
Malaria transmission pattern and local antimalarial drug resistance: various destinations, not specified
Adverse event monitoring: not performed
Participants Number enrolled: 945
Inclusion criteria: People aged ≥ 18 years were eligible if they were planning to travel for 1 to 13 weeks to one or
more malaria-endemic countries
Exclusion criteria: None stated
Factors influencing drug allocation: “Dutch national guidelines for travelers’ health advice”
Country of recruitment: Netherlands
Regions of malaria exposure: various; Asia 48%, Africa 30% and Latin America 22%
Duration of exposure to malaria: various; 49% ≤ 13 days, 35% 14 to 28 days and 9% ≥ 29 days
Type of participants: travellers
Interventions 1. Mefloquine: taken 3 weeks prior to arrival, during trip and for 4 weeks after return, dose and frequency of dose
not specified
2. Atovaquone-proguanil: 1 day prior to arrival, during trip and for 7 days after return, dose and frequency of dose
not specified
3. Proguanil: On day of arrival, during trip and for 4 weeks after return, dose and frequency of dose not specified
Outcomes Included in the review:
1. Measures of adherence to the drug regime
Outcomes assessed not included in the review:
2. Clinical cases of malaria
3. Predictors of adherence to malaria prophylaxis
4. Use of antimosquito preventive measures
Notes Funding sources: The Amsterdam Academic Collaborative Center on Public Health is financially supported by the
Netherlands Organization for Health Research and Development (ZonMw; grant number 7115 0001, http://www.
zonmw.nl/nl/)
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Belderok 2013 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Length of stay, travel destination, age and sex were not
reported across groups
2. Selection of participants into the study: moderate
Non-response rates were not reported
3. Measurement of interventions: low
Participants made daily diary entries during travel
4. Departures from intended interventions: low
Participants made daily diary entries during travel
5. Missing data: low
Information was collected at one time point
6. Measurement of outcomes: moderate
Outcome assessors were not blinded, methods were com-
parable across groups
7. Selection of the reported results: low
Outcomes were reported for 610/620 participants
8. Other: low
Government funding
Boudreau 1991
Methods Design: RCT
Study dates: July 1983 to March 1984
Malaria transmission pattern and local antimalarial drug resistance: “in this area we
believe the efficacy of chloroquine prophylaxis at the time of the study was negligible”
Adverse event monitoring: “at each 2 week visit… history of symptoms over the pre-
vious fortnight was obtained. Patients were asked about fever, chills, headache, nausea,
vomiting, diarrhoea, anorexia, rash, myalgia and dysuria or abnormally coloured urine”.
Laboratory studies were performed at baseline and at 6 weeks in participants who had
not developed malaria
Participants Number enrolled: 501
Inclusion criteria: “Only males 21 years of age or over were accepted”
Exclusion criteria: “All participants were required to have a negative malaria smear (after
examination of 200 fields on thick smear) on entry into the study”. “...the use of other
antimalarials or antibiotics”
Country of recruitment: Cambodia
Country of malaria exposure: Cambodia
Duration of exposure to malaria: ongoing in semi immune population, 14 week study
period
Type of participants: Thai gem miners with a degree of immunity
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Boudreau 1991 (Continued)
Interventions Included in review comparisons:
1. Mefloquine (2 x 250 mg tablet) fortnightly for 14 weeks*
2. Chloroquine (1 x 300 mg tablet) weekly*
Not included in review comparisons:
3. Fansidar (2 x 500 mg sufadoxine and 25 mg pyrimethamine) fortnightly and chloro-
quine (1 x 300 mg tablet) weekly*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Adverse events; other (myalgias, rash)
Outcomes assessed not included in the review:
3. Laboratory tests; haematocrit, complete blood count, transaminase levels, total and
direct bilirubin, alkaline phosphatase, blood urea nitrogen
4. Adverse events; headache, anorexia, fever, chills, nausea, diarrhoea or vomiting (data
provided on aggregate)
Notes Funding sources: Support for this study was from the USA Army Medical Research and
Development Command
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assignment… is a 4:3:2 ratio”
Comment: method of sequence generation
not reported
Allocation concealment (selection bias) Unclear risk Comment: no details of allocation conceal-
ment were reported
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk “Every two weeks in a double blind fashion
one of the investigators administered five
tablets to each subject”
Comment: not
mentioned whether placebo tablets had an
identical appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no mention of how this was achieved for
researchers and outcome assessors
Incomplete outcome data (attrition bias);
efficacy
Unclear risk “Only 194 patients completed the study
until positivity or end of the 14 weeks ob-
servation period”. “Therefore of the origi-
nal 501 enrollees, 63 were discarded due to
positivity at week 0 and 104 were discarded
since they never returned beyond week 0”
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Boudreau 1991 (Continued)
Comment: Losses to follow-up during the
study was not reported across groups
Incomplete outcome data (attrition bias);
safety
Unclear risk “Only 194 patients completed the study
until positivity or end of the 14 weeks ob-
servation period...Any subject missing one
appointment was excluded from the study
though each subject’s records up to the
time of exclusion were entered into the sur-
vival analysis...After 3weeks post treatment
and a negative malaria smear some patients
wishing to continue were reentered under
a new study number and were assigned a
double blind randomized treatment”
Selective reporting (reporting bias); efficacy Unclear risk Comment: number of people contracting
malaria in each group and person-weeks in
the study were reported
Selective reporting (reporting bias); safety Unclear risk “There were no significant differences in
frequency of complaints among the study
groups for headache, anorexia, fever, chills,
nausea, diarrhoea, or vomiting”
Comment: Data for specific adverse events
not reported. Methods section states par-
ticipants were asked about dysuria and ab-
normally coloured urine, but this was not
reported in the results
Other bias Low risk Support for this study was from the USA
Army Medical Research and Development
Command
Boudreau 1993
Methods Design: RCT
Study dates: not mentioned
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse event monitoring: “At each visit, the subject answered two computerised ques-
tionnaires (the Environmental Symptoms Questionnaire and the Profile of Mood States)
[and] a physician interview was performed”
Participants Number enrolled: 359
Inclusion criteria: “males at least 18 years old, met military weight standards, were
available for weekly administration of medications and monitoring during the 13 week
study period, and were willing to give informed consent”
Exclusion criteria: “treatment with beta-blocking agents or other cardiotropic drugs,
underlying chronic disease, history of cardiac arrhythmia, medical history of psychiatric
or neurological problems within the last 5 years, anaemia or impaired hepatic or renal
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Boudreau 1993 (Continued)
function. Women were excluded from participation in the study due to the risk of
teratogenicity involved when the drug is used in early pregnancy”
Country of recruitment: USA
Country of malaria exposure: not applicable
Duration of exposure to malaria: not applicable
Type of participants: military, non-travellers
Interventions 1. Mefloquine (1 x 250 mg tablet), larium 228 mg base (F Hoffman La Roche) weekly
for 11 weeks
2. Mefloquine (1 x 250 mg tablet), larium 228 mg base (F Hoffman La Roche) weekly
for 11 weeks, with loading dose of 1 x 250 mg tablet daily for 3 days during the first
week
3. Chloroquine (1 x 300 mg tablet), 300 mg base (F Hoffman La Roche) weekly for 11
weeks
Outcomes Included in the review:
1. Adverse events; nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness,
abnormal dreams, insomnia
2. Adverse events; other (irritability, poor concentration, anger, moodiness, abdominal
distension, anorexia, environmental symptoms questionnaire (ESQ), sleep assessment,
Profile of Mood States questionnaire)
Outcomes assessed not included in the review:
3. Laboratory tests: haemoglobin, haematocrit, platelets, white blood cell count, alanine
aminotransferase, blood urea nitrogen and creatinine
4. Analysis of the dizziness index on the ESQ
5. Spontaneous comments on the ESQ (data provided on aggregate)
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...military personnel were assigned to drug
groups in a ratio of approximately 3:3:
1…stratification was performed by major
subordinate command so that equal pro-
portions of each study group would be rep-
resented in each MSC”
Comment: not mentioned how the ran-
domisation code was generated
Allocation concealment (selection bias) Unclear risk Comment:method allocation concealment
not mentioned
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “...the ‘double dummy’ method of blind-
ing was employed with either chloroquine
or mefloquine placebos administered with
active drug… In addition, during the first
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Boudreau 1993 (Continued)
week of the study, on days two and three,
a single mefloquine tablet or placebo was
administered. Both drugs and placebos had
an extremely bitter taste... identical placebo
tablets”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no description provided of how this was
achieved for researchers and outcome asses-
sors
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Unclear risk Comment: 15 medical withdrawals are
reported within the study. It is unclear
whether these are the only losses to fol-
low up which occurred, or whether they
occurred in the mefloquine loading dose
group or weekly administration group
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety High risk ‘table 5 outlines the percent of the group
with symptoms only when significance was
demonstrated’ ‘selected haematology and
biochemistry tests were performed… no
significant differences were noted among
the three drugs when comparing the mean
values’
Comment: data is not fully reported for
‘other symptoms’; only significant results
are reported for the ESQ, anddata for spon-
taneous comments on the ESQ are not re-
ported; data is not fully reported for the
POMS
Other bias Unclear risk Comment: study sponsor not mentioned,
but the lead author is attributed to ‘Phar-
maceutical Systems Incorporated’
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Bunnag 1992
Methods Design: RCT
Study dates: July 1987 to January 1988
Malaria transmission pattern and local antimalarial drug resistance: “a malaria endemic
area”. Reports chloroquine, sulfadoxine-pyrimethamine and quinine resistance within
Thailand at the time of the study
Adverse event monitoring: “volunteers asked about adverse events at each visit (weeks 4,
9, 14, 19, 24, 28)...startingweek 14, volunteers reporting adverse events were interviewed
by members of the hospital team; most of them were also seen by principal investigators”
Participants Number enrolled: 605 randomized, 3 excluded because of baseline parasitaemia
Inclusion criteria: “...healthy male volunteers, aged between 16 and 60, living in this
area, were recruited”
Exclusion criteria: “persons with a known history of allergy against sulphonamides, with
an evidence illness of fever, or which a positive blood film (with or without symptomatic
malaria) were excluded”
Country of recruitment: Thailand
Country of malaria exposure: Thailand
Duration of exposure to malaria: trial duration 24 weeks
Type of participants: Thai residents in a malaria-endemic area (presumed semi-immune)
Interventions Included in the review:
1.Mefloquine (1 tablet containing 125 mgmefloquine) once weekly, double dose during
first 4 weeks*
2. Chloroquine (1 tablet containing 300 mg chloroquine) once weekly*
3. Placebo
Not included in the review:
4. Fansifem (1 tablet containing 125 mg mefloquine, 250 mg sulfadoxine, 12.5 mg
pyrimethamine) once weekly, double dose during first 2 weeks*
5. Fansidar (1 tablet containing500mg sulfadoxine, 25mgpyrimethamine) onceweekly*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Adverse events; any
3. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
4. Laboratory tests; haematocrit, white blood cell count and neutrophil count
Notes Funding sources: “The project was jointly organized and conducted by theMalaria Divi-
sion, Department of Communicable Disease, Ministry of Public Health; the Hoffman-
La Roche company, Basel, Switzerland; and The Faculty of Tropical Medicines, Mahidol
University, Bangkok”
Risk of bias
Bias Authors’ judgement Support for judgement
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Bunnag 1992 (Continued)
Random sequence generation (selection
bias)
Unclear risk “Eligible volunteers were randomly as-
signed to treatment groups”
Comment: method of random sequence
generation not reported
Allocation concealment (selection bias) Unclear risk “The tablets were identical in appearance;
theywere packed in numbered blister packs
and were in addition labelled weeks 1-24.
.. the coded test drugs for weeks 1-4 were
given to every subject”
Comment: no mention of concealed
opaque envelopes or central allocation
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “A randomised double blind trial…the
tablets were identical in appearance; they
were packed in numbered blister packs”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no explanation provided of how this was
achieved for researchers and outcome asses-
sors
Incomplete outcome data (attrition bias);
efficacy
Unclear risk “Of the 605 subjects originally ran-
domised, 3 were excluded because of base-
line parasitaemia... Although some of the
volunteers left the study for personal rea-
sons (moving away from the area)”
Comment: numbers lost to follow up have
not been reported
Incomplete outcome data (attrition bias);
safety
Unclear risk “94% (116/123) in the mefloquine group
and 98% (119/121) in the placebo group
were included for adverse event reporting”
“Although some of the volunteers left the
study for personal reasons (moving away
from the area)”
Comment: numbers lost to follow-up were
not reported
Selective reporting (reporting bias); efficacy Low risk Comment: Malaria cases were fully re-
ported
Selective reporting (reporting bias); safety High risk Comment: Data were collected but not re-
ported for adherence to drug regimen.Data
were provided on aggregate across all time
points. The number of adverse events were
reported but not types or severity
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Bunnag 1992 (Continued)
Other bias High risk “The projectwas jointly organized and con-
ducted by the Malaria Division, Depart-
ment of Communicable Disease, Ministry
of Public Health; the Hoffman-La Roche
company, Basel, Switzerland; and The Fac-
ulty of Tropical Medicines, Mahidol Uni-
versity, Bangkok”
Corominas 1997
Methods Design: retrospective cohort study
Study dates: June 1992 to July 1994
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 1511 questionnaires distributed, 1054 respondents
Inclusion criteria: travellers who visited areas with a risk of malaria infection who were travelling on short trips < 6
weeks duration
Exclusion criteria: none mentioned
Factors influencing drug allocation: The fact of participating in this study did not change at all the typical prophylaxis
when performing, which followed the usual criteria (Google Translate = “El hecho de participar en este estudio no
cambio en absoluto el tipico de profilaxis al realizar, que siguio los criterios habituales”
Country of recruitment: Spain
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine (1 x 250 mg tablet) weekly, starting 1 week prior to travel, during the trip and 4 weeks following
return from the malaria-endemic area
2. Chloroquine (5 mg/kg) weekly, starting 1 week prior to travel, during the trip and 4 weeks following return from
the malaria-endemic area
Outcomes assessed not included in the review:
3. Chloroquine and proguanil (chloroquine base 5 mg/kg, once weekly plus proguanil 100 mg daily, if weight < 55
kg and 200 mg daily if weight > 55 kg) starting 1 week prior to travel, during the trip and 4 weeks following return
from the malaria-endemic area
Outcomes Included in the review:
1. Adverse effects; any, vertigo, visual impairment, nausea, vomiting, abdominal pain, diarrhoea, insomnia, anxiety,
depression, pruritis
2. Adverse effects; other (irritability)
3. Discontinuations of study drugs due to adverse effects
Outcomes assessed not included in the review:
4. Mean number of symptoms reported per traveller
5. Adverse effects; other, incidence < 1% (amnesia, tremor, paraesthesia, seizures, hyper-reflexia, drowsiness, asthenia,
nervousness, difficulty concentrating, mouth ulcers, acne, cardiac rhythm disturbance)
Notes Funding sources: Not mentioned
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Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex was reported across groups. No other confounders
were reported
2. Selection of participants into the study: serious
1054/1511 (70%) response rate
3. Measurement of interventions: low
The antimalarial prescription was provided by a travel
clinic which also performed the study
4. Departures from intended interventions: moderate
Discontinuations were reported across groups. It is un-
clear if information regarding switches was obtained
5. Missing data: low
All participants were included in the analysis. All infor-
mation was included at one time point
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective, partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
The analysis of the relationship of symptoms by weight
was reported only for mefloquine
8. Other: no information
No informationwas provided regarding the study sponsor
Cunningham 2014
Methods Design: cross-sectional cohort study
Study dates: questionnaire emailed July 2012, reminder emails were circulated at 8 and 12 weeks
Malaria transmission pattern and local antimalarial drug resistance: various destinations, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 579 questionnaires emailed, 327 responses
Inclusion criteria: all Foreign and Commonwealth Office staff posted to a malaria-endemic area
Exclusion criteria: none stated
Factors influencing drug allocation: “prophylaxis based on the Advisory Committee on Malaria Prevention in UK
Travellers (ACMP) guidelines”
Country of recruitment: various, not specified
Country of malaria exposure: various, not specified
Duration of exposure to malaria: 0 to 3 months N = 16 (4.9%), 4 to 6 months N = 26 (8.0%), 7 to 12 months N =
46 (14.1%), 13 to 36 months N = 75 (22.9%), > 36 months N = 167 (51.1%)
Type of participants: UK Foreign and Commonwealth Office staff
Interventions 1. Mefloquine*
2. Atovaquone-proguanil*
3. Doxycycline*
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4. Chloroquine*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; psychiatric disorders (abnormal dreams)
2. Adverse effects; other (skin sensitivity, indigestion, other psychological)
Outcomes assessed not included in the review:
3. Clinical cases of malaria
4. Background knowledge of malaria
5. Attitudes regarding malaria prophylaxis
6. Use of personal protective measures
7. Impact of pregnancy on malaria prevention
8. Measures of adherence to drug regimen (data provided on aggregate)
Notes Funding sources: not mentioned
Communications with study authors: the study authors provided us with access to the full original data set. Thedata
set differed from findings in the published version of the paper, and we were unable to determine the cause for
differences. The included figures were from the full data set
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
No information on confounders was provided across pro-
phylaxis groups
2. Selection of participants into the study: serious
Response rate for the survey was 56.5%
3. Measurement of interventions: moderate
Participants were asked to self-report which medications
they were prescribed. Compliance rate was 25%
4. Departures from intended interventions: serious
No questions were included in the questionnaire regard-
ing switches between chemoprophylactic regimens
5. Missing data: low
All participants were included in the analysis
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
The entire questionnaire was provided in full, all out-
comes included were reported
8. Other: no information
Study sponsor not mentioned
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Davis 1996
Methods Design: RCT
Study dates: not mentioned
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse event monitoring: daily self-reported diary. Three medical check ups for labo-
ratory and other tests
Participants Number enrolled: 106 randomized, 95 completed all study procedures
Inclusion criteria: “healthy adult staff and students at teaching hospitals in Perth,Western
Australia”
Exclusion criteria: “Those with a past history of psychiatric conditions, or neurological,
cardiac, hepatic or renal disease were excluded, as were pregnant or breastfeeding females
and thosewith a knownallergy to, or takingmedication known to interactwith quinolone
drugs. None of the subjects had taken mefloquine in the 3 months before the study”
Country of recruitment: Australia
Country of malaria exposure: not applicable
Duration of follow up: 7 weeks
Type of participants: non-immune non-travellers
Interventions 1. Mefloquine (1 x 250 mg tablet), with placebo dose followed 1 week later by 250 mg
mefloquine weekly, active treatment duration 4 weeks
2. Placebo, 1 tablet weekly, duration 5 weeks
Outcomes Included in the review:
1. Measure of adherence to the drug regimen
2. Adverse events: other outcome measures (symbol digit modalities test, digit span
forwards and backwards test, ECG, hearing loss at 6kHz)
Outcomes assessed not included in the review:
3. Laboratory tests: serum glucose, insulin, ionized calcium, phosphate, magnesium and
albumin concentrations
4. Adverse events: headache, lethargy, abdominal pain, diarrhoea, cough, nausea; study
reports events occurring in the first week (after both groups had received placebo) and
the relative risk of symptoms worsening over time
Notes Funding sources: “We thank… F. Hoffman La Roche & Co. for financial support”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “...allocation… was by a random number
code generated by independent Fremantle
Hospital Pharmacy staff ”
Allocation concealment (selection bias) Low risk “...who kept the code strictly confidential
until the last volunteer had completed the
protocol”
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Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “Tablets were prepared in individually
numbered but otherwise unlabelled con-
tainers... identical placebo tablets…”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Allocation of active or placebo formula-
tion was by a random number code gen-
erated by independent Freemantle hospital
staff who kept the code strictly confiden-
tial”
Comment: not mentioned whether out-
comes assessors were blinded
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Low risk “Of 106 randomised volunteers, 95 (90%)
completed all study procedures... eight sub-
jects withdrew after initial assessment and
three after the second. Follow-up of these
individuals revealed no toxicity in those al-
located mefloquine”
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety High risk Comment: not all symptoms were re-
ported, only those occurring in > 10%
of participants in both groups. Absolute
numbers of participants experiencing each
symptom after mefloquine/placebo com-
menced not provided, only relative risk of
symptoms worsening over time
Other bias High risk “We thank… F. Hoffman La Roche & Co.
for financial support”
Eick-Cost 2017
Methods Design: Retrospective cohort study
Study dates: 1 January 2008 to 30 June 2013
Malaria transmission pattern and local antimalarial drug resistance: Various, not specified
Adverse eventmonitoring:Data collected retrospectively from theDefenseMedical Surveillance System, the Pharmacy
Data Transaction Service and the Theater Medical Data Store
Participants Number enrolled: 367,840
Inclusion criteria: Active component service members who filled a prescription for mefloquine, doxycycline or
atovaquone-proguanil
Exclusion criteria: Doxycycline and atovaquone-proguanil prescriptions were excluded if the service member previ-
ously or concurrently received mefloquine. Doxycycline prescriptions were restricted to 100 mg, once daily, tabular
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form, minimum 30 day prescription
Factors influencing drug allocation: Not specified
Country of recruitment: USA
Country of malaria exposure: Various, not specified
Duration of exposure to malaria: Various, not specified
Type of participants: Military
Interventions 1. Mefloquine (250 mg weekly)
2. Atovaquone- proguanil*
3. Doxycycline (100 mg, tabular form, daily dose, 30 day minimum prescription)
*dosing regimen not specified
Outcomes 1. Adverse events (anxiety disorders, depressive disorders, psychoses, insomnia, vertigo)
2. Adverse events; other (adjustment disorders, post-traumatic stress disorder, tinnitus, suicidal ideation, convulsions,
hallucinations, paranoia, confusion)
Notes Funding source: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Identified confounders were measured and not balanced
across groups
2. Selection of participants into the study: low
Start of intervention and start of follow-up coincided
for most participants. Retrospective medical records were
used, therefore there were no non-responders
3. Measurement of interventions: moderate
Information regarding drug prescriptions were obtained
from a medical database, without any verification that
users took the prescription
4. Departures from intended interventions: serious
Discontinuations and switches between prophylactic
regimes were not recorded in the database
5. Missing data: low
All records in the research database were included in the
analysis
6. Measurement of outcomes: moderate
Participants and outcome assessors (physicians) were not
blinded. However, information was collected anony-
mously and on aggregate. Participants were unaware of
their participation at the time of seeking healthcare
7. Selection of the reported results: low
Outcome data were reported for all outcomes prespecified
for analysis
8. Other: no information
No informationwas available regarding the study sponsor.
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Goodyer 2011
Methods Design: prospective cohort study
Study dates: December 2004 to April 2006
Malaria transmission pattern and local antimalarial drug resistance: various destinations, not specified
Adverse event monitoring: “a post travel questionnaire… approximately 1 week after they were due to complete their
course of medication”
Participants Number enrolled: 252 recruited, 185 completed pre- and post-travel questionnaires
Inclusion criteria: “...to be eligible, travelers had to be at least 18 years of age and to have been prescribed or supplied.
.. an antimalarial medication as a result of planned travel for a duration of 28 days or less.”
Exclusion criteria: “travelers participating in other prospective clinical research or observational studies, pregnant
travelers or travelers planning to get pregnant during the study were excluded”
Factors influencing drug allocation: “Treatment choice was solely at the discretion of the traveler and practitioner”
Country of recruitment: UK
Country of malaria exposure: various, not reported
Duration of exposure to malaria: various, median 14 days (interquartile range 9 to 20)
Type of participants: travellers
Interventions 1. Mefloquine*
2. Atovaquone-proguanil*
3. Doxycycline*
*dosing regimen not specified
Outcomes Included in the review:
1. Any adverse effects
2. Measures of adherence to the drug regimen
Outcomes assessed not included in the review:
3. Relative importance of factors in choice of antimalarial drugs, for both healthcare professionals and travellers
Notes Funding sources: “The study was commissioned and paid for by GlaxoSmithKline”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
“There were statistically significant differences in mean
age”
Several other confounderswere not reported across groups
2. Selection of participants into the study: moderate
No information is provided regarding people who did not
wish to participate
3. Measurement of interventions: low
The antimalarial prescription was provided by a travel
clinic which also performed the study
4. Departures from intended interventions: moderate
No information was captured regarding switches between
interventions of interest
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5. Missing data: serious
185/252 participants completed the pre- and post-travel
questionnaire. Interim loss to follow up 27%
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
The number of reported side effects was reported, but not
the types or severity
8. Other: serious
FundedbyGlaxoSmithKline; the role of the study sponsor
was not made clear
Hale 2003
Methods Design: RCT
Study dates: not mentioned
Malaria transmission pattern and local antimalarial drug resistance: “the 20-week cumu-
lative incidence of reinfection by P. falciparum to be nearly 100%”. No mention of local
drug resistance patterns
Adverse eventmonitoring: “...during the prophylaxis and follow-up phases, health work-
ers visited the subjects 3 times weekly. Subjects with physical complaints were examined
by a study physician the next day or on an emergent basis, as needed. Hematologic
analysis was done on days 4 and 10 after starting the loading dose phase and during
weeks 4, 8, 12, and 15. Biochemical analysis was done during weeks 4, 8, 12, and 15”
Participants Number enrolled: 530 enrolled and completed radical cure regimen. 509 participants
took at least 1 dose of the weekly study drug or placebo and comprised the full intention-
to-treat data set
Inclusion criteria: “Inclusion criteria included the following: age of 18-60 years (men)
or 50-60 years (women); lack of significant systemic illness as determined by history,
physical examination, and clinical laboratory test results (including negative results of
a urine pregnancy test for women); and absence of seizures or other neuropsychiatric
illness (past or present)”
Exclusion criteria: “The high rate of pregnancy and breast-feeding in women aged 18-
49 years precluded their enrollment... G6PD deficiency accounted for 179 of 338 ex-
clusions”
Country of recruitment: Ghana
Country of malaria exposure: Ghana
Duration of exposure to malaria: trial duration 12 weeks
Type of participants: Ghanain residents, semi-immune
Interventions Included in the review:
1. Mefloquine (1 x 250 mg tablet, salt), weekly, with supervised 3 day loading dose*
2. Placebo, with supervised 3 day loading dose*
Not included in the review:
3. Tafenoquine (1 x 25 mg tablet, base), weekly, with supervised 3 day loading dose*
4. Tafenoquine (1 x 50 mg tablet, base), weekly, with supervised 3 day loading dose*
5. Tafenoquine (1 x 100 mg tablet, base), weekly, with supervised 3 day loading dose*
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6. Tafenoquine (1 x 200 mg tablet, base), weekly, with supervised 3 day loading dose*
*matched placebo for each treatment arm
Outcomes Included in the review:
1.Clinical cases of malaria
2. Adverse events; any, abdominal pain, diarrhoea, headache
3. Adverse events; other (gastritis, back pain, myalgia, polyarthralgia/arthralgia, respira-
tory tract infection, sore throat, rash)
4. Discontinuation of study drug due to adverse effects
Outcomes assessed not included in the review:
5. Laboratory tests; haematological and biochemical analyses
Notes Funding sources: USA Army Medical Materiel Development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The randomization code was generated in
blocks of 11 numbers”
Comment: not mentioned how random-
ization code was produced
Allocation concealment (selection bias) Unclear risk “Code numbers were assigned according to
the chronological order of appearance of
the subjects at screening. Study drugs were
prepackaged and prelabeled with a unique
study number according to the randomiza-
tion code”
Comment: no mention of opaque sealed
envelopes
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk “A ‘double-dummy’ design allowed dou-
ble-blind administration of tafenoquine
and mefloquine active drugs and their cor-
responding placebos”
“A placebo (tafenoquine placebo, Glaxo-
Smith-Kline; mefloquine placebo, Hoff-
mann-La Roche) served as the negative
comparator”
Comment: does not report that the tablets
were identical
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “All slides positive for the presence of
malaria causing parasites, and an equal
number of randomly selected slides with
negative results were reevaluated by a sec-
ond (blinded) microscopist.”
Comment: no other mention of outcome
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assessors being blinded and does not report
that the researchers were blinded
Incomplete outcome data (attrition bias);
efficacy
Low risk “Data analysis for efficacy used 2 data sets:
the ’full, intent-to-treat’ data set (n=509),
comprising all subjects who took at least 1
dose of the weekly study drug or placebo,
and the ’per-protocol’ data set (n=428),
comprising those subjects who strictly ful-
filled the protocol criteria”
Incomplete outcome data (attrition bias);
safety
Low risk Comment: The safety and tolerability anal-
yses included data for all participants who
received at least 1 dose of the study drug or
placebo (N = 513)
Selective reporting (reporting bias); efficacy Low risk Comment: total number of participants
with positive blood smear result at any time
during prophylaxis was reported. Clinical
cases of malaria were reported
Selective reporting (reporting bias); safety High risk “There were 9 serious adverse events in the
study... No serious adverse events were con-
sidered by study physicians to be related to
the study drug, and no deaths occurred”
Comment: Data for serious adverse events
were not attributed to the drug regimen.
No information was provided on how
causality was assessed
Other bias High risk Acknowledgement of “Philip Pickford and
Rachel Moate (GlaxoSmithKline), for sta-
tistical and editorial advisement”
Hill 2000
Methods Design: retrospective cohort study
Study dates: June 1989 to May 1991
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire. “Any reported illness was followed up by telephone
interview about the nature of the illness, during which time more complete information was obtained using stan-
dardized questions”
Participants Number enrolled: 869 participants enrolled, 822 completed follow-up
Inclusion criteria: all individuals attending the International Traveler’sMedical Service at theUniversity ofConnecticut
Health Center and traveling for ≤ 90 days
Exclusion criteria: none mentioned
Factors influencing drug allocation: “prior to travel each person was given extensive counseling and written material
on the prevention of malaria and traveler’s diarrhea. They were given prescriptions for prophylactic antimalarials”
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Country of recruitment: USA
Country of malaria exposure: Various: Indian subcontinent 21%, central and east Africa 20%, South America 16%,
Southeast Asia 14%, West Africa 10%, Central America and Mexico 10%, North Africa 65, East Asia 6%, Carribean
5%, Southern Africa 5%, Middle East 3%
Duration of exposure to malaria: median 19 days (up to 90 days)
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Chloroquine*
Not included in the review:
2. Chloroquine-proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Any adverse effects
2. Discontinuations of study drug due to adverse effects
3. Measures of adherence to the drug regime
Outcomes assessed not included in the review:
4. Clinical cases of malaria
5. Adverse events (provided for entire cohort, not by type of malaria prophylaxis)
6. Adverse effects; other (all gastrointestinal disorders, all nervous system disorders - no comparative data provided)
7. Illness during and following travel
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex, destination and duration of travel weremeasured
but not reported across groups
2. Selection of participants into the study: moderate
Non-response rate was not reported.
3. Measurement of interventions: low
The antimalarial prescription was provided by a travel
clinic which also performed the study
4. Departures from intended interventions: moderate
Information was provided on discontinuations, but no
information was captured on switches between interven-
tions
5. Missing data: low
Information on adverse effects was available for all partic-
ipants who ever filled the prescription for the study drug
(571/612, 93%)
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
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Hill 2000 (Continued)
pants and personnel were not blinded
7. Selection of the reported results: moderate
It is unclear which questions were included in the ques-
tionnaire. Information was provided on aggregate
8. Other: no information
No information provided on study sponsor
Hoebe 1997
Methods Design: retrospective cohort study
Study dates: January to June 1995
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: one-off telephone interview between 4 and 20 weeks post-travell
Participants Number enrolled: 454 eligible travellers, 300 successfully contacted and agreed to participate
Inclusion criteria: subjectswho visited the travel vaccination service of the regional public health institute inMaastricht
if they had returned from their journey to tropical countries between 4 and 20 weeks previously. The group of non-
users was formed by people who travelled either to tropical countries without malaria risk or to cities in malarious
areas, and by travellers who were prescribed an antimalarial drug but did not commence use
Exclusion criteria: participants who had a serious adverse reaction to mefloquine in the first week
Country of recruitment: Netherlands
Region of malaria exposure: various; Asia, Africa, South America
Duration of exposure to malaria: mean ~3 weeks (range 1 to 9 weeks)
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine (1 x 250 mg tablet) weekly, taken 1 week prior to leaving, during travel and 4 weeks after departure
2. Non-users of antimalarials
Not included in the review:
3. Proguanil (1 x 100 mg tablet) twice daily, taken during travel and 4 weeks after departure
Outcomes 1. Adverse events; any, nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness, abnormal dreams, insomnia,
anxiety, depression, pruritis
2. Adverse events; other (palpitations, severity of symptoms, time point of symptoms in relation to drug taking)
3. Discontinuations of study drug due to adverse effects
4. Measure of adherence to the drug regimen
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Travel destination varies significantly between users of
mefloquine and non-users of prophylaxis (6.7% America
mefloquine versus 29.0% non-users)
2. Selection of participants into the study: low
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13/454 (2.8%) of travellers successfully contacted refused
to participate
3. Measurement of interventions: low
Prescription was provided by a travel clinic which also
performed the study, and discontinuations were reported
4. Departures from intended interventions: moderate
No information regarding switches been interventions of
interest was reported
5. Missing data: moderate
“If somebody discontinued drug use within a certain pe-
riod, symptoms that occurred in the followingperiodwere
not counted”
Comment: Mefloquine has a half life of 17 to 21 days
6. Measurement of outcomes: moderate
“The participants were specifically asked about symptoms
instead of adverse effects...To hide our focus on symptoms
as adverse effects of the drugs, participants were informed
that the aim of the study was to investigate symptoms
during travelling.We structured the questionnaire so that
the interviewers asked about symptoms first and drug use
last, in order to blind them to the drug used when ad-
dressing symptoms”
7. Selection of the reported results: low
All prespecified outcomes were reported.
8. Other: no information
Funding source was not mentioned
Jute 2007
Methods Design: cross-sectional cohort study
Study dates: 2003
Malaria transmission pattern and local antimalarial drug resistance: during the dry season (considered a low risk
malaria season). Local chloroquine/proguanil resistance
Adverse event monitoring: Patient self-reported questionnaire
Participants Number enrolled: 90 questionnaires distributed, 68 responses
Inclusion criteria: “all expatriate employees at the mine”
Exclusion criteria: non mentioned
Country of recruitment: Mali
Country of malaria exposure: Mali
Duration of exposure to malaria: various, not specified
Type of participants: long-term expatriates
Interventions Included in the review:
1. Mefloquine
2. Doxycycline
3. Atovaquone-proguanil
Not included in the review:
4. Chloroquine-proguanil
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Outcomes 1. Adverse effects; any
Notes Study sponsor not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex was recorded but not reported across chemoprophy-
laxis groups. Duration of travel was not reported. Desti-
nation of travel was set by the study design
2. Selection of participants into the study: serious
68/90 response rate (76%)
3. Measurement of interventions: no information
It was unclear whether information on participants
chemoprophylaxis was taken from medical records or pa-
tient self-reporting
4. Departures from intended interventions: moderate
No information regarding switches between interventions
of interest were reported. Discontinuations were reported
5. Missing data: low
All information was collected at one time point
6. Measurement of outcomes: serious
The outcome measure was subjective. There was no men-
tion of participants or outcome assessors being blinded
7. Selection of the reported results: no information
No informationwas provided regardingwhich topicswere
included within the questionnaire
8. Other: no information
Funding source was not mentioned
Kato 2013
Methods Design: cross-sectional cohort study
Study dates: June 2009 to June 2011
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 1119 eligible travellers, 316 enrolled
Inclusion criteria: ”travelers who visitedHibiyaClinic, and requested antimalarial drugs formalaria chemoprophylaxis
from June 2009 to June 2011“
Exclusion criteria: none mentioned
Factors influencing drug allocation: ”The choice of anti-malarial drug was supported by sufficient explanation about
the advantages and disadvantages (efficacy, method, duration, side effect, cost and approval) of each drug“
Country of recruitment: Japan
Region of malaria exposure: various (n): East Africa 76, West Africa 63, South Africa 50, Southeast Asia 36, Central
76Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Kato 2013 (Continued)
Africa 36, South Pacific 21, South America 16, India 8, North Africa 5, Central America 1
Duration of exposure to malaria: mean 20.0 ± 9.6 days in the atovaquone-proguanil group and 59.0 ± 15.9 days in
the mefloquine group
Type of participants: travellers
Interventions 1. Mefloquine (1 x 250 mg tablet, Mephaquin; Mepha) weekly, starting 1 week prior to arrival, during the stay, and
continuing for 4 weeks after leaving the endemic area
2. Atovaquone-proguanil (1 tablet containing 250 mg atovaquone and 100 mg proguanil, Malarone; GlaxoSmithK-
line) daily, starting 2 days prior to arrival, during the stay, and for 1 week after leaving the endemic area
Outcomes 1. Adverse effects (any vertigo/dizziness, nausea, abdominal pain, diarrhoea, headache, insomnia, depression, any
cardiovascular, any gastrointestinal, any psychoneurotic, allergic reaction)
2. Discontinuations of study drug due to adverse effects
Notes Funding sources: not mentioned
Communicationswith the study authors: the study authors provided uswith disaggregated study data for the following
outcomes: vertigo/dizziness, nausea, abdominal pain, diarrhoea, headache, insomnia, depression. Because we did not
get receive the full disaggregated data set, we also retained this study in the analysis of groups of symptoms
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
PTravellers in the mefloquine group were significantly
younger than travellers in the A/P group (p=0.01)”
2. Selection of participants into the study: serious
“316 of 1119 travelers (28.2 %) were enrolled”
3. Measurement of interventions: low
The prescription has been provided by travel clinic which
also performed the study and discontinuations have been
reported
4. Departures from intended interventions: moderate
No information was available regarding switches between
interventions of interest
5. Missing data: low
One participant in the mefloquine group appears to be
missing from the adverse events analysis. No reason was
given
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
Study authors provided us with disaggregated study data
for individual outcomes
8. Other: serious
“The authors wish to acknowledge that Makoto Ono and
Tomoko Kawamura of GlaxoSmithKline are highly ap-
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preciated for conducting DataManagement and Statistics
Analysis of this study”
Korhonen 2007
Methods Design: prospective cohort study
Study dates: 1 August 2005 to 31 July 2006.
Malaria transmission pattern and local antimalarial drug resistance: various, chloroquine resistance specified by
country of destination
Adverse eventmonitoring: “Peace Corps medical staff in these countries were provided surveys for distribution during
mandatory in-country volunteer training sessions”
Participants Number enrolled: 2701 (6216 Peace Corps volunteers during the time period)
Inclusion criteria: “all Peace Corps countries with malaria risk”
Exclusion criteria: none mentioned
Factors influencing drug allocation: “Volunteers are provided chemoprophylaxis (either chloroquine, mefloquine,
doxycycline, or atovaquone/proguanil)... medical officers can provide alternative chemoprophylaxis regimens for
volunteers when adverse events or other factors require the cessation of any medication”
Country of recruitment: various
Country of malaria exposure: various
Duration of exposure to malaria: “6 months or longer”
Type of participants: Peace Corps volunteers
Interventions Included in the review:
1. Mefloquine*
2. Chloroquine*
3. Doxycycline*
4. Atovaquone-proguanil*
*dosing regimen not specified
Outcomes 1. Adverse effects; any (mild, moderate, severe, sought medical advice), nausea, vomiting, abdominal pain, diarrhoea,
headache, dizziness, abnormal dreams, insomnia, depression, anxiety, visual disturbance
2. Adverse effects; other (unsteadiness, hair loss, weakness, itchy skin, photosensitivity, yeast infection)
3. Serious adverse effects
4. Discontinuations of study drug due to adverse effects
Notes Funding sources: “CK and PJ are employed by the Peace Corps, which has a significant number of volunteers taking
anti-malarial medications. There were no other financial disclosures”
Communications with study authors:
The study authors provided us with access to the disaggregated study data for the specific symptoms mentioned
above. The questionnaire in the paper allowed participants to describe side effects from the antimalarial they were
currently taking, and any regimen they had previously used. For non-serious side effects, in line with the original
paper, we only included side effects for the subject’s original regimen. Where subjects had previously taken more
than one regimen, we only include side effects for whichever regimen to which the participant attributed the greater
number of side effects; this affected 70/2701 participants. This analysis resulted in a decrease in the effect size for
side effects attributed to mefloquine. For serious side effects (hospitalizations) and discontinuations we included all
participants entries for all regimens. In addition, our denominator differed from the original paper because we did
not exclude participants who had been in post for fewer than six months
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Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
“The questionnaire did not collect demographic informa-
tion because of privacy concerns”
Comment: destination has been reported, but not by type
of antimalarial chemoprophylaxis. Duration was set by
the study design
2. Selection of participants into the study: serious
“A total of 2701 surveys were received yielding a response
rate of 43%”
3. Measurement of interventions: moderate
Participants were asked to self-report which prophylaxis
they were currently taking and had previously taken
4. Departures from intended interventions: moderate
Switches between interventions of interest were reported.
Approximately 1/3 of study participants had switched
prophylactic regimens
5. Missing data: low
We were able to include all participants in the study anal-
ysis because we had access to the original data set
6. Measurement of outcomes: serious
“If respondents identified any adverse event, the survey
instructed them to self-report which drug they believed
caused the adverse event”
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
We were able to include all results in the analysis because
we had access to the original data set
8. Other: low
No evidence of pharmaceutical company funding
Kuhner 2005
Methods Design: prospective cohort study
Study dates: 2000 to 2003
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: retrospective patient self-reporting questionnaire
Participants Number enrolled: 495 enrolled, 284 response rate
Inclusion criteria: unclear. Users of the travel medicine department of the lower Saxony regional health office in
Hanover, Germany
Exclusion criteria: None mentioned
Factors influencing drug allocation: “the prescriptions of medications followed individual consultation”
Country of recruitment: Germany
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Country of malaria exposure: various, not specified
Duration of exposure to drug: atovaquone-proguanil mean 2.6 weeks, mefloquine mean 7 weeks
Type of participants: short-term travellers
Interventions Included in the review:
1. Mefloquine*
2. Atovaquone-proguanil*
Not included in the review:
3. Chloroquine-proguanil*
4. Chloroquine (not included in the study analysis)
*dosing regimen not specified
Outcomes 1. Adverse effects; any, nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness, abnormal dreams, insomnia,
pruritis
2. Adverse effects; other (concentration difficulties, palpitations, circulation disorders, rash)
3. Discontinuations of study drug due to adverse effects
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex, age and duration of travel were reported but not
balanced across groups
2. Selection of participants into the study: serious
284/495 (59.8%) response rate
3. Measurement of interventions: low
The prescription was provided by a travel clinic which
also performed the study; switches and discontinuations
were recorded and reported
4. Departures from intended interventions: moderate
No information was provided regarding switches between
prophylactic regimens
5. Missing data: low
All information was collected at one time point
6. Measurement of outcomes: serious
The outcome measure was subjective. There was no men-
tion of outcome assessors being blinded
7. Selection of the reported results: moderate
Insufficient information was provided regarding the ques-
tionnaire to know whether all outcomes were reported
8. Other: no information
Study sponsor not mentioned
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Methods Design: prospective cohort study
Study dates: 19 August to 30 September 2013
Malaria transmission pattern and local antimalarial drug resistance: various
Adverse event monitoring: participant self-reported questionnaire
Participants Number enrolled: 3207 emails sent, 1184 unique, valid responses received
Inclusion criteria: “(volunteers in) Peace Corps offices of all 23 countries with active posts in the Africa region to all
active Volunteers in-country”
Exclusion criteria: Volunteers serving in Ethiopia, Kenya, Tanzania, Namibia, Botswana, South Africa
Region of recruitment: African region except Ethiopia, Kenya, Tanzania, Namibia, Botswana, South Africa
Factors influencing drug allocation: “all prophylaxis options (mefloquine, doxycycline, atovaquone-proguanil) [are]
equally available... They are instructed to individualize their choice of agent based on area-specific recommendations,
drug contraindications and precautions, drug tolerance, and dosing schedule”
Country of malaria exposure: various: Togo (3.7%), Sierra Leone (6.3%), Uganda (7.8%), Liberia (5.6%), Malawi
(2.0%), Cameroon (11.4%), Benin (10.2%), Burkina Faso (1.9%), Zambia (6.0%), Mozambique (4.5%), Ghana
(10.8%), Rwanda (5.4%), Gambia (4.4%), Madagascar (11.1%), Swaziland (2.3%)
Duration of exposure to malaria: various, not specified
Type of participants: Peace Corps volunteers
Interventions 1. Mefloquine*
2. Atovaquone-proguanil*
3. Doxycycline*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any, vertigo, headache, abnormal dreams, insomnia, anxiety, depression, psychosis
2. Adverse effects; other (any neuropsychiatric disorder, any gastrointestinal disorder, any skin or subcutaneous
disorder, limb numbness, tinnitus, ’constitutional’, genitourinary)
3. Measures of adherence to the drug regimen
Outcomes assessed not included in the review:
4. Reasons for non-adherence (not ascribed to prophylactic regimen, provided on aggregate),
5. Malaria knowledge
6. Health behaviours
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
The age, sex and BMI of included participants was not
recorded. The destination and duration of travel was not
reported by prophylactic regimen
2. Selection of participants into the study: serious
1184/3248 (36%) response rate
3. Measurement of interventions: moderate
Travellerswere asked to self-reportwhich prophylaxis they
were taking at various time points during treatment
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4. Departures from intended interventions: serious
“Two hundred seventy-six (35%) respondents reported
having changed prophylaxis at some point during their
service”
Comment: this was not provided by prophylactic regimen
5. Missing data: low
703/781 (90%) participants reported data for adherence;
733/781 (94%) participants reported data for adverse
events. Data were only included from the 2015 version
of the publication
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
All outcomes prespecified in the methods section were
reported
8. Other: no information
Study sponsor not mentioned
Laver 2001
Methods Design: cross-sectional cohort study
Study dates: February 2000
Malaria transmission pattern and local antimalarial drug resistance: “during February 2000, which was a peak period
of malaria transmission in Zimbabwe”
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 660
Inclusion criteria: Passengers in Harare and Victoria Falls international airport during February 2000
Exclusion criteria: “Children under the age of 18 were excluded on the assumption that parents probably influence
their health seeking behavior... Excluded, were travelers from the African continent and VIP travelers who exited
through special departure lounges”
Factors influencing drug allocation: no infromation provided
Country of recruitment: Zimbabwe
Country of malaria exposure: Zimbabwe
Duration of exposure to malaria: various: 1 week or less, N = 317; 8 days to 2 weeks, N = 144; 15 days to 4 weeks,
N = 90; > 4 weeks, N = 41
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Doxycycline*
3. Chloroquine*
Not included in the review:
4. Proguanil*
5. Dapsone and pyrimethamine*
6. Chloroquine and proguanil*
*dosing regimen not specified
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Outcomes Included in the review:
1. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
2. Sources of pre-travel health advice
3. Knowledge about malaria transmission
4. Knowledge about malaria prevention
5. Threat and risk perception
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex (P < 0.008), education (P < 0.022), previous episodes
of malaria (P < 0.001) and access to pre-travel advice (P
< 0.001) were all significantly associated with reduced
compliance at the significance value set by the study.None
of these factors were adjusted for in the analysis
2. Selection of participants into the study: moderate
“The nonresponse rate was about 10% (n = 65), with the
main reason being the short transit time”
3. Measurement of interventions: low
Participants were asked to self-report which prophylactic
regimen they were taking while they were still taking it
4. Departures from intended interventions: moderate
No information was provided regarding switches between
prophylactic regimens
5. Missing data: low
Adherence information was not available for 4/595 par-
ticipants
6. Measurement of outcomes: serious
The outcome measure was based on participant self-re-
porting; participants and personnel were not blinded
7. Selection of the reported results: moderate
There was insufficient information provided to know
what questions were asked regarding adherence
8. Other: low
“The authors had no financial or other conflicts of interest
to disclose”
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Methods Design: retrospective cohort study
Study dates: 1 January 2003 to 31 December 2004
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: “An anonymous survey in a post-travel situation”
Participants Number enrolled: 1176 agreed to participate, 1237 approached
Inclusion criteria: “travellers who had already completed their journey for which they had undergone immunization
prophylaxis and who had returned to complete their vaccination schedule”
Exclusion criteria: none mentioned
Factors influencing drug allocation: “offered health advice following the World Health Organization guidelines for
international travel”
Country of recruitment: Italy
Regions of malaria exposure: 97 countries: 39 states in Africa, 25 in Asia, 16 in North and Central America, 8 in
South America, 6 in Europe and 3 in Oceania
Duration of exposure to malaria: 1 to 7 days, 8.9%; 8 to 14 days, 30.1%; 15 to 21 days, 34.6%; 22 to 30 days, 16.
8%; > 30 days, 8.9%; not available 0.7%
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Atovaquone-proguanil*
3. Chloroquine*
Not included in the review:
4.Chloroquine-proguanil*
5. Proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any, visual impairment (blurred vision), nausea, vomiting, abdominal pain, diarrhoea, headache,
dizziness, abnormal dreams (nightmares), insomnia, anxiety (anxiety disorder), depression, psychosis (hallucinations)
2. Adverse effects; other (slight illness, tiredness, restlessness, drowsiness, palpitations, weakness, photosensitization,
mental confusion, rash)
Outcomes assessed not included in the review:
3. Adverse effects; other, incidence < 1% (liver pain, aerophagy, rise in transaminase levels, gastrointestinal disturbance,
epistaxis, fever)
4. Compliance with vaccinations
5. Side effects from vaccinations
6. Occurrence of health problems and unforeseen events during travel in the countries visited
7. Attention to avoiding potentially risky food and drink
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Demographic information was collected, but provided on
aggregate for the entire cohort
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2. Selection of participants into the study: low
1176 of 1237 (95.1%) response rate
3. Measurement of interventions: serious
Participants were asked to self-report which prophylactic
regimen they had used, up to over 12 months since trav-
elling
4. Departures from intended interventions: serious
No switches were reported, and this information was not
sought in the questionnaire
5. Missing data: low
642/646 (99%) participants were included in the analysis
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
The questionnaire was provided in full, and all outcomes
were reported
8. Other: no information
No informationwas provided regarding the study sponsor
Lobel 2001
Methods Design: cross-sectional cohort study
Study dates: 13 July to 9 August 1997
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 6633 respondents, 5626 met inclusion criteria
Inclusion criteria: “travelers departing Nairobi, or Mombasa, Kenya, from July 13 to August 9, 1997, on flights to
Europe, including London, Paris, Frankfurt, Amsterdam, and Rome”
Exclusion criteria: residents of African countries, individuals who had remained in Africa for more than 1 year,
individuals who visited only non malarious areas, including Nairobi and Lesotho
Factors influencing drug allocation: no information available
Region of recruitment: Nairobi or Mombasa, Kenya
Region of malaria exposure: Nairobi or Mombasa, Kenya
Duration of exposure to malaria: < 5 weeks
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Doxycycline*
3. Chloroquine*
Not included in the review:
4. Chloroquine-proguanil*
5. Proguanil*
*dosing regimen not specified
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Outcomes Included in the review:
1. Adverse effects; any,
2. Serious adverse outcomes
3. Adverse effects; other (neuropsychologic, gastrointestinal, respiratory)
4. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
5. Pre-travel medical advice
6. Compliance with antimosquito measures
7. Self-treatment of presumed malaria
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
The number of travellers and country of origin was re-
ported, but was not adjusted for in the analysis. Sex, age
and duration of stay were reported on aggregate
2. Selection of participants into the study: serious
Response rate 6633/15,487 (43%)
3. Measurement of interventions: low
Participants were asked to provide information regarding
their prophylactic regimen during their flight home, while
they should have still been using it
4. Departures from intended interventions: moderate
No information was available regarding switches between
alternative prophylactic regimens
5. Missing data: low
4934/4982 (99%) participants included in adverse event
reporting
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
Therewas insufficient informationprovided regarding the
questions included in the questionnaire. Symptoms were
grouped together to report outcomes
8. Other: low
“The authors had no financial or other conflicts of interest
to disclose”
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Mavrogordato 2012
Methods Design: retrospective cohort study
Study dates: October to December 2005, with a 2 year follow-up
Malaria transmission pattern and local antimalarial drug resistance: “Malaria endemic area. Local chloroquine/
proguanil resistance”
Adverse event monitoring: Not clear
Participants Number enrolled: 33
Inclusion criteria: not explicitly stated. Participants were travellers who took part in a scientific survey and rafting
expedition in Ethiopia between October and December 2005
Exclusion criteria: none stated
Country of recruitment: various, participants were from “a non-malarious area, mainly the UK”
Country of malaria exposure: Ethiopia
Duration of exposure to malaria: 3 months
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine, dose not specified, during travel and 4 weeks after return
2. Atovaquone-proguanil, dose not specified, during travel and for 1 week after return
3. Doxycycline, dose not specified, during travel and 4 weeks after return
Not included in the review:
4. Chloroquine-proguanil, dose not specified, during travel and 4 weeks after return
Outcomes Included in the review:
1. Measures of adherence to the drug regimen
Outcomes assessed not included in the review:
2. Clinical cases of malaria
3. Adverse effects (information not provided by drug class)
4. Factors influencing choice of prophylaxis
Notes Funding sources: Work was supported by the Biomedical Research Centre (Grant RG561620 to AMLL)
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Demographic information is provided for the entire co-
hort
2. Selection of participants into the study: low
No participants refused to participate in the study. Start
of follow-up began at the start of travel and not at the start
of treatment, but this was judged to have a low impact on
monitoring self-reported adherence
3. Measurement of interventions: low
Intervention status was determined by one of the partic-
ipants on the expedition
4. Departures from intended interventions: low
There are no documented switches between interventions
of interest
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5. Missing data: low
Two people (6%) were lost to follow-up in respect to data
on efficacy. No participants were lost to follow-up when
monitoring adherence
6. Measurement of outcomes: serious
Adherence was monitored by the medical officer on the
trip, and reporting may have been influenced by social
desirability bias
7. Selection of the reported results: low
All prespecified outcomes have been reported
8. Other: low
Government funding
Meier 2004
Methods Design: retrospective cohort study
Study dates: 1 January 1990 and 31 December 1999
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: incident cases of depression, psychoses and panic attacks severe enough to require hos-
pitalisation, referral to a specialist or specific pharmacological treatment within the UK general practice research
database
Participants Number enrolled: 35,370
Inclusion criteria: “men andwomen aged17-79 yearswho received betweenone and four prescriptions formefloquine,
proguanil and/or chloroquine, or subjects who received one prescription only for doxycycline... we included only those
subjects who medical record contained a code indicating that the person received the drug for malaria prophylaxis
within 1 week of the prescription date e.g. ‘travel advice’ or ‘prophylactic drug use”’
Exclusion criteria: “participants who received the study drugs on a longer-term basis...subjects had to be enrolled in
the database for at least 12 months before the date of the first prescription for a study drug and had to have had some
recorded activity (diagnoses or drug prescriptions) after the prescription(s) for an antimalarial drug... subjects with a
history of alcoholism”
Country of recruitment: UK
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Doxycycline*
Not included in the review:
3. Chloroquine-proguanil*
4. Proguanil*
5. Chloroquine* (data reported combined with proguanil and chloroquine-proguanil)
*dosing regimen not specified
Outcomes 1. Serious adverse events
2. Adverse events; psychiatric disorders (depression, psychosis)
3. Adverse events; other (panic attacks, suicide)
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Notes Funding sources: “This studywas fundedby anunconditional grant by F.Hoffmann-LaRoche Ltd, Basel, Switzerland”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Women and those aged 40 to 49 years were at higher risk
of depression but this was not adjusted for in the analysis.
Risk ratio estimates for psychoses and panic attacks could
not be adjusted for because numbers were too small for
themultivariate model. Data on destination and duration
of travel were not available
2. Selection of participants into the study: low
Recruitment onto theGeneral PracticeResearchDatabase
was unlikely to be related to exposure or outcome
3. Measurement of interventions: moderate
“Antimalarial drugs can be used for malaria prophylaxis,
for treatment of an acute malaria infection, or as a reserve
drug… In order to distinguish these options, we included
only those subjects whose medical records contained a
code indicating ‘travel advice’ or ‘prophylactic drug use”’
4. Departures from intended interventions: serious
Discontinuations and switches between prophylactic reg-
imens were not recorded in this database
5. Missing data: low
All participants in the research database were included in
the analysis
6. Measurement of outcomes: moderate
“...we reviewed all computer records of potential cases
and included or excluded cases on the available clinical
information, blinded to exposure status”
Comment: general practitioners diagnosing patients
would have been aware of their exposure status
7. Selection of the reported results: low
Information on all outcomes prespecified in the methods
section were reported for all participants
8. Other: serious
Funded by Roche pharmaceuticals
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Methods Design: retrospective cohort study
Study dates: 1 October 2005 to 30 June 2006
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: telephone questionnaire to all travellers to tropical countries for whom antimalarial
chemoprophylaxis was prescribed
Participants Number enrolled: 1906 questionnaires returned
Inclusion criteria: participants staying in high risk malarial areas, aged between 18 and 65 years, with no severe
underlying disease (e.g. heart disease, diabetes) with an available phone number
Exclusion criteria: immigrants (due to potential difficulty in linguistic communication)
Country of recruitment: Italy
Country of malaria exposure: various: Kenya, Tanzania/Zanzibar, India, Madagascar, Brazil, other countries of South
America, South Africa, Senegal, Mali, Myanmar, Ghana, Congo, and others
Duration of exposure to malaria: mean stay 2 weeks
Type of participants: Travellers
Interventions Included in the review:
1. Mefloquine*
2. Chloroquine*
3. Atovaquone + proguanil*
4. Doxycycline*
Not included in the review:
5. Chloroquine + proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any
2. Serious adverse effects
3. Adverse effects; other (any gastrointestinal, any neuropsychiatric)
4. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
5. Clinical cases of malaria
6. Eating habits during travel
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Demographic information was provided on aggregate for
the entire cohort
2. Selection of participants into the study: moderate
Non-response rates to the questionnairewere not reported
3. Measurement of interventions: moderate
The prescription was provided by several travel clinics
which also performed the study. However, it was unclear
whether this information was used to determine interven-
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tion status or relied on participant self-reporting
4. Departures from intended interventions: low
Discontinuations were reported, with detailed reasons
for discontinuations. No switches to alternative regimens
were reported
5. Missing data: low
All participants were included in the analysis
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: low
The methods section makes clear which outcomes were
being assessed; all outcomes were reported
8. Other: no information
No informationwas provided regarding the study sponsor
Nosten 1994
Methods Design: RCT
Study dates: January 1987 to November 1990
Malaria transmission pattern and local antimalarial drug resistance: ”in an area of seasonal
malaria transmission... mefloquine and quinine resistance is increasing in this area, and
the proportion of recrudescent infections is rising“
Adverse event monitoring: trial occurred over two phases. Phase 1: Weekly basic obser-
vations and simple symptom questionnaire. ECG, haematological and biochemical tests
were done fortnightly. Children born to women in the trial were assessed at birth and
at 3, 6, 12, and 24 months. Phase 2: weekly basic observations and expanded simple
symptom questionnaire. ECG and blood tests were performed at baseline, at midstudy
and at term. Each delivery was supervised. Additional assessments at 1 week and 2 and
9 months for children born to women in the trial
Participants Number enrolled: 339
Inclusion criteria: ”Women attending the weekly clinic were admitted to the study if
they were at > 20 weeks of estimated gestation“
Exclusion criteria: Not mentioned
Region of recruitment: Thai-Burmese border
Region of malaria exposure: Thai-Burmese border
Duration of exposure to malaria: ongoing exposure in a semi-immune population, mon-
itored until delivery
Type of participants: Pregnant Thai residents in malaria-endemic area (presumed semi-
immune)
Interventions 1. Mefloquine (1 x 250 mg tablet, Lariam; Hoffmann-La Roche) weekly for 4 weeks,
then 125 mg weekly until delivery, with 500 mg base loading dose in phase 1 but not
phase 2
2. Placebo (1 tablet) weekly until delivery
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Outcomes Included in the review:
1. Clinical cases of malaria
2. Episodes of parasitaemia
3. Serious adverse events (including childhood deaths)
4. Adverse events; vertigo, visual impairment (visual abnormalities), nausea, vomiting,
abdominal pain, headache, dizziness, pruritis
5. Adverse events; other (weakness, anorexia, cough, falls, constipation, unsteadiness)
6. Discontinuation of study drug due to adverse effects
7. Adverse pregnancy outcomes (spontaneous abortions, still births, congenital malfor-
mations)
Outcomes assessed not included in the review:
8. Laboratory tests; haematologic (full blood count, haematocrit) and biochemical (cre-
atinine, blood urea, transaminases, alkaline phosphatase, albumin, globulin)
9.Outcomes related to pregnancy;weight gain during follow-up, complications of labour,
mean duration of labour, maternal anaemia
10. Fetal outcomes; mean birth weight, percent premature, fetal distress
11. Infant follow up; mean age at which children could crawl, sit, walk or talk, Romberg
test
Notes Funding sources: United Nations Development Programme/World Bank/World Health
Organization Special Programme for Research and Training in Tropical Diseases; Well-
come Trust of Great Britain; Praevention Foundation. The Hague (to FLK)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”...women were randomized to receive ei-
ther mefloquine…or placebo“
Comment: unclear what method of ran-
domization was used
Allocation concealment (selection bias) Unclear risk ”...the investigators were unaware of the
randomisation“
Comment: no mention of method used to
conceal allocation
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk ”...double blind...women were randomised
to receive either mefloquine…or identical
placebo“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”...the investigators were unaware of the
randomisation“
Incomplete outcome data (attrition bias);
efficacy
Low risk Comment: total number of participants
with positive blood smear result at any time
during prophylaxis was reported. Clinical
cases of malaria were reported”
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Incomplete outcome data (attrition bias);
safety
High risk “Ten women (8%) in phase I (3 meflo-
quine, 7 placebo) and 18 (8%) in phase
II (9 in each group) dropped out of the
study. The main reason was the discomfort
of blood sampling (26 cases) and, in 1 case,
pruritus attributed to mefloquine”
Comment: 28womendroppedout but rea-
sons were provided for only 27 women;
numbers were not provided across groups
Selective reporting (reporting bias); efficacy Low risk Comment: all episodes of parasitaemia and
clinical cases of malaria were reported
Selective reporting (reporting bias); safety High risk Comment: Data on adverse effects were re-
ported for only participants fromphase 2 of
the trial (220/339 women). Fifteen symp-
toms were listed in the comparative table,
but the narrative states “twenty questions
were asked”. Romberg test results were not
reported. Biochemical, haematological and
ECG parameters were not reported other
than “there were no differences”
Other bias Low risk Funding: United Nations Development
Programme/World Bank/World Health
Organization Special Programme for Re-
search and Training in Tropical Diseases;
Wellcome Trust of Great Britain; Praeven-
tion Foundation. The Hague (to FLK)
Ohrt 1997
Methods Design: RCT
Duration of study: May to July 1994
Malaria transmission pattern and local drug resistance: “P. falciparum resistant to sulfa-
doxine-pyrimethamine and both P falciparum and P vivax resistant to chloroquine”
Adverse event monitoring: symptoms reported in the first week of the study, daily ques-
tioning about symptoms, exit questionnaire
Participants Number enrolled: 204
Inclusion criteria: “All soldiers from military posts that were considered to have high
malaria attack rates”
Exclusion criteria: history of frequent travel, allergy to one of the study drugs, glucose-
6-phosphate dehydrogenase deficiency, history of underlying illness
Country of recruitment: Indonesia
Country of malaria exposure: Indonesia
Duration of exposure to malaria: Study duration was approximately 13 weeks
Type of participants: military, semi-immune (60% of participants had prior exposure to
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malaria)
Interventions 1. Mefloquine (1 x 250 mg tablet, containing the equivalent of 228 mgmefloquine base)
once weekly (after a loading dose of 250 mg per day for 3 days).*
2. Doxycycline hyclate (1 x 100 mg capsule) once daily*
3. Placebo*
Co-interventions: All soldiers were given doxycycline tablets for 4 to 6 weeks to enable
clearance of sulfadoxine-pyrimethamine from the blood before study prophylaxis began.
All participants received radical treatment for pre-existing malaria parasites in the blood
and liver prior to beginning study prophylaxis
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Adverse events; any, nausea, vomiting, abdominal pain, diarrhoea, headache, dizziness,
insomnia, abnormal dreams
3. Serious adverse events
4. Adverse events; other (all gastrointestinal, all neurologic, constipation, anorexia, fever,
malaise, skin related, cough, somnolence, palpitations, sexual dysfunction)
5. Discontinuation of study drug due to adverse effect
Outcomes assessed not included in the review:
6. Exit questionnaire (incomplete data reported)
Notes Funding source: Pfizer Indonesia supplied active and placebo doxycycline; F. Hoffman-
LaRoche supplied active and placebomefloquine, and gave financial support; USAArmy
Medical Research and Materiel Command gave financial support; USA Naval Medical
Research and Development Command gave financial support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Block randomization was used (block size,
15)”
Comment:Used a randomization code, but
it was not stated how it was generated
Allocation concealment (selection bias) Unclear risk “The randomization code was stored in
individual envelopes in a locked box at
the study site...Drugs were packaged into
weekly ziplock plastic bags”
Comment: Unclear whether the investi-
gators or participants would foresee as-
signment. There was no mention of cen-
tral allocation, sequentially numbered drug
containers or sequentially numbers opaque
sealed envelopes
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Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “Drugs were packaged into weekly zipper-
lock plastic bags: each bag contained a
mefloquine or mefloquine placebo tablet
and a blister pack of seven doxycycline
or doxycycline placebo capsules (double-
dummy technique)”
The placebo medication had an “identical
appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The randomisation code was stored in in-
dividual envelopes in a locked box at the
study site. All investigators and study per-
sonnel did not have access to or know the
randomisation code throughout the study”
Incomplete outcome data (attrition bias);
efficacy
Unclear risk “Sixteen of the 204 participants did not
complete the study”
Comment: It was unclear whether the du-
ration of follow up included the post-pro-
phylaxis period to monitor for relapses
Incomplete outcome data (attrition bias);
safety
High risk Exit questionnaire: “Only data from per-
sons who were still receiving the study drug
at the time of the questionnaire were in-
cluded”
Comment: numbers not reported
Selective reporting (reporting bias); efficacy Low risk “The primary end point for efficacywas the
first occurrence of malaria, as documented
by a positive malaria smear”
Comment: all cases of malaria were re-
ported.
Selective reporting (reporting bias); safety High risk Comment: Not all data were reported from
the exit questionnaire; the study reports “.
..the only statistically significant finding”.
Data on adverse symptoms were not re-
ported for the placebo group
Other bias Low risk “Neither of the pharmaceutical companies
that provided support played any role in
the gathering, analysing or interpreting the
data”
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Overbosch 2001
Methods Design: RCT
Duration of study: April to October 1999
Malaria transmission pattern and local drug resistance: not mentioned
Adverse eventmonitoring: “evaluated 7, 28 and60days after return to obtain information
about a targeted list of adverse events”
Participants Number enrolled: 1013
Inclusion criteria: “travellers aged ≥ 3 years and weighing ≥ 11 kg with planned travel
of ≤ 28 days to a malaria-endemic area”
Exclusion criteria: “poor general health; drug hypersensitivity (to atovaquone, chloro-
quine or proguanil); history of alcoholism, seizures or psychiatric or severe neurological
disorders; generalized psoriasis; severe blood disorders; pregnancy/lactation; renal, hep-
atic or cardiac dysfunction; clinical malaria within previous 12 months; travel to malaria
endemic area within previous 60 days”
Countries of recruitment: Canada, Germany, Netherlands, South Africa, UK
Regions of malaria exposure: various malaria-endemic destinations (79% Africa, 6%
South America)
Mean duration of exposure to malaria: 2.5 weeks
Type of participants: travellers, non-immune
Interventions 1. Mefloquine (1 x 250 mg tablet; or alternatively ¼, ½ or ¾ of a tablet, according to
body weight) once weekly, starting 1 to 3 weeks before travel and continuing for 4 weeks
after travel*
2. Atovaquone-proguanil (1 combined tablet containing 250 mg atovaquone and 100
mg proguanil hydrochloride; or alternatively 1 to 3 combined tablets for children accord-
ing to body weight, each tablet containing 62.5 mg atovaquone and 25 mg proguanil
hydrochloride) once daily, starting 1 to 2 days before travel and continuing for 1 week
after leaving the malaria-endemic area*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria (antibody to blood-stage malaria parasites)
2. Adverse events; any
3. Serious adverse events
4. Adverse effects; any (moderate or severe), visual impairment, nausea, vomiting, ab-
dominal pain, diarrhoea, headache, dizziness, abnormal dreams, insomnia, anxiety, de-
pression, pruritis
5. Adverse effects; other (mouth ulcers)
6. Discontinuation of study drug due to adverse effects
7. Measures of adherence to the drug regimen
Outcomes assessed not included in the review:
8. Laboratory tests; haematology (haemoglobin level, white blood cell count and platelet
count) and chemistry (creatinine and alanine aminotransferase)
Notes Funding source: GlaxoSmithKline
“Subjects were enrolled in study MAL30010”- Enrollment criteria and study conduct
were described in a separate publication (Høgh 2000) which refers to a different study
population (atovaquone-proguanil versus chloroquine-proguanil)
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated code was used to
randomly assign a treatment number” (
Høgh 2000)
Allocation concealment (selection bias) Low risk “Treatment codes were provided to inves-
tigators in opaque sealed envelopes, to be
opened only if knowledge of study drug as-
signment was required for management of
a medical emergency” (Høgh 2000)
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “For each active drug, capsules or film-
coated tablets were identical in appearance
to the matching placebo”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All subjects and study personnel remained
blinded to treatment assignment with 5 ex-
ceptions. Two subjects in the atovaquone-
proguanil group and 3 in the mefloquine
group lost their study drug during their
return trip from a malaria-endemic area,
and the investigator broke the blind to en-
able completion of postexposure prophy-
laxis with active drug”
Incomplete outcome data (attrition bias);
efficacy
Low risk “A total of 963 subjects completed the 60-
day follow-up period and had efficacy in-
formation recorded. A total of 915 subjects
hadpaired serum samples available for sero-
logical testing”
Comment: 963/976 (randomized and re-
ceived first dose of study drug) = 98.7%.
915/976 = 93.75%. Reasons for leaving
the study early were reported and numbers
were balanced across groups
Incomplete outcome data (attrition bias);
safety
Unclear risk Comment: 96.35% of randomized partic-
ipants were included in adverse event re-
porting. Reasons for leaving the study early
were reported and numbers were balanced
across groups
Selective reporting (reporting bias); efficacy Low risk Comment: Full clinical details were pro-
vided for every episode in which an episode
of malaria was considered (4 cases)
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Selective reporting (reporting bias); safety High risk Comment: Data on adverse symptoms
were not reported for the placebo group
due to a shorter durationof follow-up.Data
were collected 7, 28 and60days after travel.
However, data were only presented for 7
days after return
Other bias High risk Funding: GlaxoSmithKline
It was not made clear whether the interpre-
tation of the study findings was indepen-
dent of the study sponsor
Pearlman 1980
Methods Design: RCT
Study dates: unclear, during 1977
Malaria transmission pattern and local antimalarial drug resistance: “subjects were resi-
dent in an area highly endemic for P. vivax and chloroquine resistant P. falciparum”
Adverse event monitoring: “a physician visited the study area each week and conducted
a sick call for participating and nonparticipating villagers...Between physician visits,
residents were taken to a nearby health centre for serious medical problems”
Participants Number enrolled: 990
Inclusion criteria: “All eligible and consenting villagers over 10 years of age were included
in the study”
Exclusion criteria: “Female villagers of childbearing age (15-44 years) were not considered
for inclusion”
Country of recruitment: The Bhu Phram Valley, Thailand
Country of malaria exposure: The Bhu Phram Valley, Thailand
Duration of exposure to malaria: study duration 26 weeks
Type of participants: Thai residents, semi-immune
Interventions 1. Mefloquine (1 x 180 mg tablet, children 22 to 35 kg ½ dose) weekly
2. Mefloquine (1 x 360 mg tablet, children 22 to 35 kg ¼ dose) weekly
3. Mefloquine (1 x 360 mg tablet, children 22 to 35 kg ¼ dose) every 2 weeks
4. Placebo (1 x tablet) weekly
Co-interventions: “Those who had experienced falciparum parasitemias were given a
therapeutic dose of sulfadoxine (1,500 mg)-pyrimethamine (75 mg), and those with
vivax or malariae parasitemias were treated with the standard regimen of chloroquine
(1,500 mg over a 3-day period), followed by primaquine, 15 mg daily for 14 days, for
those study subjects known to be G-6-PD normal”
Outcomes Included in the review:
1. Clinical cases of malaria
2. Episodes of parasitaemia
3. Adverse events; any
Outcomes assessed not included in the review:
4. Laboratory tests; haematocrit, white cell count, white cell differential, serum glutamic
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oxaloacetic transaminase, alkaline phosphatase and blood urea nitrogen
Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Assignment to one of six treatment groups
was made on a stratified random number
basis”
Comment: no details of how randomnum-
bers were generated
Allocation concealment (selection bias) Unclear risk “In the course of this visit, the technician
opened a sealed, numbered envelope, gave
the enclosed tablets, and observed the sub-
ject swallow them”
Comment: no mention of the envelope be-
ing opaque
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “Each subject received two tablets each
week (medication, placebo or a combina-
tion) in order to maintain the double blind
nature of the study”
“All tablets were identical in appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
not clear how this was achieved
Incomplete outcome data (attrition bias);
efficacy
Unclear risk “Nine hundred andninety nine subjects be-
gan the 25-week field trial and 856 com-
pleted it (86.5%). 160/189 (85%) of the
mefloquine 180mgweekly group, 169/191
(88%) of the mefloquine 360 mg weekly,
158/184 (86%) of the mefloquine 360 mg
fortnightly and 36/44 (82%) of the placebo
group completed the trial”
Comment: reasons for losses to follow-up
were not reported
Incomplete outcome data (attrition bias);
safety
Low risk “Therewas no clinical evidence of drug tox-
icity in the 990 study participants, nor were
there significant changes in the biochemi-
cal parameters”
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Selective reporting (reporting bias); efficacy Low risk “Table 2 shows the number of subjects in
each group who completed the study, the
number infected with P. falciparum, and
the number of episodes of asexual para-
sitemia”
Selective reporting (reporting bias); safety High risk “Therewas no clinical evidence of drug tox-
icity in the 990 study participants”
Comment: it was unclearwhether all events
that occurred during the 6 month trial pe-
riod were included
Other bias Unclear risk Comment: study sponsor not reported
Petersen 2000
Methods Design: retrospective cohort study
Study dates: 1 May 1996 to 30 April 1998
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 5446 questionnaires mailed, 4158 respondents
Inclusion criteria: “travellers 18 years old or older, who were not pregnant and had no previous adverse reactions to
any of the prescribed drugs”
Exclusion criteria: none mentioned
Factors influencing drug allocation: “the standard recommendations to Danish travelers were followed”
Country of recruitment: Denmark
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Chloroquine*
Not included in the review:
3. Chloroquine + proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; any
2. Serious adverse outcomes
3. Adverse effects; visual impairment (blurred vision), nausea, vomiting, abdominal pain, diarrhoea, dizziness, de-
pression
4. Adverse effects; other (loss of appetite, strange thoughts, tingling, altered spatial perception, mouth ulcers)
Outcomes assessed not included in the review:
5. Discontinuation of study drug due to adverse effects (data reported on aggregate)
6. Measure of adherence to the drug regimen (data reported on aggregate)
7. Duration in days of symptoms
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Notes Funding sources: Not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
The questionnaire collected information regarding age,
body weight and gender, destination and duration of
travel but these were not reported
2. Selection of participants into the study: serious
Response rate 4158/5446 (76.3%)
3. Measurement of interventions: low
The prescriptionwas provided by a travel clinic which also
performed the study, and switches and discontinuations
have been recorded and reported
4. Departures from intended interventions: moderate
Discontinuations were reported. Although changes in
prophylaxis were mentioned, it was unclear whether par-
ticipants were analysed according to original or subse-
quent prophylactic grouping
5. Missing data: low
4020/4158 (97%) of participants are included in the anal-
ysis for adverse events
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partic-
ipants and personnel were not blinded. It was unclear
whether the questionnaire implied causality to the drug
regimen
7. Selection of the reported results: moderate
The questionnaire included demographic information,
but this was not reported. All results were reported ac-
cording to short-term or long-term users of prophylaxis,
which was not specified in the methods section
8. Other: no information
No information is provided regarding the study sponsor
Philips 1996
Methods Design: cross-sectional cohort study
Study dates: November 1993 to October 1994
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient questionnaire sent 2 weeks after travellers return
Participants Number enrolled: 741 respondents, 918 questionnaires sent
Inclusion criteria: “...travelers were asked to participate in the study when they attended TMVC clinics in Adelaide
or Melbourne for pretravel consultation. If either doxycycline or mefloquine malaria chemoprophylaxis was recom-
mended for part, or whole, of their itinerary, permission was sought to have them receive a mailed questionnaire”
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Exclusion criteria: “...under 18 years old, if doxycycline was recommended at doses other than 100mg daily, if other
antimalarials were to be used during the intended journey, or if a traveller was not returning home in under 6months”
Factors influencing drug allocation: “Unless a contraindication existed for one or the other drug, the choice of which
one to take was left to the traveler, the physician having already discussed, at some length, the different regimens,
cost, and commonly reported adverse effects”
Country of recruitment: Australia
Region of malaria exposure: various (Southeast Asia, Africa, South Asia (India), Pacific)
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions 1. Mefloquine*
2. Doxycycline*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; any, nausea/vomiting, abdominal pain, diarrhoea, headache, dizziness, abnormal dreams, insomnia,
anxiety
2. Serious adverse events
3. Adverse events; other (mood change, palpitations, itching, rash, red skin, vaginal itch)
4. Adverse effects; any
5. Adverse effects; abdominal pain, diarrhoea
6. Discontinuation of study drug due to adverse effects
7. Measure of adherence to the drug regimen
Outcomes assessed not included in the review
8. Reasons for choice of antimalarial drug regimen
Notes Funding sources: “Thanks to Roche and Pfizer pharmaceutical companies for their financial support”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Identified confoundersweremeasured and reported across
groups. Mefloquine users were more likely to be female
and had longer duration of treatment
2. Selection of participants into the study: serious
Response rate 668 of 918 (73%)
3. Measurement of interventions: low
The prescription was provided by a travel clinic which
also performed the study; discontinuations were recorded
and reported
4. Departures from intended interventions: moderate
Discontinuations were recorded. It was unclear whether
information regarding switches was recorded
5. Missing data: low
All information was collected at one time point and all
participants were included in the analysis
102Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Philips 1996 (Continued)
6. Measurement of outcomes: serious
Comment: The outcome measure was subjective; partic-
ipants and personnel were not blinded
7. Selection of the reported results: serious
Information was reported for all adverse events recorded,
but participants’ assessment of causality to the study drug
was only reported for two side effects
8. Other: serious
“Sponsored by Roche and Pfizer pharmaceuticals”
The role of the study sponsor was not made clear
Potasman 2002
Methods Design: RCT
Study dates: unclear
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse eventmonitoring: “Two days after drug ingestion, a second EEGwas performed,
and a blood sample for mefloquine level was obtained...Travelers were given forms on
which to record adverse effects that appeared within 48 hours after drug intake”
Participants Number enrolled: 90
Inclusion criteria: not explicitly mentioned, included travellers from the Bnia Zion med-
ical centre, Haifa, Israel
Exclusion criteria: “Travelers younger than 18 years; with a history of epilepsy or de-
pression, known allergy to mefloquine, cardiac conduction block; using beta-blockers;
or who were pregnant...Travelers with an abnormal baseline EEG (unifocal or repetitive
bursts)”
Country of recruitment: Israel
Country of malaria exposure: not applicable
Duration of follow up: 48 hours
Type of participants: non-travellers
Interventions 1. Mefloquine (1 x Mephaquine 250 mg tablet, Mepha, Aesch, Switzerland) one dose
2. Mefloquine (1 x Larium 250 mg tablet, Roche, Basel, Switzerland) one dose
3. Placebo
Outcomes 1. Adverse events; any
2. Adverse events; other (neuropsychiatric, abnormal EEG 48 hours after ingestion)
Notes Funding sources: “Partially funded by Mepha Ltd, Aesch, Switzerland”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Eligible travelers were randomly assigned
to one of three groups” “Randomization
and statistical tests were carried out using
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Statmate and InStat”
Allocation concealment (selection bias) Unclear risk Comment: not mentioned
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk “Participants were unaware of their group
assignment until they completed their
tests”
Comment: methods used to blind partici-
pants not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “EEG pairs (pre- and post-mefloquine)
were examined separately by two senior
neurologists whowere unaware of group al-
location”
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Unclear risk Comment: data were provided for all par-
ticipants who were not excluded on the ba-
sis of abnormal baseline EEG
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety Unclear risk “Adverse effects, mainly gastrointestinal
and neuropsychiatric were noted in 26 trav-
ellers”
Comment: specific nature of each adverse
effect is not noted per group
Other bias High risk Partially funded by Mepha Ltd, Aesch,
Switzerland.
Comment: the role of the study sponsor
was not clear
Rack 2005
Methods Design: retrospective cohort study
Study dates: July 2003 to June 2004
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 794
Inclusion criteria: Travellers who were visiting five popular tropical regions or countries
Exclusion criteria: aged < 18 years, travelling for more than 2 months, and major acute or chronic diseases
Country of recruitment: Germany
Country of malaria exposure: Kenya/Tanzania, Senegal/Gambia, India/Nepal, Thailand, Brazil
Duration of exposure to malaria: various, mean duration of travel 23.9 days
Type of participants: travellers
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Interventions Included in the review:
1. Mefloquine*
2. Doxycycline*
3. Atovaquone-proguanil*
4. Chloroquine*
Not included in the review:
5. Chloroquine-proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Narrative description of adverse effects
Outcomes assessed not included in the review:
2. Risk behaviours during travel
3. Illness during travel
4. Seeking medical care owing to illness or accident
5. Accidents during travel
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Demographic information was provided for the entire co-
hort, not by prophylactic regimen
2. Selection of participants into the study: moderate
Numbers of participants choosing not to participate in
the study were not reported
3. Measurement of interventions: serious
Participants were asked to self-report which prophylaxis
they took after return. The time after return was not spec-
ified
4. Departures from intended interventions: no infor-
mation
There was insufficient information provided to determine
whether the questionnaire contained information regard-
ing discontinuations or switches
5. Missing data: moderate
Follow up was obtained for 658 (83%) travellers
6. Measurement of outcomes: serious
There was insufficient information on the questionnaire
about how adverse effects were sought and if outcome
measures were objective. There was no mention of blind-
ing of outcome assessors
7. Selection of the reported results: moderate
Therewas insufficient informationprovided regarding the
questionnaire to determine if all questions were reported.
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Side effects were grouped to report symptoms
8. Other: no information
No informationwas provided regarding the study sponsor
Rieckmann 1993
Methods Design: cohort study
Study dates: 1989
Malaria transmission pattern and local antimalarial drug resistance: higher levels of P falciparum than P vivax locally.
Local chloroquine and primaquine resistance
Adverse event monitoring: unclear
Participants Number enrolled: 349
Inclusion criteria: Unclear
Exclusion criteria: Unclear
Country of recruitment: Australia
Country of malaria exposure: Papua New Guinea
Duration of exposure to malaria: 3 to 13 week training exercises
Type of participants: Soldiers
Interventions Included in the review:
1. Mefloquine (1 x 250 mg weekly)
2. Doxycycline (1 x 100 mg tablet, daily, starting one day before deployment and continuing until 3 days after return)
Not included in the review:
3. Doxycycline + primaquine
4. Doxycycline + chloroquine
Outcomes Included in the review:
1. Narrative description of adverse effects
Outcomes assessed not included in the review::
2. Clinical cases of malaria
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
No demographic information was provided
2. Selection of participants into the study: moderate
Numbers of participants choosing not to participate in
the study not reported
3. Measurement of interventions: low
All participants were soldiers who were issued with med-
ication
4. Departures from intended interventions: moderate
No information was provided regarding discontinuations
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or switches
5. Missing data: moderate
No losses to follow-up or treatment withdrawals were re-
ported, but the paper does not clearly state that none oc-
curred
6. Measurement of outcomes: serious
There was insufficient information on how adverse ef-
fects were sought and if outcomemeasures were objective.
There was no mention of blinding outcome assessors
7. Selection of the reported results: moderate
Therewas insufficient informationprovided regarding the
questionnaire to determine if all questions were reported.
Side effects were grouped to report symptoms
8. Other: no information
No information is provided regarding the study sponsor
Rietz 2002
Methods Design: cross-sectional cohort study
Study dates: June to December 2000
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 491
Inclusion criteria: “visitors over fifteen who were travelling to South or Central America, Africa, India or South-East
Asia, including China, and who were not suffering from any chronic illness”
Exclusion criteria: none mentioned
Factors influencing drug allocation: “After talking to the doctor, the doctor wrote whether malaria prophylaxis had
been decided on and if so which kind”
Country of recruitment: Sweden
Region of malaria exposure: various, including South or Central America, Africa, India or Southeast Asia, including
China
Duration of exposure to malaria: “most were abroad between two to four weeks”
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Chloroquine*
3. Non-users
Not included in the review:
4. Chloroquine-proguanil*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; any, seriously negative effect on the journey
2. Adverse effects; any
3. Adverse effects; other (neuropsychiatric, skin problems)
Outcomes assessed not included in the review:
4. Importance attached to prophylaxis
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5. Whether travellers had any anxiety about side effects prior to taking prophylaxis
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex, destination and duration of travel data were col-
lected but not reported across groups. BMI was not mea-
sured
2. Selection of participants into the study: serious
Response rate 62%
3. Measurement of interventions: low
The prescription was provided by a travel clinic which
also performed the study
4. Departures from intended interventions: moderate
Discontinuations were reported, but not across groups.
Switches were not recorded
5. Missing data: low
All participants who completed both questionnaires were
included in the analysis
6. Measurement of outcomes: moderate
The outcome measure was subjective; participants and
personnel were not blinded. Participants were asked to
report all symptoms, and which they felt were due to
prophylaxis
7. Selection of the reported results: moderate
Symptoms were grouped to report outcomes
8. Other: low
Source of funding not mentioned. “competing interests:
none declared”
Salako 1992
Methods Design: RCT
Study dates: July 1987 to June 1988
Malaria transmission pattern and local antimalarial drug resistance: “holoendemic for
malaria... at the time of the trial, chloroquine resistance was not a problem”
Adverse eventmonitoring: “study participantswere seenweekly up toweek 28”. Interview
with study personnel for events such as “fever, chills, malaise, nausea and vomiting, rashes
and other symptoms and signs that could be regarded as adverse events”
Participants Number enrolled: 567
Inclusion criteria: “...adult males aged 16 to 60 years, judged healthy on clinical grounds
(no history of any illness and physical examination revealed no evidence of an acute or
chronic illness). The patients were not on any drugs”
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Exclusion criteria: “...known hypersensitivity to sulphonamides, antimalarial drug treat-
ment in the preceeding four weeks, presence of chronic debilitating disease and inability
to attend regularly for follow up”
Country of recruitment: Nigeria
Country of malaria exposure: Nigeria
Duration of exposure to malaria: study duration 24 weeks
Type of participants: Nigerian residents, semi-immune.
Interventions 1. Mefloquine (1 x 250 mg tablet, Hoffman-La Roche) weekly for 4 weeks followed by
1 x 125 mg tablet weekly for 20 weeks, total duration 24 weeks*
2. Chloroquine (1 x 300 mg base tablet, Hoffman-La Roche) weekly, total duration 24
weeks*
3. Placebo, 1 tablet (Hoffman-La Roche) weekly, total duration 24 weeks*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Episodes of parasitaemia
3. Adverse events; any, abdominal pain, diarrhoea, headache, dizziness, pruritis, visual
impairment (blurred sight)
4. Serious adverse events
5. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
6. Laboratory tests; white blood cell counts, haematocrit, serum glutamic oxaloacetic
transaminase and serum glutamic-pyruvic transaminase
7. Adverse events: rash, muscle stiffness (occurred in < 1% of study participants)
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “...subjects were allocated randomly into
five groups on the basis of a pre-determined
randomisation list”
Comment: no mention of how the list was
generated
Allocation concealment (selection bias) Unclear risk “...blister packs containing a total of 24
tablets were provided for each subject ...
The packs and tablets were identical in ap-
pearance and were labelled with the appro-
priate double-blind number”
Comment: no mention of opaque sealed
envelopes or central allocation
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Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “The packs and tablets were identical in
appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no description provided of how this was
achieved for researchers and outcome asses-
sors
Incomplete outcome data (attrition bias);
efficacy
Low risk Comment: numbers lost to follow up were
provided across groups, with reasons pro-
vided. 107/113 (95%) mefloquine recip-
ients, 103/115 (90%) chloroquine recipi-
ents and 101/114 (89%) placebo recipients
completed the trial
Incomplete outcome data (attrition bias);
safety
Low risk Comment: reports “number of individuals
suffering adverse events during the trial”.
Numbers lost to follow up were provided
across groups, with reasons provided. 107/
113 (95%)mefloquine recipients, 103/115
(90%) chloroquine recipients and 101/114
(89%) placebo recipients completed the
trial
Selective reporting (reporting bias); efficacy Low risk Comment: clinical cases of malaria and
episodes of parasitaemia are reported for all
participants
Selective reporting (reporting bias); safety Unclear risk “No change of clinical relevance occurred
in any of the groups in the above laboratory
tests”
Comment: there was insufficient informa-
tion available regarding the collection of
adverse events to determine whether the re-
ported list included all events or only a tar-
geted list. Data not fully reported for blood
tests
Other bias Unclear risk Comment: study sponsor not mentioned,
but four of the authors are attributed to F
Hoffman-La Roche
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Methods Design: RCT
Study dates: August 1982 to January 1983
Malaria transmission pattern and local antimalarial drug resistance: region considered
hyperendemic. P falciparum resistant to chloroquine and “high prevalence of multiresis-
tant Plasmodium falciparum transmission”
Adverse event monitoring: during the initial screening visit, weekly visits, and a final visit
at study end, participants were asked about illnesses, mainly about signs and symptoms
compatible withmalaria, and blood tests were done, including haematocrit and leucocyte
count
Participants Number enrolled: 122
Inclusion criteria: “volunteer soldiers and civilians aggregated to the 5th Battalion of
Engineering and Construction in a community in Porto Velho”
Exclusion criteria: aged < 12 years and > 55 years, pregnancy, people with debilitating
disease, people who took antimalarial drugs in the previous four weeks and people with
allergy to sulphonamides
Country of recruitment: Brazil
Country of malaria exposure: Brazil
Duration of exposure tomalaria: Mean duration within study (across groups) 16.9 weeks
Type of participants: Brazilian soldiers and civilians, semi-immune
Interventions Included in review comparisons:
1. Mefloquine (2 x 250 mg tablets, Roche) every 4 weeks*
2. Mefloquine (1 x 250 mg tablet, Roche) every 2 weeks*
3. Placebo
Not included in review comparisons:
4. Fansidar*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Clinical cases of malaria
2. Adverse effects; any, anxiety
Outcomes assessed not included in the review:
3. Laboratory tests; haematocrit, white blood cell counts, serum glutamic oxaloacetic
transaminase and serum glutamic-pyruvic transaminase
Notes Funding sources: Laboratory Roche provided mefloquine and “support” for conducting
the study. Comando do 5o Batalhão de Engenharia e Construção, Porto Velho, RO,
provided laboratory and field installations
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: described as a randomized con-
trolled trial, but no details were given on
the sequence generation
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Allocation concealment (selection bias) Unclear risk Comment: no description of allocation
concealment provided
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “Each week... participants ingested 4
tablets of equal appearance, contained in
sealed envelopes”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “Each week... participants ingested 4
tablets of equal appearance, contained in
sealed envelopes, with a code pre-deter-
mined for each individual and not opened
after the completion of the study”
Comment: no mention of blinding of out-
come assessors
Incomplete outcome data (attrition bias);
efficacy
High risk “120 participants were initially recruited
(30 in each group). Six of them were then
excluded andwere not included in the anal-
ysis. 8 participants left the area of study
(one after the 10th week and 7 after the 11
th week of exposure)”
Outcomes were included in the analysis,
and were substituted by eight new par-
ticipants. With these six excluded partici-
pants and eight substituted participants, fi-
nal sample size was 122
Comment: participants were not followed
up beyond the active phase of treatment for
relapses
Incomplete outcome data (attrition bias);
safety
Unclear risk Comment: reasons for losses to follow-up
were not reported
Selective reporting (reporting bias); efficacy Low risk Comment: all cases of malaria were re-
ported
Selective reporting (reporting bias); safety Unclear risk Comment: there was insufficient informa-
tion provided regarding the method of
adverse effects monitoring to determine
whether all outcomes had been reported
Other bias High risk Roche provided mefloquine and “support”
for conducting the study
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Saunders 2015
Methods Design: retrospective cohort study
Study dates: January to June 2007
Malaria transmission pattern and local antimalarial drug resistance: “malaria risk and transmission patterns have been
known to shift rapidly in Afghanistan”
Adverse event monitoring: “A retrospective, anonymous survey was completed by soldiers returning to Fort Drum,
NY from Afghanistan”
Participants Number enrolled: 2601 surveys distributed, 2351 (90%) returned
Inclusion criteria: none mentioned
Exclusion criteria: none mentioned
Factors influencing drug allocation: “oral mefloquine 250 mg per week was the primary alternative to doxycycline...
In some cases, mefloquine was chosen as the first-line therapy based on either perceived advantages in compliance,
unit force protection, and/or operational concerns”
Country of recruitment: USA
Country of malaria exposure: Afghanistan
Duration of exposure to malaria: various, not specified
Type of participants: military
Interventions Included in review comparisons:
1. Mefloquine*
2. Doxycycline*
Not included in review comparisons:
3. Atovaquone-proguanil* (data on adverse events not collected; data on compliance not reported)
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any, vomiting, diarrhoea
2. Adverse effects; other (heartburn/dyspepsia)
3. Discontinuations of study drug due to adverse effects
4. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
5. Clinical cases of malaria
6. Adverse effects: numbers not reported in both groups (nausea, headache, dizziness, abnormal dreams, insomnia,
depression, photosensitivity, rash, loss of appetite, pain and/or difficulty swallowing, vaginitis, lightheadedness,
nervousness, ringing in ears, chills)
7. Use of personal protective measures to prevent mosquito bites
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Information was provided on duration of deployment,
area of deployment, sex, age group and rank across reg-
imens. Area deployed in Afghanistan and sex were dif-
ferent across groups. No adjustment for confounders was
made in the analysis
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2. Selection of participants into the study: low
Response rate 2351/2601 surveys (90%)
3. Measurement of interventions: moderate
Participants were asked to self-report which prophylaxis
was used on return to the USA. It is unclear if participants
were still receiving the intervention at this time
4. Departures from intended interventions: serious
“There were 520 respondents (25.2%) reporting more
than one medication used to prevent malaria over the
course of the deployment”
5. Missing data: low
Analysis included 1898/2011 (94.4%) respondents for
doxycycline, 564/596 (94.6%) respondents for meflo-
quine
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded. Different criteria
were used to assess adverse effects related to mefloquine
and doxycycline
7. Selection of the reported results: serious
There was insufficient information provided regarding
the questionnaire to determine whether all included out-
comes were reported. Data for doxycycline were provided
by severity gradings but not for mefloquine
8. Other: no information
No information is provided regarding the study sponsor
Schlagenhauf 1997
Methods Design: cross-over RCT
Study dates: 1993 to 1994
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse event monitoring: “Throughout dosing, the participants were monitored and
questioned regarding their general well-being. The participants were seen 1) prior to
taking any medication, 2) at the end of the first week (during which the loading dose was
administered, 3) one week before testing, and 4) on the testing day itself when they were
asked to report any changes from normal and questioned with regard to any symptoms
experienced while taking the drug”
Participants Number enrolled: 23
Inclusion criteria: “conducted with trainee pilots attending the Swiss Civil Aviation
School during the classroom phases of their study”
Exclusion criteria: “history of a seizure disorder; psychosis or severe depression; known
allergy or sensitivity to mefloquine or related compounds; concurrent use of cardioac-
tive medication; compromised renal or hepatic function; pregnancy or the intention
to become pregnant within three months of mefloquine use; use of mefloquine in the
preceding two months, and use of hypnotics or tranquillizers during the two weeks prior
to testing and alcohol within 12 hr of testing”
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Country of recruitment: Switzerland
Country of malaria exposure: not applicable
Duration of follow up: 4 weeks
Type of participants: Swissair trainee pilots, did not travel
Interventions 1. Mefloquine (1 x 250 mg tablet) given daily on 3 consecutive days followed from day
8 by once a week administration of 1 tablet for three consecutive weeks
2. Placebo (1 tablet) given daily on 3 consecutive days followed from day 8 by once a
week administration of one tablet for 3 consecutive weeks
Outcomes Included in the review:
1. Adverse events; any
2. Discontinuations of study drug due to adverse effects
3. Adverse events; other outcomes (instrument co-ordination analyser, sleep assessment,
sway, neurobehavioural evaluation system, profile of mood states)
Notes Funding sources: This study was sponsored by the F. Hoffmann La Roche Tropical
Medicine Unit (Basel, Switzerland)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: method of randomization not
reported
Allocation concealment (selection bias) Unclear risk Comment: no details of allocation conceal-
ment reported
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk Comment: described as double blind but
no mention of whether placebo was iden-
tical to the active formulation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no description of whowas blinded and how
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Unclear risk “There was one withdrawal due to dizzi-
ness, diarrhea, and flu-like symptoms and
three volunteers spontaneously reported
minor sleep-related AEs (adverse events)
, including insomnia, unpleasant dreams,
superficial sleep, and early awakening.
These events all occurred in themefloquine
loading dose phase”
Comment: not clear whether this with-
115Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Schlagenhauf 1997 (Continued)
drawal was included in the data analysis
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety High risk “The individual Environmental Symptom
Questionnaire (ESQ) symptoms were also
analyzed and items selected for their rele-
vance to mefloquine administration were
assessed by Cochran’s Q test for related
samples”
Comment: intra-individual changes in
scores were obtained during the study, but
outcomes were presented as means across
groups. Data from the ESQ were not re-
ported, only “no significant differences”.
Data for the Profile of Mood States ques-
tionnaire was presented in a graph with no
standard deviations
Other bias High risk This study was sponsored by the F. Hoff-
mann La Roche Tropical Medicine Unit
(Basel, Switzerland). The role of the study
sponsor was not clear
Schlagenhauf 2003
Methods Design: RCT
Study dates: 1998 to 2001
Malaria transmission pattern and local drug resistance: not mentioned
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 674
Inclusion criteria: adult travellers aged 18 to 70 years, with planned travel of 1 to 3 weeks
to a malaria-endemic area, and consulting at a travel clinic ≥ 17 days before departure
Exclusion criteria: glucose-6-phosphate dehydrogenase deficiency, history of severe ad-
verse events with any of the four study drugs or a contra-indication for their use, preg-
nancy or unwillingness to adhere to reliable contraception, history of seizures, psychi-
atric disorders, severely impaired renal or hepatic function, concurrent or recent vaginal
infections or bacterial enteric disorders, a history of photosensitivity, or unwillingness to
adhere to the study protocol
Countries of recruitment: Switzerland, Germany and Israel
Region of malaria exposure: sub-Saharan Africa
Duration of exposure to malaria: 1 to 3 weeks
Type of participants: travellers
Interventions 1. Mefloquine (1 capsule containing mefloquine hydrochloride 274.09 mg, equivalent
to mefloquine 250 mg base) once weekly, starting 17 days before travel and continuing
for 4 weeks after travel*
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2. Chloroquine-proguanil (1 combined capsule containing chloroquine diphosphatase
161.21 mg, equivalent to chloroquine 100 mg base; and 200 mg proguanil hydrochlo-
ride) once daily, starting 17 days before travel and continuing for 4 weeks after travel*
3. Doxycycline (1 capsule containing doxycycline monohydrate 100 mg) once daily,
starting 17 days before travel and continuing for 4 weeks after travel*
4. Atovaquone-proguanil (1 combined capsule containing 250 mg atovaquone and 100
mg proguanil hydrochloride) once daily, starting 17 days before travel and continuing
for 1 week after travel*
*matched placebo for each treatment arm
Outcomes Included in the review:
1. Adverse events; any
2. Serious adverse events
3. Adverse events; other (’gastrointestinal’, ’skin symptoms’, ’neuropsychological’) - any
severity, mild, moderate, severe
4. Discontinuation of study drug due to adverse effects
5. Adverse events; other outcomes (profile of mood states, quality of life score)
Notes Funding sources: GlaxoSmithKline supplied atovaquone-proguanil and gave financial
support; Zeneca supplied chloroquine-proguanil; Pfizer supplied doxycycline; Roche
supplied mefloquine and gave financial support
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation was from a computer gen-
erated table of numbers in permuted blocks
of five”
Allocation concealment (selection bias) Unclear risk “Participants were allocated treatment se-
quentially in order of study numbers. Al-
location concealment was by sealed enve-
lope”
Comment: not reportedwhether envelopes
were opaque
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “The drugs were provided as identical cap-
sule blister packs in weekly cards”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: Described as double blind but
no mention of how this was achieved for
researchers and outcome assessors
Incomplete outcome data (attrition bias);
efficacy
High risk Comment: Method of detection for
malaria, frequency and duration of follow
up were not reported
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Incomplete outcome data (attrition bias);
safety
Unclear risk “Adverse events were analysed in 623 par-
ticipants who completed questionnaires at
recruitment and at least one of the follow
up periods”
“Data was collected during recruitment
and at follow up 13-11 days before depar-
ture, 6-4 days before departure and 7-14
days after departure”
Comment: it was unclear how many par-
ticipants provided data at each time point
Selective reporting (reporting bias); efficacy Low risk “No cases of malaria were reported for any
study arm”
Selective reporting (reporting bias); safety High risk “Adverse events were analysed in 623 par-
ticipants who completed questionnaires at
recruitment and at least one of the follow
up periods”
“Data was collected during recruitment
and at follow up 13-11 days before depar-
ture, 6-4 days before departure and 7-14
days after departure”
Comment: Data were presented on aggre-
gate across multiple time points
Other bias High risk Funding: Pfizer, GlaxoSmithKline, Roche,
and Zeneca provided the drugs free of
charge. GlaxoSmith Kline and Roche pro-
vided research grants
“Competing interests: PS has received
speakers’ honorariums and travel expenses
from Roche and GlaxoSmithKline. She
acted as a consultant to Roche in a drug
safety database evaluation. RS has received
speakers’ honorariums and travel expenses
from GlaxoSmithKline, Roche, and Pfizer.
He is also a member of the advisory board
of GlaxoSmithKline for malaria prophy-
laxis related questions. BB has received a
speaker’s honorarium and travel expenses
from GlaxoSmithKline. HN has received
speakers’ honorariums and travel expenses
from GlaxoSmithKline on different occa-
sions. He has been principal or coinvesti-
gator in several vaccine trials sponsored by
GlaxoSmithKline”
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Schneider 2013
Methods Design: retrospective cohort study
Study dates: 1 January 2001 and 1 October 2009
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: Incident cases of a neuropsychiatric disorder including anxiety, stress-related disorders
or psychosis, depression, epilepsy or peripheral neuropathies during or after anti-malarial drug use within the UK
general practice research database
Participants Number enrolled: Not available
Inclusion criteria: ”We identified in the general practice research database all patients who had ≥ 1 prescription of
mefloquine, chloroquine and/or proguanil or atovaquone/proguanil between January 1, 2001 and October 1, 2009,
and who had a pre-travel consultation within 1 week of the prescription“
Exclusion criteria: ”We only included subjects who used anti-malarial drugs for malaria prophylaxis... Furthermore,
individuals had at least 12 months of information on prescribed drugs and medical diagnoses before the first pre-
scription date for a study drug. In addition, subjects had recorded activity (diagnoses or drug prescriptions) at any
time after the prescription for an anti-malarial drug to include only subjects who returned to the UK. We excluded
all patients with a diagnosis of malaria prior to the start of anti-malarial drug use, patients with a history of cancer,
alcoholism, rheumatoid arthritis; or with an outcome of interest prior to using anti-malarial drugs. The date of the
first neuropsychiatric disorder was the index date for each case“
Country of recruitment: UK
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions Included in review comparisons:
1. Mefloquine*
2. Atovaquone-proguanil*
Not included in review comparisons:
3. Chloroquine-proguanil*
4. Unexposed (case-control design)
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; psychiatric disorders (anxiety, depression, psychosis)
2. Adverse events; other (’anxiety or stress related disorders or psychosis’, epilepsy, neuropathy, phobia, panic attack)
Notes Funding sources: F. Hoffmann-La Roche Ltd., Basel, Switzerland
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex and BMI were measured but only reported for
people experiencing adverse events
2. Selection of participants into the study: moderate
”We excluded all patients with a personal history of
recorded neuropsychiatric disorders from the study pop-
ulation, but family history is not consistently recorded in
the database“
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3. Measurement of interventions: moderate
”We only included subjects who used anti-malarial drugs
for malaria prophylaxis. We identified prescriptions for
which the GP recorded - within a week of the anti-malar-
ial drug prescription - specific codes indicating that the
person received the prescription for malaria prophylaxis,
such as ’travel advice’ or “prophylactic drug use”
4. Departures from intended interventions: serious
It is possible that participants discontinued or switched
medication and this would not have been captured in the
study
5. Missing data: moderate
The study did not report the total number of participants,
only those who experienced adverse events
6. Measurement of outcomes: moderate
General practitioners diagnosing patients would have
been aware of their exposure status
7. Selection of the reported results: moderate
Data for anxiety, stress-related disorders and psychosis
were reported on aggregate
8. Other: serious
Study was sponsored by Roche. The role of the funding
source was not made clear
Schwartz 1999
Methods Design: cross-sectional cohort study
Study dates: October 1995 to April 1998
Malaria transmission pattern and local antimalarial drug resistance: ”bothP. falciparum andP. vivax are hyperendemic“
Adverse eventmonitoring: ”...we directly contacted all travelers for complete follow-up and assessment of compliance.
Fifty travelers taking primaquine completed a questionnaire regarding side effects“
Participants Number enrolled: 158
Inclusion criteria: Israelis participating in rafting trips in Southern Ethiopia
Exclusion criteria: none mentioned
Country of recruitment: Israel
Country of malaria exposure: Ethiopia
Duration of exposure to malaria: 14 to 20 days
Type of participants: travellers
Interventions Included in review comparisons:
1. Mefloquine (1 x 250 mg tablet) weekly, Starting 1 week prior to departure, during travel and for 4 weeks after
return
2. Doxycycline (1 x 100 mg tablet) daily
Not included in review comparisons:
3. Primaquine 15 mg daily for travellers with body weight < 70 kg and 30 mg for those weighing > 70 kg, starting 1
day prior to departure and continuing for up to 2 days after departure
4. Hydroxychloroquine*
*dosing regimen not specified
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Outcomes Included in the review:
1. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
2. Clinical cases of malaria
3. Measure of adherence to the drug regimen (not fully reported)
4. Adverse effects; any (methods of detection different for primaquine versus other regimens)
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex and BMI were not reported for any participants.
Destination and duration of travel was roughly equivalent
across all groups
2. Selection of participants into the study: moderate
Subjects were selected on the basis of their travel destina-
tion. Start of follow up and start of intervention coincide.
No non-responses were reported
3. Measurement of interventions: moderate
”Prior to the trip, participants consulted one of a number
of travel clinics in Israel, among them our clinic“
Comment: it was unclear how intervention status was
ascertained for participants who visited other clinics
4. Departures from intended interventions: low
Two discontinuations (158 participants) were reported
5. Missing data: serious
”In addition, we directly contacted all travelers for com-
plete follow-up and assessment of compliance. Fifty trav-
elers taking primaquine completed a questionnaire re-
garding side effects“
It was unclear how information on discontinuations and
side effects were obtained for participants who did not
take primaquine”
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: serious
“In addition, we directly contacted all travelers for com-
plete follow-up and assessment of compliance. Fifty trav-
elers taking primaquine completed a questionnaire re-
garding side effects”
It was unclear how information on discontinuations and
side effects was obtained for participants who did not take
primaquine
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8. Other: no information
No informationwas provided regarding the study sponsor
Shamiss 1996
Methods Design: cross-sectional cohort study
Study dates: not mentioned
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 45
Inclusion criteria: none mentioned
Exclusion criteria: none mentioned
Factors influencing drug allocation: “Prior knowledge about the side effect profile of mefloquine forced us to prescribe
doxycycline 100 mg daily for aviators and mefloquine 250 mg weekly for non-aviator crew”
Country of recruitment: Israel
Country of malaria exposure: Rwanda and Zaire
Duration of exposure to malaria: “biweekly flights to and from Rwanda to Zaire with an average of 4 hours stay in
the field over a period of 2 months”
Type of participants: military
Interventions 1. Mefloquine (1 x 250 mg tablet) weekly, starting on the day of travel (< 12 hours before the first flight) and
continuing until 4 weeks after return
2. Doxycycline (1 x 100 mg tablet) daily, starting on the day of travel (< 12 hours before the first flight) and continuing
until 4 weeks after return
Outcomes Included in the review:
1. Adverse effects; any, nausea, abdominal pain, dizziness
2. Adverse effects; other (fatigue)
3. Discontinuations of study drug due to adverse effects
4. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
5. Clinical cases of malaria
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex and BMI were not measured. Destination and dura-
tion of travel were set by the study design
2. Selection of participants into the study: low
“Prior knowledge about the side effects profile of meflo-
quine forced us to prescribe doxycycline 100 mg daily for
aviators and mefloquine 250 mg weekly for non-aviator
aircrew up to 1 mo after the last return”
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All participants completed questionnaires.
3. Measurement of interventions: low
Type of prophylaxis usedwas set by the job of the included
participants
4. Departures from intended interventions: low
“Two non-aviators were dropped from the study because
of receiving the wrong prescription”
5. Missing data: low
“Two non-aviators were dropped from the study because
of receiving the wrong prescription”
Information was provided for the remaining 43 partici-
pants.
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
“...the questionnaire included questions about compli-
ance, side effects attributed to chemoprophylaxis, and any
illness after return”
No information was provided regarding illness after re-
turn.
8. Other: no information
No information is provided regarding the study sponsor
Sharafeldin 2010
Methods Design: retrospective cohort study
Study dates: July 2006 to December 2008
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: “Participants… were sent an informative email asking them to complete a web-based
questionnaire”
Participants Number enrolled: 242 students sent questionnaire, 180 respondents
Inclusion criteria: “all medical students who had performed an elective abroad between July 2006 and December
2008, who had visited countries where hepatitis A is endemic, and who had notified the student registrar to obtain
study credits”
Exclusion criteria: none mentioned
Factors influencing drug allocation: “...students are free to visit [our occupational health department] or any other
travel clinic including the LUMC in-hospital travel clinic or their general practitioner”
Country of recruitment: Netherlands
Country of malaria exposure: none mentioned
Duration of exposure to malaria: mean duration of stay = 74 days (range 10 to 224 days )
Type of participants: travellers
Interventions Included in review comparisons:
1. Mefloquine*
2. Atovaquone-proguanil*
3. Doxycycline*
Not included in review comparisons:
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Sharafeldin 2010 (Continued)
4. Primaquine*
5. Proguanil*
6. Chloroquine* (no data reported)
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any
2. Serious adverse outcomes
3. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
4. Clinical cases of malaria
5. Risk of infection with bloodborne viruses
6. Health risks while abroad
7. Health problems experienced whilst abroad
8. Health problems experienced on return
Notes Funding sources: There was no dedicated funding for this project
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex, destination and duration of travel weremeasured
but information not provided across groups. BMI was not
measured
2. Selection of participants into the study: serious
Response rate 180/242 (74.4%)
3. Measurement of interventions: serious
“...six students did not remember which prophylaxis had
been prescribed”
Students were asked to self-report which prophylaxis they
took an average of 235 days after completing their trip
4. Departures from intended interventions: moderate
“Eight students who used mefloquine (20%) stopped the
drug prematurely as did ten students on atovaquone-
proguanil (16%) and the student on doxycycline. Only
two of these students switched to another prophylaxis”
5. Missing data: low
“none of the questionnaires was incomplete”
All participants were included in the analysis
6. Measurement of outcomes: serious
The outcome measure was subjective; participants and
personnel were not blinded
7. Selection of the reported results: moderate
Insufficient information was provided on how data on
adverse effects were sought
8. Other: low
“There was no dedicated funding for this project”
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Sonmez 2005
Methods Design: prospective cohort study
Study dates: April 2002 to October 2003
Malaria transmission pattern and local antimalarial drug resistance: “20% of recent cases were due to P. falciparum’
’chloroquine resistant P. falciparum”
Adverse event monitoring: “common questionnaires were used to investigate the compliance to and side effects of
both regimes”
Participants Number enrolled: 1400 soldiers worked in the region
Inclusion criteria: “...all Turkish soldiers were examined in detail and serum samples were taken before heading for
the region”
Exclusion criteria: “...none of the participants had any chronic disease”
Factors influencing drug allocation: “The preference of the preventive regime was related to the availability of the
drugs... the prophylaxis was started with doxycycline, which was at hand in March 2002. Then again the soldiers
who came after July 2002 were given mefloquine”
Country of recruitment: Afghanistan
Country of malaria exposure: Afghanistan
Duration of exposure to malaria: “The average time of presence for a single soldier in Kabul region was approx. 6
month [sic]”
Type of participants: military
Interventions 1. Mefloquine*
2. Doxycycline*
*dosing regimen not specified
Outcomes Included in the review:
1. Serious adverse effects
2. Adverse effects; any, nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, dyspepsia, anorexia
Outcomes assessed not included in the review:
3. Clinical cases of malaria
Notes Funding sources: Not mentioned
Communications with study author:
Sonmez 2005 no longer had access to the original study data. However, the study authors confirmed that for table
1: “The comparisons of the number of side effects of both regimes” the number of side effects for specific symptoms
e.g. nausea was equivalent to the number of soldiers reporting that side effect. In addition, the authors were able to
clarify a discrepancy in the original text: the paper states “27 mefloquine takers (41.2%) reported 43 side effects at the
2nd week of prophylaxis”. The total number of mefloquine participants was 228; 41.2% equates to 94 participants.
The authors confirmed that the correct figure was 27 mefloquine users (11%)
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age of participants was balanced across groups. Destina-
tion and duration of travel were set by the study design.
Sex and BMI were not reported
2. Selection of participants into the study: serious
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734 soldiers returned questionnaires (52.2%)
3. Measurement of interventions: low
All soldiers were issued with prophylaxis
4. Departures from intended interventions: low
Switches betweenprophylactic regimenswere not possible
5. Missing data: low
The data were collected at 2 time points. The reported
denominator for each time point was the same
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
There was insufficient information provided to be sure
that all outcomes included in the questionnaire were re-
ported
8. Other: no information
No informationwas provided regarding the study sponsor
Sossouhounto 1995
Methods Design: RCT
Study dates: January 1989 to June 1989
Malaria transmission pattern and local antimalarial drug resistance: “region endemic for
P. falciparum malaria”
Adverse event monitoring: “participants had access to a village health center, where
they could notify personnel of any malaise or side effects. Clinical examinations and
parasitologic tests were performed every 4 weeks. Blood counts were carried out at the
end of weeks 4, 19 and 24”
Participants Number enrolled: 500
Inclusion criteria: “five-hundred male volunteers, aged 16-60 years, who were residents
of a local village, were randomly assigned”
Exclusion criteria: none mentioned
Country of recruitment: Adzope region, Ivory Coast
Country of malaria exposure: Adzope region, Ivory Coast
Duration of exposure to malaria: study duration 20 weeks
Type of participants: Ivory Coast residents, semi-immune
Interventions Included in review comparisons:
1. Mefloquine (1 x 250 mg tablet) weekly in weeks 1 to 4, (1 x 125 mg tablet) weekly in
weeks 5 to 20
2. Chloroquine (1 x 300 mg tablet) weekly for 20 weeks
3. Placebo (1 tablet) weekly for 20 weeks
Not included in review comparisons:
4. Fansidar
5. Fansifem
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Outcomes Included in the review:
1. Clinical cases of malaria
2. Episodes of parasitaemia
3. Serious adverse events
4. Adverse events: any, diarrhoea, headache, pruritis
Outcomes assessed not included in the review:
5. Laboratory tests; haematocrit and white blood cell count
6. Adverse events: other (leukopenia, malaise; did not occur in any study participants)
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Five-hundredmale volunteers…were ran-
domised”
Comment: Method of randomization was
not described
Allocation concealment (selection bias) Unclear risk Comment: no description of allocation
concealment was provided
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk “double blind”. “The medications and
placebo were identical in appearance”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no information was provided on how this
was achieved for researchers and outcome
assessors
Incomplete outcome data (attrition bias);
efficacy
Low risk “Four hundred and ninety-nine subjects
were evaluated for safety (at least one tablet
taken and one visit) as well as for efficacy”
Comment: 499/500 (99.8%) participants
included in the analysis
Incomplete outcome data (attrition bias);
safety
Low risk “Four hundred and ninety-nine subjects
were evaluated for safety (at least one tablet
taken and one visit) as well as for efficacy”
Comment: 499/500 (99.8%) participants
included in the analysis
Selective reporting (reporting bias); efficacy Low risk Comment: all outcomes prespecified in the
methods section were reported
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Selective reporting (reporting bias); safety Unclear risk “Blood counts were carried out at the end
of weeks 4, 19 and 24”
Comment: blood counts were reported
only for one participant who developed re-
versible leukopenia
Other bias Unclear risk Comment: no information provided re-
garding the study sponsor
Steffen 1993
Methods Design: cohort study
Study dates: Malpro 1- April 1985 to July 1988, Malpro 2- July 1988 to December 1991
Malaria transmission pattern and local antimalarial drug resistance: various, not stated
Adverse event monitoring: self-completed questionnaires were distributed and collected by cabin crews to all passen-
gers returning on charter planes
Participants Number enrolled: 145,003
Inclusion criteria: not explicitly stated. This trial includes two publications, Steffen 1993 states “All passengers
returning on charter planes from Mombasa, Kenya, to Europe”, whereas Steffen 1990 states “all passengers flying
back to Europe from East Africa (Kenya) or West Africa (9 countries)”. Data have been included from Steffen 1993
Exclusion criteria: “All travellers who stayed longer than one year in tropical Africa were excluded, as were those who
did not spend the main part of their visit in East Africa (Kenya, Tanzania and Uganda)”
Country of recruitment: not applicable
Region of malaria exposure: East Africa (Kenya, Tanzania, Uganda)
Duration of exposure to malaria: various, not stated
Type of participants: travellers
Interventions Included in review comparisons:
1. Mefloquine*
2. Chloroquine (1 x 300 mg tablet) weekly
Not included in review comparisons:
3. Chloroquine (1 x 600 mg tablet) weekly
4. Proguanil*
5. Chloroquine + proguanil*
6. Pyrimethamine + sulfadoxine*
7. Non-users (this population was asked about side effects (adverse effects) and instead answered regarding adverse
events
*dosing regimen not specified
Outcomes Included in the review:
1. Serious adverse effects
2. Adverse effects; any (mild, moderate or severe), visual impairment, nausea, headache, dizziness, insomnia, depres-
sion, pruritis
3. Adverse effects; other (’other skin’, medical consultations due to side effects, incapacitation due to side effects,
’cutaneous’, ’redness of the skin’, consulted a doctor)
4. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
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Steffen 1993 (Continued)
5. Clinical cases of malaria
6. Measures taken against mosquito bites
7. Sources of pre-travel health information
8. Places visited in tropical Africa
Notes Funding sources: “This study was sponsored by F. Hoffman-La Roche Ltd, Basel, Switzerland”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex and BMI were not reported across different pro-
phylactic groups
2. Selection of participants into the study: moderate
“In Malpro 1, 80.1% of all passengers completed the in-
flight questionnaire… inMalpro 2 the response rate [was]
83.9%”
3. Measurement of interventions: low
Passengers were asked to self-report which malaria pro-
phylaxis was used. Data were collected on the journey
home, meaning it was likely that passengers were still tak-
ing this medication
4. Departures from intended interventions: low
Handschin 1997: “2.9% of passengers changed the pro-
phylactic regimen during the observation period”
5. Missing data: moderate
Malpro 1 losses to follow-up 4.1%, Malpro 2 losses to
follow-up 14.1%
6. Measurement of outcomes: moderate
The outcome measure was subjective; participants and
personnel were not blinded. Serious adverse events were
verified independently
7. Selection of the reported results: serious
Data on non-serious side effects were not included from
Malpro 1- 31% of participants (44,667) were not in-
cluded
8. Other: serious
The study was funded by Roche. The role of the study
sponsor was not made clear
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Methods Design: quasi-RCT
Study dates: September 1987 to June 1990
Malaria transmission pattern and local antimalarial drug resistance: “primarily P falci-
parum (> 90%), some P malariae and minimal P ovale... High levels of Plasmodium fal-
ciparum resistance to CQ... sensitivity of P. falciparum to mefloquine was documented”
Adverse event monitoring: “At the time of each dose, a questionnaire was administered
to record symptoms including fever and reported drug side effects since the last visit”
Participants Number enrolled: 4220
Inclusion criteria: “...consecutive attenders at first antenatal clinic visit were enrolled at
three sites… At a fourth side, consecutive attenders in their first and second pregnancy
were enrolled”
Exclusion criteria: “At this site [fourth site, government district hospital] women with
two or more pregnancies were not enrolled because of the large number of patients
attending the clinic and the limited number of study staff ”
Country of recruitment: Malawi
Country of malaria exposure: Malawi
Duration of exposure to malaria: Ongoing in semi-immune population - monitored
from enrolment for various periods of time
Type of participants: pregnant Malawian residents, semi-immune
Interventions 1. Mefloquine (1 x 250 mg tablet) weekly, with a single loading dose of 750 mg
2. Chloroquine (1 x 300 mg tablet) weekly, with a loading dose 25 mg of base/kg given
as a divided dose over 2 days
3. Chloroquine (1 x 300 mg tablet) weekly
Outcomes Included in the review:
1. Episodes of parasitaemia
2. Adverse events; any
3. Serious adverse events
4. Discontinuations of study drug due to adverse effects
5. Adverse pregnancy outcomes; still births, abortions
Outcomes assessed not included in the review:
6. Frequency of placental malarial infection
7. Frequency of prematurity or intra-uterine growth retardation
8. Frequency of maternal febrile illness or anaemia
9. Likelihood of infant acquisition of malarial infection
Notes Funding sources: “This work was supported and made possible by the Africa Bureau,
Office of Operations and New Initiatives and the Office of Analysis, Research and
Technical Support, theUSAID through the AfricaChild Survival initiative…TheGlobal
Program on AIDS, World Health Organisation provided support for the HIV testing
and evaluation portion of this study”
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
High risk “Systematic assignment of regimens was
done based on the clinic and day of enrol-
ment… All women making their first an-
tenatal clinic on a given day were assigned
to the same regimen; the following day, en-
rolled women were assigned to the follow-
ing regimen”
Allocation concealment (selection bias) High risk “Systematic assignment of regimens was
done based on the clinic and day of enrol-
ment… All women making their first an-
tenatal clinic on a given day were assigned
to the same regimen; the following day, en-
rolled women were assigned to the follow-
ing regimen”
Blinding of participants and personnel
(performance bias)
Adverse effects/events
High risk Comment: no mention of participants be-
ing blinded to which prophylactic regimen
they were taking
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “All blood smear examinations were done
with the microscopist blinded to the study
subject’s antimalarial regimen”
Comment: No mention of outcome asses-
sors being blinded to the treatment regi-
men used when assessing safety outcomes
Incomplete outcome data (attrition bias);
efficacy
Unclear risk “Among the 4187 enrolled women, 3380
(81%) [were analysed]… 94 did not have
an initial blood smear result for compari-
son, 89 left the study area before follow up,
397delivered before the followup visit, 133
missed their appropriate follow up visit,
and 94 did not have documented adher-
ence to the drug regimen”
Comment: numbers lost to follow up were
not reported across groups
Incomplete outcome data (attrition bias);
safety
High risk “A total of 4101 women had informa-
tion available after their first dose and
2976 women had information available af-
ter their dose at four weeks”
Comment: reasons for missing data were
not reported
Selective reporting (reporting bias); efficacy Unclear risk “Only P falciparum infections were of in-
terest for this study… when P malariae
alone was identified these infections were
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excluded from the analysis”
“For the purposes of malaria prevention
and infant outcome we analysed the group
of women… only if they were enrolled in
the study for six or more weeks and had
received the appropriate amount of medi-
cation during their participation”
“A total of 1,790 women delivered in study
health facilities had received proper dosing
on their antimalarial regimen, andhad their
peripheral blood examined”
Comment: women who had reported fever
during pregnancy, and during the 2 weeks
prior to delivery was reported, but not re-
ported across antimalarial drug regimens
Selective reporting (reporting bias); safety High risk “All other complaints e.g. weakness, heart
palpitations accounted for less than 15% of
reported symptoms”
Comment: Data were collected weekly but
only reported after the first and the fourth
dose
Other bias Low risk “This work was supported and made pos-
sible by the Africa Bureau, Office of Oper-
ations and New Initiatives and the Office
of Analysis, Research and Technical Sup-
port, the USAID through the Africa Child
Survival initiative… The Global Program
on AIDS,World Health Organisation pro-
vided support for theHIV testing and eval-
uation portion of this study”
Stoney 2016
Methods Design: Prospective cohort study
Study dates: 2009 to 2011
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: “...participants were asked to complete a survey each week during travel and a post-travel
survey within 2-4 weeks after return”
Participants Number enrolled: 628 participants completed all three surveys, 370 included in the analysis
Inclusion criteria: “Travelers were included from among all those enrolled if they received a prescription for chemo-
prophylaxis, traveled to at least one malaria-endemic area, and completed pre- and post-travel surveys and at least
one during-travel survey”
Exclusion criteria: “To complete the study in a reasonable amount of time, only participants with shorter durations
of travel (approximately 2 months) were included”
Factors influencing drug allocation: “Several different medications are available for malaria chemoprophylaxis, de-
pending on the traveler’s destination and medical history”
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Country of recruitment: USA
Country of malaria exposure: India (13%), Tanzania (8%), Kenya (7%), South Africa (7%), and Haiti (7%)
Duration of exposure to malaria: median travel duration 13 days
Type of participants: travellers
Interventions Included in the review:
1. Mefloquine*
2. Doxycycline*
3. Atovaquone-proguanil*
4. Chloroquine*
Not included in the review:
5. Primaquine*
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse effects; any, headache, abnormal dreams ’intense nightmares’, any gastrointestinal
2. Discontinuations of study drug due to adverse effects
3. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
4. Clinical cases of malaria
5. Reasons for non-compliance with chemoprophylaxis (data provided on aggregate),
6. Use of personal protective measures for malaria prevention
Notes Funding sources: “This work was supported by a cooperative agreement [1 U19CI000508-01] between the Centers
for Disease Control and Prevention and Boston Medical Center”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex, destination and duration of travel were recorded
but figureswere not reported across prophylactic regimens
2. Selection of participants into the study: moderate
No informationwas provided regarding travellers who did
not wish to participate in the study
3. Measurement of interventions: low
“The type of chemoprophylaxis prescribed were collected
from data entered by clinicians into patients’ medical
records”
4. Departures from intended interventions: moderate
No switches or discontinuations were reported. It was un-
clear whether this information was captured in the ques-
tionnaire
5. Missing data: low
364/370 (98%) participants were included in the analysis
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective, partici-
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pants and personnel were not blinded
7. Selection of the reported results: moderate
Insufficient information provided on how data on adverse
effects were obtained to determine whether all outcomes
had been reported
8. Other: low
Government funding
Tan 2017
Methods Design: retrospective cohort study
Study dates: 18 July to 16 September 2016
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 8931
Inclusion criteria: Returned Peace Corps volunteers (RPCV) who served between 1995 and 2014 and had an e-mail
address in Peace Corps’ RPCV database
Exclusion criteria: None mentioned
Factors influencing drug allocation: none specified
Country of recruitment: USA
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: returned Peace Corps volunteers
Interventions 1. Mefloquine*
2. Doxycycline*
3. Atovaquone-proguanil*
4. Chloroquine*
*dosing regimen not specified
Outcomes Included in the review:
1. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
2. “Questions about medications before, during, or after Peace Corps, as well as habits such as drinking”
Notes Funding source: “this research did not receive any specific grant from funding agencies in the public, commercial, or
not-for-profit sectors”
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Important confounders were measured but not been re-
ported across groups. Duration and destination of travel
were not measured
2. Selection of participants into the study: serious
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8931/47,238 potential respondents included (13% re-
sponse rate)
3. Measurement of interventions: serious
Participants were asked to self-report which chemopro-
phylaxis they had taken at least 2 years after they had fin-
ished the course
4. Departures from intended interventions: serious
Limited information was provided regarding switches be-
tween interventions. Participants were asked to self-report
this information at least 2 years after finishing treatment
5. Missing data: low
Information on adherence was reported for all partic-
ipants who answered this question (5026 respondents/
5055 who reported taking malaria prophylaxis)
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
There was insufficient information provided to be sure
that all outcomes included in the questionnaire were re-
ported
8. Other: low
“This research did not receive any specific grant from
funding agencies in the public, commercial, or not-for-
profit sectors”
Terrell 2015
Methods Design: cross-sectional cohort study
Study dates: 2012 and 2013
Malaria transmission pattern and local antimalarial drug resistance: ”...high risk of malaria (mainly P. falciparum)
in Kenya, although the risk is assessed as very low in Nairobi and in the highlands above 2,500 m... widespread
resistance to chloroquine“
Adverse event monitoring: ”...questionnaire-based, two-arm cohort study“
Participants Number enrolled: 2032 completed questionnaires available, 220 failed to indicate which drug they were taking
Inclusion criteria: all military personnel on deployment to Kenya who travelled on one of three main body flights on
their return to the UK
Exclusion criteria: none mentioned
Factors influencing drug allocation: ”...the choice of drugs considered in this study was limited to mefloquine or
doxycycline... participants were free to use another drug should they experience unacceptable adverse effects or where
there was an occupational reason“
Country of recruitment: UK
Country of malaria exposure: Kenya
Duration of exposure to malaria: ”The majority of participants spent approximately 6 weeks in Kenya with a small
number spending a few weeks longer if they filled an administrative role“
Type of participants: military
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Interventions Included in review comparisons:
1. Mefloquine*
2. Doxycycline*
Not included in review comparisons:
3. Atovaquone-proguanil* (results not included in the analysis)
*dosing regimen not specified
Outcomes Included in the review :
1. Adverse effects; any
2. Measure of adherence to the drug regimen
Outcomes assessed not included in the review:
3. Clinical cases of malaria
4. Impact of adverse effects on self-reported ability to work
Notes Funding sources: ”The research was not sponsored by any external body“
After we submitted the review for peer referee, the author sent us a spreadsheet containing numbers of events relating
to a variety of symptoms after the review had been submitted for publication. These data are not included in the
review and will require some clarification over how they were collected to allow us to assess risk of bias. This additional
information will be considered in future updates
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
”Although not formally recorded, each unit can be as-
sumed to be composed of similar populations in terms of
number, age, gender, occupation, and general health“
2. Selection of participants into the study: serious
”Completion rates were consistently poor throughout the
study period with only 150 to 250 questionnaires re-
turned per tranche of around 1,000 troops“
3. Measurement of interventions: low
Participants were asked to self-report which medication
they were on while still taking the medication”
4. Departures from intended interventions: moderate
“...[participants] were invited to complete the question-
naire for whichever drug they took for the longer period”
5. Missing data: moderate
“2,032 completed questionnaires available for analysis of
which 10.8% (220) failed to indicate which drug they
were taking”
6. Measurement of outcomes: serious
The outcome measure was subjective; participants and
personnel were not blinded
7. Selection of the reported results: serious
“In both arms, some participants indicated that they had
experienced an adverse effect but did not report how it had
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impacted upon their ability to work. They were excluded
from the final analysis”
Mefloquine: 71 participants, doxycycline: 67 participants
8. Other: low
“The research was not sponsored by any external body”
Tuck 2016
Methods Design: cohort study
Study dates: 15 to 22 February 2015
Malaria transmission pattern and local antimalarial drug resistance: not specified
Adverse event monitoring: patient self-reported questionnaire
Participants Number enrolled: 115 (337 eligible)
Inclusion criteria: all land-based members of a UK military expedition to Sierra Leone
Exclusion criteria: none specified
Country of recruitment: Sierra Leone
Country of malaria exposure: Sierra Leone
Duration of exposure to malaria: not specified
Type of participants: military
Interventions 1. Mefloquine
2. Doxycycline
3. Atovaquone-proguanil
Outcomes Included in the review:
1. Adverse effects: any, nausea, abdominal pain, diarrhoea, dizziness, insomnia ’disturbed sleep’, pruritis, indigestion,
mouth ulcers, lethargy
2. Measure of adherence to the drug regime
Notes Funding source: unfunded
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Age, sex and BMI were not measured. Demographic in-
formation not reported across groups
2. Selection of participants into the study: serious
151 (46.3%) returned survey forms
3. Measurement of interventions: low
Participants were asked to self-report which medication
they were taking while taking it
4. Departures from intended interventions: moderate
Switches between groups were recorded. 8/151 recipients
had medications switched due to unacceptable adverse
effects. It was unclear to which drug adverse effects were
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attributed
5. Missing data: low
Data were reported for all survey respondents.
6. Measurement of outcomes: serious
The outcome measure was subjective; participants and
personnel were not blinded
7. Selection of the reported results: moderate
There was insufficient information provided to be sure
that all outcomes included in the questionnaire were re-
ported
8. Other: low
“This audit was unfunded”
van Riemsdijk 1997
Methods Design: prospective cohort study
Study dates: 24 February to 24 May 1994
Malaria transmission pattern and local antimalarial drug resistance: various, not stated
Adverse event monitoring: participant self-reporting questionnaire
Participants Number enrolled: 1791 eligible and willing to co-operate, data obtained from 1501 participants
Inclusion criteria: “...persons who visited the Travel Clinic in the period between 24 February and 24 May, 1994,
and who had an anticipated date of return to the Netherlands before the end of the study period, and who had given
informed consent”
Exclusion criteria: none stated
Country of recruitment: Rotterdam, Netherlands
Region of malaria exposure: various; Africa, South America, Asia or the Middle East
Duration of exposure to malaria: various, not specified
Type of participants: travellers
Interventions Included in review comparisons:
1. Mefloquine (1 x 250 mg tablet) weekly
2. Non-users of antimalarials
Not included in review comparisons:
3. Proguanil (1 x 200 mg tablet) daily
Outcomes Included in the review:
1. Adverse events; nausea, diarrhoea, dizziness, abnormal dreams, insomnia, anxiety, depression, visual impairment
2. Adverse events; other (agitation, confusion)
Outcomes assessed not included in the review:
3. Profile of mood states (only reported in comparison with proguanil)
Notes Funding sources: Not stated
Risk of bias
Bias Authors’ judgement Support for judgement
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Other bias Unclear risk 1. Counfounding: low
Identified confounders were measured and balanced
across groups
2. Selection of participants into the study: moderate
1501/1791 (86% response rate)
3. Measurement of interventions: moderate
Comment: the prescription was provided by a travel clinic
which also performed the study but no information re-
garding switches and discontinuations were recorded or
reported
4. Departures from intended interventions: moderate
No information was provided on discontinuations or
switches
5. Missing data: moderate
1227/1449 (85%) participants were included in the anal-
ysis; chloroquine-proguanil users were not included. The
number of non-users decreased from 392 to 340 without
explanation
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
It was clear what was asked in the questionnaire. Infor-
mation was sought on the severity of adverse events but
this was not reported
8. Other: no information
No informationwas provided regarding the study sponsor
van Riemsdijk 2002
Methods Design: RCT
Malaria transmission pattern and local drug resistance: not mentioned
Study dates: unclear
Adverse event monitoring: baseline evaluation prior to travel, and follow up date 7 days
after the participant left the endemic area and two scheduled telephone conversations
Participants Number enrolled: 140
Inclusion criteria: travellers aged≥ 3 years and weighing ≥ 11 kg with planned travel≤
28 days to a malaria-endemic area (Overbosch 2001)
Exclusion criteria: In the published report “We excluded those who had risk factors
for concentration impairment (e.g. use of opioids, hypnotics, or tranquillizers or use of
alcohol 4 hours before testing)”
Within Høgh 2000 (unclear if the same exclusion criteria were applied): poor general
health; drug hypersensitivity (to atovaquone, chloroquine or proguanil); history of alco-
holism, seizures, psychiatric disorders, severe neurological disorders, severe blood disor-
ders; renal, hepatic or cardiac dysfunction; clinical malaria within previous 12 months;
travel to malaria-endemic area within previous 60 days; risk factors for concentration
impairment (e.g. use of opioids, hypnotics, or tranquillizers; or use of alcohol 4 hours
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before testing)
Country of recruitment: Rotterdam Travel Clinic, Netherlands
Regions of malaria exposure: various malaria endemic destinations (66% in Africa, 13%
South America, 24% other)
Mean duration of exposure to malaria: 19 days
Type of participants: travellers, non-immune
Interventions 1. Mefloquine (1 x 250 mg tablet; or ¼, ½ or ¾ of a tablet, according to body weight)
once weekly, starting 7 days before travel and continuing for 4 weeks after travel*
2. Atovaquone-chloroguanil (1 combined tablet containing 250 mg atovaquone and 100
mg proguanil hydrochloride; or alternatively 1 to 3 combined children’s tablets accord-
ing to body weight, each tablet containing 62.5 mg atovaquone and 25 mg proguanil
hydrochloride) once daily, starting 1 to 2 days before travel and continuing for 1 week
after leaving the malaria-endemic area*
*matched placebo for each treatment arm
Outcomes 1. Adverse events; other outcomes (profile of mood states, neurobehavioural evaluation
system)
2. Measures of adherence to the drug regimen
3. Discontinuations of the study drug due to adverse effects
Notes Funding source: Netherlands Inspectorate for Healthcare gave financial support
’independently performed in a sample of patients from one center that participated
in the MAL30010 multicenter clinical trial’- Enrollment criteria and study conduct
were described in a separate publication (Høgh 2000) which refers to a different study
population (atovaquone-proguanil versus chloroquine-proguanil)
’This study was planned and performed independently from the trial by other researchers
and without knowledge of its results.’
’Subjects were separately recruited and asked for consent during the initial screening visit
of the trial.’
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated code was used to
randomly assign a treatment number to the
three bottles of study drug for every indi-
vidual. At all sites consecutively enrolled in-
dividuals who satisfied all entry criteria re-
ceived the next treatment number” (Høgh
2000)
Allocation concealment (selection bias) Low risk “Treatment codes were provided to inves-
tigators in opaque sealed envelopes, to be
opened only if knowledge of study drug as-
signment was required for management of
a medical emergency” (Høgh 2000)
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Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk “To mask differences between the dosing
regimes, placebo tablets were used... All
placebo treatment regimens were identical
to the aforementioned scheme for the active
ingredient of mefloquine and atovaquone
plus chloroguanide”
Comment: did not mention whether the
placebo and intervention tablets were iden-
tical in appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The assessments were made by researchers
who were unaware of the treatment alloca-
tion”
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
High risk “We enrolled a total of 140 subjects in the
cohort, 119 of whom completed the follow
up”
Comment: Those who did not complete
follow up were not included in the sub-
sequent statistical analysis. The propor-
tion of participants who did not com-
plete the study due to adverse outcomes
varied significantly between groups (67%
mefloquine and 33% atovaquone plus
chloroguanide)
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety Low risk “Data were collected on concurrent med-
ications, as well as subject’s use of coffee,
alcohol and illicit drugs”
“stratification for sex and adjustment for
potential confounders such as smoking and
the use of coffee and tea did not affect the
result”
Comment: these data were not presented
Other bias Low risk Funding: “For this study came from the
Inspectorate for Health Care. Glaxo Well-
come kindly provided us with the treat-
ment allocation codes after completion
of the study. No financial support, how-
ever, was received from any pharmaceutical
company”
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Vuurman 1996
Methods Design: RCT
Study dates: not mentioned
Malaria transmission pattern and local antimalarial drug resistance: not applicable
Adverse event monitoring: ”After each driving test, subjects [described]... the presence
and severity of adverse effects - drowsiness, weakness, headache, fatigue, nervousness,
nausea, dizziness and memory disturbance“
Participants Number enrolled: 42
Inclusion criteria: ”...[volunteers] were medically screened by routine blood chemistry
and haematology tests, a physical examination including an 12-lead ECG recording, and
urine tests for pregnancy and drugs of abuse“
Exclusion criteria: ”...clinically relevant abnormalities in any blood test; far-field, binoc-
ular visual acuity that deviated by more than 0.65 dioptres from normal, corrected or
uncorrected; known hypersensitivity to any drug; history of any serious gastrointestinal,
hepatic, renal neurologic or psychiatric disorder; evidence of drug or alcohol abuse, ex-
cessive alcohol or nicotine use; blood donation or participation in a drug trial within
the prior 2 months; and for premenopausal females, pregnancy, lactation or failure to
exercise reliable birth control“
Country of recruitment: Netherlands
Country of malaria exposure: not applicable
Duration of follow up: 30 days
Type of participants: non-exposed Dutch nationals
Interventions 1. Mefloquine (1 x 250 mg tablet) weekly, with loading dose of one tablet daily for 3
days in week 1
2. Placebo (1 tablet) weekly, with identical loading regimen of placebo tablets
Outcomes 1. Adverse events; any, nausea, diarrhoea, headache, dizziness
2. Adverse events; other (fatigue)
3. Discontinuations of study drug due to adverse effects
4. Adverse events; other outcome measures (critical flicker/fusion frequency, critical
instability tracking test, standardized stabilimetry method of the International Society
of Posturography, tests of driving performance)
Notes Funding sources: ”The study was sponsored by F. Hoffmann-La Roche Ltd“
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”The study followed a randomised, 2-arm,
double-blind, parallel group design“
Comment: method of sequence generation
not described
Allocation concealment (selection bias) Unclear risk ”The study followed a randomised, 2-arm,
double-blind, parallel group design“
Comment: method of allocation conceal-
ment not described
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Blinding of participants and personnel
(performance bias)
Adverse effects/events
Low risk ”They received mefloquine 250 mg or
placebo in identically appearing tablets“
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: described as double blind but
no description of how this was achieved for
researchers and outcome assessors
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Low risk Comment: dropouts were reported. 2/20
participants dropped out of themefloquine
group, one due to adverse effects related to
the study drug
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety High risk ”...subjects used 10 cm visual-analogue
scales to describe their mood in three
dimensions - ’Alertness’, ’Contentedness’,
and ’Calmness’”
Comment: outcomes relating to these de-
scriptions were not reported. The study re-
ports “events occurring more than once” in
each group
Other bias High risk “The studywas sponsored by F.Hoffmann-
La Roche Ltd”
Waner 1999
Methods Design: cross-sectional cohort study
Study dates: April to May 1996
Malaria transmission pattern and local antimalarial drug resistance: “a high risk Malaria area... Chloroquine-resistant
P. falciparum malaria”
Adverse event monitoring: “In-flight self administered questionnaires were distributed and completed by travelers on
flights returning to Johannesburg International Airport”
Participants Number enrolled: 4035 questionnaires distributed, 3051 returned
Inclusion criteria: All travelers boarding the only commercial airline serving this area during April and May 1996
were included in the survey
Exclusion criteria: None mentioned
Country of recruitment: South Africa
Country of malaria exposure: South Africa
Duration of exposure to malaria: various, not specified
Type of participants: travellers
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Interventions Included in review comparisons:
1. Mefloquine*
2. Doxycycline*
3. Chloroquine*
Not included in review comparisons:
4. Chloroquine-proguanil*
5. Proguanil*
*dosing regimen not specified
Outcomes Included in review comparisons:
1. Adverse effects; any
Outcomes assessed not included in the review:
2. Sources of information on malaria prior to visit,
3. Use of personal protective measures against mosquitoes,
4. Measures of adherence to the drug regimen (information provided on aggregate),
5. Travellers knowledge of malaria symptoms
Notes Funding sources: not mentioned
Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Confounding: moderate
Sex of travellers was not provided by prophylactic regi-
men. Destination of travel was set by the study design.
BMI of travellers and duration of travel were not recorded
2. Selection of participants into the study: serious
Response rate 3051/4035 (75%)
3. Measurement of interventions: low
Travellers were asked to self-report which prophylactic
regimen they were taking while still using the drug
4. Departures from intended interventions: moderate
No discontinuations or switches were reported. This in-
formation was not included in the questionnaire
5. Missing data: low
Outcome data were available for 973/978 mefloquine re-
cipients and 80/80 doxycycline recipients
6. Measurement of outcomes: serious
Comment: the outcome measure was subjective; partici-
pants and personnel were not blinded
7. Selection of the reported results: moderate
Insufficient information provided on how data on adverse
effects were obtained to determine whether all outcomes
were reported
8. Other: no information
No information was provided regarding the study spon-
sor.
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Weiss 1995
Methods Design: RCT
Study dates: April to July 1993
Malaria transmission pattern and local antimalarial drug resistance: “Incidence of new
cases of falciparummalaria during the rainy seasons has been measured at 90% in adults.
P. falciparum accounts for > 95% of all malaria in Saradidi”
Adverse event monitoring: “Each subject was visited daily at home by an assigned field
worker, who asked about symptoms of malaria or drug side effects, obtained malaria
smears, or administered drug doses if the subject was not at school”
Participants Number enrolled: 169
Inclusion criteria: aged 9 to 14 years. “Screening consisted of a physical examination,
a urine pregnancy test for girls, and blood tests for complete blood cell count; blood
urea nitrogen, serum alanine aminotransferase, and glucose-6 phosphate dehydrogenase
(G6PD) levels; and hemoglobin electrophoresis”
Exclusion criteria: none mentioned
Country of recruitment: Saradidi Rural Health Project, Nyanza province, Kenya on the
shores of Lake Victoria
Country of malaria exposure: Saradidi Rural Health Project, Nyanza province, Kenya
on the shores of Lake Victoria
Duration of exposure to malaria: study duration 4 months
Type of participants: Kenyan residents, semi-immune
Interventions 1. Melfoquine (1 x 125 mg tablet) weekly, with a second dose given on the third day of
the study, equal to their usual weekly medication
2. Doxycycline (1 x 50 mg tablet) daily
3. Primaquine
4. Multivitamin (1 x tablet containing vitamin A, 2500 IU, thiamine, 1 mg, riboflavin,
0.5 mg, nicotinamide, 7.5 mg, ascorbic acid, 15 mg, vitamin 0 3, 250 IU) daily
Co-interventions: After baseline malaria smears, all subjects received curative therapy for
preexistingmalaria: 7 days of quinine bisulfate, 300mg three times daily, anddoxycycline,
50 mg twice daily. The first dose of prophylactic drug was given starting the day after
curative therapy finished
Outcomes Included in the review:
1. Clinical cases of malaria
2. Episodes of parasitaemia
3. Discontinuations of study drug due to adverse effects
Outcomes assessed not included in the review:
4. Laboratory tests; complete blood cell counts, blood urea nitrogen and serum alanine
aminotransferase
5. Mean number of symptoms reported per subject: nausea, abdominal pain, diarrhoea,
headache, fever
Notes Funding sources: Financial support: USA Naval Medical Research and Development
Command (work unit no. 623002A.81 0.00 J0 I.HFX. J433). Kenya Medical Research
Institute. USA Army Medical Research and Materiel Command Provisional (contract
no. DAMDI7-92-V-20J2)
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Students from each village school were
separately randomized, to control for geo-
graphic variation in malaria transmission”
Comment: no description of how random-
ization was performed
Allocation concealment (selection bias) Unclear risk “All medications were in brown envelopes
and were administered 7 days each week by
I field worker at each school”
Comment: no mention of whether en-
velopes were sealed or if field workers had
access to their content
Blinding of participants and personnel
(performance bias)
Adverse effects/events
Unclear risk Comment: no mention of whether partic-
ipants were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “None of the malaria slide readers knew
which drugs the subjects were taking.None
of the field workers visiting the homes daily
to ask about symptoms or clinical staff eval-
uating and treating subjects at the Saradidi
Clinic knew which drugs the subjects were
taking. If there was concern about a drug
side effect, the clinical staff would consult
the medical monitor, who would break the
code for that subject. This occurred only
four times during the studies”
Incomplete outcome data (attrition bias);
efficacy
Unclear risk N/A
Incomplete outcome data (attrition bias);
safety
Unclear risk Comment: number included in the safety
analysis not reported
Selective reporting (reporting bias); efficacy Unclear risk N/A
Selective reporting (reporting bias); safety Unclear risk Comment: mean number of symptoms re-
ported per subject during 11 weeks of
the study were reported. A targeted list of
symptoms was reported, with everything
else included in ‘all other’. It was unclear
what this list included
Other bias Low risk Financial support: USA Naval Medical Re-
search and Development Command (work
unit no. 623002A.81 0.00 J0 I.HFX.
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J433). Kenya Medical Research Institute.
USA Army Medical Research and Ma-
teriel Command Provisional (contract no.
DAMDI7-92-V-20J2)
Wells 2006
Methods Design: retrospective cohort study
Study dates: January 2002 to December 31 2002
Malaria transmission pattern and local antimalarial drug resistance: various, not specified
Adverse event monitoring: “The study cohort was electronically linked to the Standardized Inpatient Data Record
(SIDR) and the Health Care Service Record (HCSR) to identify hospitalization... We analyzed any-cause hospital-
ization (excluding complications of pregnancy, childbirth, and the puerperium, congenital anomalies, and certain
conditions originating in the perinatal period)”
Participants Number enrolled: 397442
Inclusion criteria: “All active-duty US service members during the period January 1, 2002, and December 31, 2002,
as reported by the Defense Manpower Data Center (DMDC), Monterey, CA. The mefloquine prescribed group was
defined as service members who had been prescribed a minimum of seven mefloquine tablets beginning in 2002 and
who were identified as having been deployed at some point during the same time period. We used two reference
groups. The first reference group was comprised of service members who had duty zip codes for either Europe or
Japan at some time during 2002 and had no evidence of having been deployed from October 1, 2001 through the
individual’s period of observation... The second reference group consisted of US service members who were identified
as having been deployed for a minimum of 1 month during 2002”
Exclusion criteria: “Both reference groups were restricted to individuals who had no evidence of having received a
prescription for mefloquine or chloroquine or a doxycycline prescription for more than 14 tablets.’ ‘Individuals who
could not be followed a minimum of 2 months were excluded from the study”
Country of recruitment: USA
Country of malaria exposure: various, not specified
Duration of exposure to malaria: various, not specified
Type of participants: military
Interventions 1. Mefloquine*
2. Non-users of antimalarials
*dosing regimen not specified
Outcomes Included in the review:
1. Adverse events; serious (any hospitalization, hospitalizations due to vertiginous syndromes, migraine, dizziness
and giddiness, anxiety disorders, somatoform disorders, mood disorders, PTSD, substance use disorders, personality
disorders, nystagmus or adjustment reaction)
Outcomes assessed not included in the review:
2. Hospitalizations coded according to classification system: infectious/parasitic, neoplasms, endocrine, nutritional,
metabolic, blood and blood-forming organs, mental disorders, nervous system, circulatory system, respiratory system,
digestive system, genitourinary system, skin and subcutaneous tissues, musculoskeletal and connective tissue, ill-
defined conditions, injury and poisoning
Notes Funding sources: “This represents report 05-05, supported by the Department of Defense, under work unit no.
60002”
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Risk of bias
Bias Authors’ judgement Support for judgement
Other bias Unclear risk 1. Counfounding: moderate
BMI, destination and duration of travel have not been
recorded
2. Selection of participants into the study: serious
“Follow-up time began on return from deployment for
mefloquine-prescribed members, and for the deployed
reference group, on assignment to Europe or Japan, or
January 1, 2002, whichever occurred last for the Europe/
Japan reference group”
Start of follow up began a long time after start of inter-
vention
3. Measurement of interventions: serious
Surrogate measure used for mefloquine exposure. There
was a possiblity that some participants in the second de-
ployed reference group took mefloquine
4. Departures from intended interventions: moderate
“Both reference groups were restricted to individuals who
had no evidence of having received a prescription for
mefloquine or chloroquine or a doxycycline prescription
for more than 14 tablets”
5. Missing data: moderate
“Individuals who could not be followed a minimum of 2
months were excluded from the study”
Comment: number of participants in this group not re-
ported
6. Measurement of outcomes: low
The outcome measure (hospitalizations) was objective
7. Selection of the reported results: low
All prespecified outcomes were reported
8. Other: low
Government funding
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abraham 1999 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
Adera 1995 Cohort study. R eported on efficacy but no other relevant outcomes
Adshead 2014 Single arm cohort study
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Angelin 2014 No relevant outcomes reported
Anonymous 1991 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Anonymous 1998 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Anonymous 1998a Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Anonymous 2005 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Anonymous 2009 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Artaso 2004 Not a randomiz ed or cohort study e.g. case report or case control study
Arthur 1990a Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Banerjee 2001 No relevant outcomes reported
Barbero Gonzalez 2003 No relevant outcomes reported
Barrett 1996 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
Berger 1998 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Berman 2004 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Bernado 1994 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Bijker 2014 This trial evaluated chemoprophylaxis plus sporozoite immunization
Bjorkman 1991 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Black 2007 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Blanke 2003 Cohort study. R eported on efficacy but no other relevant outcomes
Botella de Maglia 1999 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Bourgeade 1990 Not a randomiz ed or cohort study e.g. case report or case control study
Brenier-Pinchart 2000 Not a randomiz ed or cohort study e.g. case report or case control study
Brisson 2012 No relevant outcomes reported
Bruguera 2007 Not a randomiz ed or cohort study e.g. case report or case control study
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Burke 1993 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Caillon 1992 Not a randomiz ed or cohort study e.g. case report or case control study
Carme 1997 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
Castot 1988 Not a randomiz ed or cohort study e.g. case report or case control study
Cave 2003 No relevant outcomes reported
Charles 2007 No relevant outcomes reported
Chin 2016 No relevant outcomes reported
Clifford 2009 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Clift 1996 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Clyde 1976 Single-arm cohort study
Cobelens 1997 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Cohen 1997 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Conget 1993 Not a randomiz ed or cohort study e.g. case report or case control study
Conrad 1997 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Corbett 1996 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
Coulaud 1986 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Croft 1996 Not a randomiz ed or cohort study e.g. case report or case control study
Croft 1997 RCT. C ompared mefloquine with a regimen that is no longer used routinely
Del Cacho 2001 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
Dia 2010 No relevant outcomes reported
Durrheim 1999 Cohort study. Compare d mefloquine with a regimen that is no longer used routinely
Eamsila 1993 Cohort study. Compare d mefloquine with a regimen that is no longer used routinely
El Jaoudi 2010 Single arm cohort study
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Fernando 2016 No relevant outcomes reported
Fujii 2007 Single arm cohort study
Hamer 2008 No relevant outcomes reported
Hellgren 1990 No relevant outcomes reported
Hopperus 1996 Single arm cohort study
Jaspers 1996 Single arm cohort study
Jensen 1998 Not a randomiz ed or cohort study e.g. case report or case control study
Karbwang 1991 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Karbwang 1991a Mefloquine was used as a combination regimen with sulph adoxine and pyrimethamine
Khaliq 2001 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Kimura 2006 No relevant outcomes reported
Kitchener 2003 No relevant outcomes reported
Kitchener 2005 Cohort study. A llocation to study drug was based on the occurrence of adverse effects
Kok 1997 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Kollaritsch 2000 Single arm cohort study
Kozarsky 1993 Single arm cohort study
Landry 2006 Single arm cohort study
Lapierre 1983 Single arm cohort study
Lim 2005 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Lobel 1993 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely. C hloroquine users
we re not clearly separated from users of chloroquine-proguanil
Looareesuwan 1987 No relevant outcomes reported
MacArthur 2002 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
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Malvy 2006 Cohort study. R eported on efficacy but no other relevant outcomes
Marcy 1996 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Massey 2007 No relevant outcomes reported
Matsumura 2005 Single arm cohort study
Meszaros 1996 Not a randomiz ed or cohort study e.g. case report or case control study
Michel 2007 Cohort study. R eported on efficacy but no other relevant outcomes
Mimica 1983 No relevant outcomes reported
Mizuno 2006 Single arm cohort study
Mizuno 2010 Single arm cohort study
Moon 2011 No relevant outcomes reported
Morales de Naime 1989 No relevant outcomes reported
Munawar 2012 Single arm cohort study
Mølle 2000 Cohort selected on basis of adverse events
Namikawa 2008 No relevant outcomes reported
Nasveld 2010 RCT. C ompared mefloquine with a regimen which is not used routinely
Nevin 2010 No relevant outcomes reported
Nevin 2012 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Nosten 1990 RCT. Did not include a comparator; compared alternate mefloquine doses
Nosten 1999 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Nwokolo 2001 Cohort study. Compared mefloquine with a regimen that is no longer used routinely
Olanrewaju 2000 Single arm cohort study
Ollivier 2004 Single arm cohort study
Peetermans 2001 Cohort study. Compared mefloquine with a regimen that is no longer used routinely
152Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Peragallo 1999 Cohort study. Compared mefloquine with a regimen that is no longer used routinely
Peragallo 2002 Single arm cohort study
Peragallo 2014 Single arm cohort study
Philips 1994 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Phillips 1996 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Phillips-Howard 1998 Cohort study. Compared mefloquine with a regimen that is no longer used routinely
Pistone 2007 No relevant outcomes reported
Port 2011 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Potasman 2000 Cohort selected on basis of adverse events
Quinn 2016 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Reisinger 1989 RCT. C ompared mefloquine with a regimen that is no longer use d routinely
Rieckmann 1974 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Rieke 1993 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Ries 1993 Not a randomiz ed or cohort study e.g. case report or case control study
Ringqvist 2015 Cohort selected on basis of adverse events
Rombo 1993 RCT. C ompared mefloquine with a regimen that is no longer used routinely
Rønn 1998 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Sallent 1997 No relevant outcomes reported
Schlagenhauf 1996 Single arm cohort study
Scott 1993 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Smail 1991 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Smoak 1997 Single arm cohort study
153Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
(Continued)
Suriyamongkol 1991 Single arm cohort study
Tansley 2010 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
ter Kuile 1993 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Todd 1997 No relevant outcomes reported
Turner 2014 No relevant outcomes reported
Valerio 2005 No relevant outcomes reported
Van Genderen 2007 No participants received mefloquine prophylaxis
Van Grootheest 1999 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
van Riemsdijk 2004 Single arm cohort study
Venturini 2011 Single arm cohort study
Wagner 1986 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Wallace 1996 Field study in which troops switched extensively between mefloquine and doxycycline. Unable to attribute
side effects to either prophylactic regimen
Weinke 1991 Cohort selected on basis of adverse events
White 2016 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Win 1985 Mefloquine not used at a prophylactic dose (e.g. treatment dose or i ntermittent preventive treatment of
malaria in pregnancy dose)
Winstanley 1999 Not a research study of malaria prophylaxis e.g. letter to the editor or editorial
Wolters 1997 Cohort study. C ompared mefloquine with a regimen that is no longer used routinely
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D A T A A N D A N A L Y S E S
Comparison 1. Mefloquine versus placebo/non users
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cases of malaria 9 1908 Risk Ratio (M-H, Random, 95% CI) 0.09 [0.04, 0.19]
2 Malaria; episodes of parasitaemia
in semi-immune populations
5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Trials reporting number of
participants with parasitaemia
3 414 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.06, 0.55]
2.2 Trials reporting number of
episodes of parasitaemia
2 510 Risk Ratio (M-H, Random, 95% CI) 0.05 [0.00, 5.25]
3 Serious adverse events or effects
(all studies)
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 RCTs (adverse events) 6 1221 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.14, 3.53]
3.2 Cohort studies (adverse
effects)
2 1167 Risk Ratio (M-H, Fixed, 95% CI) 3.08 [0.39, 24.11]
4 Discontinuations due to adverse
effects (all studies)
7 1130 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.55, 4.88]
4.1 RCTs (adverse effects) 7 1130 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.55, 4.88]
5 Nausea (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 RCTs (adverse events) 2 244 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [1.05, 1.73]
5.2 Cohort studies (adverse
events)
3 1901 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.42, 2.43]
6 Vomiting (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 RCTs (adverse events) 1 202 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.50, 1.19]
6.2 Cohort studies (adverse
events)
2 1167 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.45, 1.21]
7 Abdominal pain (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 RCTs (adverse events) 3 550 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.84, 1.40]
7.2 Cohort studies (adverse
events)
2 1167 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.66, 1.42]
8 Diarrhoea (all studies) 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 RCTs (adverse events) 4 589 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.32, 1.62]
8.2 Cohort studies (adverse
events)
3 1901 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.93, 1.68]
9 Headache (all studies) 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 RCTs (adverse events) 5 791 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.71, 0.99]
9.2 Cohort studies (adverse
events)
1 197 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.63, 4.26]
10 Dizziness (all studies) 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 RCTs (adverse events) 3 452 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.90, 1.17]
10.2 Cohort studies (adverse
events)
3 1901 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [1.29, 2.49]
11 Abnormal dreams (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
11.1 Cohort studies (adverse
events)
2 931 Risk Ratio (M-H, Fixed, 95% CI) 2.35 [1.15, 4.80]
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12 Insomnia (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Cohort studies (adverse
events)
2 931 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [1.06, 2.02]
13 Anxiety (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Cohort studies (adverse
events)
2 931 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.67, 2.21]
14 Depressed mood (all studies) 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Cohort studies (adverse
events)
3 1901 Risk Ratio (M-H, Random, 95% CI) 2.43 [0.65, 9.07]
15 Abnormal thoughts and
perceptions
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Cohort studies (adverse
events)
1 970 Risk Ratio (M-H, Fixed, 95% CI) 5.77 [0.79, 42.06]
16 Pruritis (all studies) 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 RCTs (adverse events) 3 609 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.60, 1.24]
16.2 Cohort studies (adverse
events)
1 197 Risk Ratio (M-H, Fixed, 95% CI) 6.71 [1.58, 28.55]
17 Visual impairment (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 RCTs (adverse events) 1 202 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.66, 1.46]
17.2 Cohort studies (adverse
events)
1 970 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.27, 3.19]
18 Vertigo (all studies) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 RCTs (adverse events) 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.78, 1.34]
19 Other adverse events (RCTs) 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Arthralgia 1 140 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.02, 5.48]
19.2 Back pain 1 140 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.61]
19.3 Blurred vision 1 208 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.89]
19.4 Cough 1 202 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.71, 1.14]
19.5 Constipation 1 202 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.53, 1.11]
19.6 Decreased appetite 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.95, 1.28]
19.7 Falls 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.82, 1.43]
19.8 Fatigue 1 42 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.14, 5.86]
19.9 Gastritis 1 140 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.10, 10.98]
19.10 Myalgia 1 140 Risk Ratio (M-H, Fixed, 95% CI) 1.53 [0.36, 6.57]
19.11 Rash 1 140 Risk Ratio (M-H, Fixed, 95% CI) 0.29 [0.04, 2.30]
19.12 Respiratory tract
infection
1 140 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [1.04, 6.61]
19.13 Sore throat 1 140 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.04, 2.75]
19.14 Unsteadiness 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.74, 1.52]
19.15 Weakness 1 202 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.96, 1.17]
20 Other adverse effects (cohort
studies)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Agitation 1 734 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.61, 1.82]
20.2 Altered spatial perception 1 970 Risk Ratio (M-H, Fixed, 95% CI) 9.4 [0.57, 153.97]
20.3 Confusion 1 734 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.25, 1.78]
20.4 Loss of appetite 1 970 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.54, 1.50]
20.5 Mouth ulcers 1 970 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.39, 2.56]
20.6 Palpitations 1 197 Risk Ratio (M-H, Fixed, 95% CI) 8.06 [0.44, 147.68]
20.7 Tingling 1 970 Risk Ratio (M-H, Fixed, 95% CI) 1.92 [0.59, 6.24]
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Comparison 2. Mefloquine versus doxycycline
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cases of malaria (RCTs) 4 744 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.35, 5.19]
2 Serious adverse events or effects
(all studies)
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 RCTs (adverse events) 3 682 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.16]
2.2 Cohort studies (adverse
effects)
3 3722 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.23, 10.24]
3 Discontinuations due to adverse
effects (all studies)
14 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RCTs 4 763 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.41, 2.87]
3.2 Cohort studies 10 10165 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.54, 1.55]
4 Nausea (all studies) 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Cohort studies (adverse
effects)
5 2683 Risk Ratio (M-H, Fixed, 95% CI) 0.37 [0.30, 0.45]
4.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [0.75, 9.74]
4.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Fixed, 95% CI) 1.61 [1.06, 2.43]
5 Vomiting (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Cohort studies (adverse
effects)
4 5071 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.12, 0.27]
5.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.19, 21.84]
6 Abdominal pain (all studies) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Cohort studies (adverse
effects)
4 2569 Risk Ratio (M-H, Random, 95% CI) 0.30 [0.09, 1.07]
6.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Random, 95% CI) 1.65 [0.74, 3.70]
6.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 1.34 [0.83, 2.18]
7 Diarrhoea (all studies) 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Cohort studies (adverse
effects)
5 5104 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.11, 0.73]
7.2 RCTs (adverse events) 2 376 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.78, 1.29]
7.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 3.58 [1.69, 7.59]
8 Dyspepsia (all studies) 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Cohort studies (adverse
effects)
5 5104 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.09, 0.74]
9 Headache (all studies) 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Cohort studies (adverse
effects)
5 3322 Risk Ratio (M-H, Random, 95% CI) 1.21 [0.50, 2.92]
9.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Random, 95% CI) 2.31 [1.25, 4.27]
9.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 2.45 [1.38, 4.34]
10 Dizziness (all studies) 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Cohort studies (adverse
effects)
5 2633 Risk Ratio (M-H, Random, 95% CI) 3.49 [0.88, 13.75]
10.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Random, 95% CI) 3.05 [1.30, 7.16]
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10.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 2.40 [1.47, 3.90]
10.4 Retrospective healthcare
record analysis (adverse events)
1 354959 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.62, 0.73]
11 Abnormal dreams (all studies) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Cohort studies (adverse
effects)
4 2588 Risk Ratio (M-H, Random, 95% CI) 10.49 [3.79, 29.10]
11.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.07, 15.89]
11.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 4.33 [2.08, 9.00]
12 Insomnia (all studies) 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Cohort studies (adverse
effects)
4 3212 Risk Ratio (M-H, Random, 95% CI) 4.14 [1.19, 14.44]
12.2 RCTs (adverse events) 1 123 Risk Ratio (M-H, Random, 95% CI) 2.03 [0.65, 6.40]
12.3 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Random, 95% CI) 4.54 [2.09, 9.83]
12.4 Retrospective healthcare
record analysis (adverse events)
1 354959 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.43, 0.49]
13 Anxiety (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 Cohort studies (adverse
effects)
3 2559 Risk Ratio (M-H, Fixed, 95% CI) 18.04 [9.32, 34.93]
13.2 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Fixed, 95% CI) 8.74 [1.99, 38.40]
13.3 Retrospective healthcare
record analysis (adverse events)
1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.47, 0.56]
14 Depressed mood (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Cohort studies (adverse
effects)
2 2445 Risk Ratio (M-H, Fixed, 95% CI) 11.43 [5.21, 25.07]
14.2 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Fixed, 95% CI) 6.27 [1.82, 21.62]
14.3 Retrospective healthcare
record analysis (adverse events)
2 376024 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.51, 0.60]
15 Abnormal thoughts and
perceptions
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Cohort studies (adverse
effects)
2 2445 Risk Ratio (M-H, Fixed, 95% CI) 6.60 [0.92, 47.20]
15.2 Retrospective healthcare
record analyses (adverse events)
2 376024 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.26, 0.66]
16 Pruritis (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 Cohort studies (adverse
effects)
2 1794 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.30, 0.91]
16.2 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Fixed, 95% CI) 2.69 [0.93, 7.78]
17 Photosensitivity (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Cohort studies (adverse
effects)
2 1875 Risk Ratio (M-H, Fixed, 95% CI) 0.08 [0.05, 0.11]
17.2 Cohort studies (adverse
events)
1 668 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.49]
18 Yeast infection (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 Cohort studies (adverse
effects)
1 1761 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.06, 0.16]
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18.2 Cohort studies (adverse
events)
1 354 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.06, 0.63]
19 Visual impairment (all studies) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Cohort studies (adverse
effects)
2 1875 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [1.41, 3.99]
20 Other adverse effects (cohort
studies)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Alopecia 2 1875 Risk Ratio (M-H, Fixed, 95% CI) 3.44 [1.96, 6.03]
20.2 Asthenia 1 1761 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.89, 3.76]
20.3 Balance disorder 1 1761 Risk Ratio (M-H, Fixed, 95% CI) 2.87 [1.48, 5.59]
20.4 Decreased appetite 1 734 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.42, 3.64]
20.5 Fatigue 2 74 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.03, 1.77]
20.6 Hypoaesthesia 2 2445 Risk Ratio (M-H, Fixed, 95% CI) 11.48 [3.01, 43.70]
20.7 Malaise 1 734 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.11, 0.71]
20.8 Mouth ulcers 1 33 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.02, 11.42]
20.9 Palpitations 1 1761 Risk Ratio (M-H, Fixed, 95% CI) 2.76 [0.16, 48.91]
20.10 Tinnitus 1 684 Risk Ratio (M-H, Fixed, 95% CI) 7.20 [0.39, 133.30]
21 Other adverse events (RCTs) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 Constipation 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.19, 21.84]
21.2 Cough 1 123 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.28, 1.01]
21.3 Decreased appetite 1 123 Risk Ratio (M-H, Fixed, 95% CI) 3.56 [1.24, 10.20]
21.4 Malaise 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.88, 4.69]
21.5 Palpitations 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.19, 21.84]
21.6 Pyrexia 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [1.09, 7.42]
21.7 Sexual dysfunction 1 123 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.33, 28.51]
21.8 Somnolence 1 123 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.19, 21.84]
22 Other adverse events (cohort
studies)
3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
22.1 Adjustment disorder 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.40, 0.45]
22.2 Confusion 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 2.18 [0.24, 19.49]
22.3 Convulsions 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.45, 0.75]
22.4 Hallucinations 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.08, 0.45]
22.5 Paranoia 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.10, 1.63]
22.6 Palpitations 1 668 Risk Ratio (M-H, Fixed, 95% CI) 13.44 [1.73, 104.38]
22.7 Panic attacks 1 21065 Risk Ratio (M-H, Fixed, 95% CI) 4.16 [0.55, 31.49]
22.8 PTSD 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.53, 0.64]
22.9 Rash 1 668 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.50, 2.94]
22.10 Suicidal ideation 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.31, 0.47]
22.11 Suicide 2 376024 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.32, 4.56]
22.12 Tinnitus 1 354959 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.61, 0.71]
23 Adherence (cohort studies) 14 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
23.1 Adherence during travel 13 15583 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [1.12, 1.18]
23.2 Adherence in the post-
travel period
4 840 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.95, 1.22]
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Comparison 3. Mefloquine versus atovaquone-proguanil
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cases of malaria (RCTs) 2 1293 Odds Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
2 Serious adverse events or effects
(all studies)
3 3591 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.08, 23.22]
2.1 Cohort studies 3 3591 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.08, 23.22]
3 Discontinuations due to adverse
effects (all studies)
12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RCTs 3 1438 Risk Ratio (M-H, Random, 95% CI) 2.86 [1.53, 5.31]
3.2 Cohort studies 9 7785 Risk Ratio (M-H, Random, 95% CI) 2.73 [1.83, 4.08]
4 Nausea (all studies) 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 2.72 [1.52, 4.86]
4.2 Cohort studies (adverse
effects)
7 3509 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [1.54, 4.06]
5 Vomiting (all studies) 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.49, 3.50]
5.2 Cohort studies (adverse
effects)
3 2180 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.08, 4.09]
6 Abdominal pain (all studies) 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.52, 1.56]
6.2 Cohort studies (adverse
effects)
7 3509 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.38, 1.07]
7 Diarrhoea (all studies) 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.60, 1.47]
7.2 Cohort studies (adverse
effects)
7 3509 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.53, 1.35]
8 Mouth ulcers (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 1.45 [0.70, 3.00]
8.2 Cohort studies (adverse
effects)
2 783 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.04, 0.37]
9 Headache (all studies) 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.99, 2.99]
9.2 Cohort studies (adverse
effects)
8 4163 Risk Ratio (M-H, Fixed, 95% CI) 3.42 [1.71, 6.82]
10 Dizziness (all studies) 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 3.99 [2.08, 7.64]
10.2 Cohort studies (adverse
effects)
8 3986 Risk Ratio (M-H, Fixed, 95% CI) 3.83 [2.23, 6.58]
10.3 Retrospective healthcare
record analysis (adverse events)
1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [1.04, 1.46]
11 Abnormal dreams (all studies) 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Random, 95% CI) 2.04 [1.37, 3.04]
11.2 Cohort studies (adverse
effects)
7 3848 Risk Ratio (M-H, Random, 95% CI) 6.81 [1.65, 28.15]
12 Insomnia (all studies) 10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 4.42 [2.56, 7.64]
12.2 Cohort studies (adverse
effects)
8 3986 Risk Ratio (M-H, Fixed, 95% CI) 7.29 [4.37, 12.16]
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12.3 Retrospective healthcare
record analysis (adverse events)
1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [1.06, 1.44]
13 Anxiety (all studies) 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
13.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 6.12 [1.82, 20.66]
13.2 Cohort studies (adverse
effects)
4 2664 Risk Ratio (M-H, Fixed, 95% CI) 10.10 [3.48, 29.32]
13.3 Retrospective healthcare
record analysis (adverse events)
1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.54 [1.28, 1.85]
14 Depressed mood (all studies) 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 5.78 [1.71, 19.61]
14.2 Cohort studies (adverse
effects)
6 3624 Risk Ratio (M-H, Fixed, 95% CI) 8.02 [3.56, 18.07]
14.3 Retrospective healthcare
record analysis (adverse events)
1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.93 [1.56, 2.38]
15 Abnormal thoughts and
perceptions (all studies)
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 Cohort studies (adverse
effects)
3 2433 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.30, 7.42]
15.2 Retrospective healthcare
record analysis (adverse events)
1 49419 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.69, 12.97]
16 Pruritis (all studies) 4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.60, 2.70]
16.2 Cohort studies (adverse
effects)
3 1824 Risk Ratio (M-H, Fixed, 95% CI) 2.07 [0.40, 10.68]
17 Visual impairment (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 RCTs (adverse effects) 1 976 Risk Ratio (M-H, Fixed, 95% CI) 2.04 [0.88, 4.73]
17.2 Cohort studies (adverse
effects)
2 1956 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.29, 4.72]
18 Other adverse effects (cohort
studies)
8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
18.1 Allergic reaction 1 316 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.04, 14.48]
18.2 Alopecia 1 1469 Risk Ratio (M-H, Fixed, 95% CI) 4.55 [0.30, 70.01]
18.3 Asthenia 2 1956 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [0.26, 13.12]
18.4 Balance disorder 1 1469 Risk Ratio (M-H, Fixed, 95% CI) 2.86 [0.19, 44.19]
18.5 Cough 1 652 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.08, 2.92]
18.6 Disturbance in attention 3 1363 Risk Ratio (M-H, Fixed, 95% CI) 4.45 [1.84, 10.77]
18.7 Dyspepsia 2 362 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.17, 1.46]
18.8 Fatigue 2 618 Risk Ratio (M-H, Fixed, 95% CI) 4.62 [0.47, 45.56]
18.9 Hypoaesthesia 2 1946 Risk Ratio (M-H, Fixed, 95% CI) 4.45 [0.93, 21.26]
18.10 Loss of appetite 1 652 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.33, 1.43]
18.11 Muscle pain 1 652 Risk Ratio (M-H, Fixed, 95% CI) 7.57 [0.45, 127.80]
18.12 Palpitations 3 2180 Risk Ratio (M-H, Fixed, 95% CI) 3.34 [0.73, 15.26]
18.13 Photosensitization 2 718 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.10, 4.92]
18.14 Pyrexia 1 652 Risk Ratio (M-H, Fixed, 95% CI) 4.28 [0.24, 75.57]
18.15 Rash 2 711 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.15, 6.09]
18.16 Restlessness 1 487 Risk Ratio (M-H, Fixed, 95% CI) 5.24 [0.32, 84.52]
18.17 Slight illness 1 487 Risk Ratio (M-H, Fixed, 95% CI) 5.83 [0.36, 93.84]
18.18 Somnolence 1 487 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.21, 11.40]
18.19 Tinnitus 1 477 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [0.13, 42.64]
18.20 Circulatory disorders 1 224 Risk Ratio (M-H, Fixed, 95% CI) 6.38 [0.36, 114.01]
19 Other adverse events (cohort
studies)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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19.1 Adjustment disorder 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [1.54, 2.02]
19.2 Confusion 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.04, 25.96]
19.3 Convulsions 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.79, 2.30]
19.4 Hallucinations 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.08, 0.79]
19.5 Paranoia 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [0.08, 36.72]
19.6 PTSD 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 2.51 [1.93, 3.26]
19.7 Suicidal ideation 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.03, 2.77]
19.8 Suicide 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.06, 7.78]
19.9 Tinnitus 1 49419 Risk Ratio (M-H, Fixed, 95% CI) 1.42 [1.21, 1.68]
20 Adherence (RCTs) 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
20.1 van Riemsdijk 2002 1 119 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.02]
20.2 Overbosch 2001; during
travel
1 966 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.95, 1.01]
20.3 Overbosch 2001; post-
travel
1 966 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.74, 0.85]
21 Adherence (cohort studies) 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
21.1 During travel 6 5577 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.86, 1.34]
21.2 Post-travel 2 422 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.64, 1.23]
Comparison 4. Mefloquine versus chloroquine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical cases of malaria (RCTs) 4 877 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.28, 0.52]
2 Serious adverse events or effects
(all studies)
10 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 RCTs 4 1000 Risk Ratio (M-H, Fixed, 95% CI) 2.77 [0.32, 23.85]
2.2 Cohort studies 6 79257 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.62, 2.07]
3 Discontinuations due to adverse
effects (all studies)
11 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 RCTs 3 815 Risk Ratio (M-H, Fixed, 95% CI) 1.60 [0.61, 4.18]
3.2 Cohort studies in short-
term travellers
6 55397 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.78, 1.26]
3.3 Cohort studies in longer
term occupational travellers
2 6085 Risk Ratio (M-H, Fixed, 95% CI) 2.97 [2.41, 3.66]
4 Nausea (all studies) 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Cohort studies (adverse
effects)
6 58984 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.89, 1.68]
4.2 RCTs (adverse events) 1 359 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.57, 1.79]
5 Vomiting (all studies) 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 Cohort studies (adverse
effects)
5 5577 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.78, 1.40]
5.2 RCTs (adverse events) 1 359 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.36, 3.49]
6 Abdominal pain (all studies) 6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Cohort studies (adverse
effects)
4 5440 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.80, 1.22]
6.2 RCTs (adverse events) 2 569 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.37, 1.36]
7 Diarrhoea (all studies) 8 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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7.1 Cohort studies (adverse
effects)
5 5577 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.74, 0.95]
7.2 RCTs (adverse events) 3 772 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.46, 1.50]
8 Headache (all studies) 9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Cohort studies (adverse
effects)
6 56998 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.53, 1.34]
8.2 RCTs (adverse events) 3 772 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.61, 1.31]
9 Dizziness (all studies) 7 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
9.1 Cohort studies (adverse
effects)
5 58847 Risk Ratio (M-H, Fixed, 95% CI) 1.51 [1.34, 1.70]
9.2 RCTs (adverse events) 2 569 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.35, 1.46]
10 Abnormal dreams (all studies) 5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
10.1 Cohort studies (adverse
effects)
4 2845 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [1.10, 1.33]
10.2 RCTs (adverse events) 1 359 Risk Ratio (M-H, Fixed, 95% CI) 2.70 [1.05, 6.95]
11 Insomnia (all studies) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Cohort studies (adverse
effects)
5 56952 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.73, 4.51]
11.2 RCTs (adverse events) 1 359 Risk Ratio (M-H, Random, 95% CI) 1.19 [0.76, 1.84]
12 Anxiety (all studies) 3 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
12.1 Cohort studies (adverse
effects)
3 3408 Risk Ratio (M-H, Fixed, 95% CI) 6.30 [4.37, 9.09]
13 Depressed mood (all studies) 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 Cohort studies (adverse
effects)
5 58855 Risk Ratio (M-H, Random, 95% CI) 3.14 [1.15, 8.57]
14 Abnormal thoughts and
perceptions
4 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
14.1 Cohort studies (adverse
effects)
4 4831 Risk Ratio (M-H, Fixed, 95% CI) 5.49 [2.65, 11.35]
15 Pruritis (all studies) 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Cohort studies (adverse
effects)
2 55544 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.92, 1.40]
15.2 RCTs (adverse events) 2 413 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.03, 2.93]
16 Visual impairment (all studies) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
16.1 Cohort studies (adverse
effects)
5 58847 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.50, 2.44]
16.2 RCTs (adverse events) 1 210 Risk Ratio (M-H, Random, 95% CI) 0.14 [0.01, 2.63]
17 Vertigo (all studies) 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
17.1 Cohort studies (adverse
effects)
1 746 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.05, 23.43]
18 Cohort studies in travellers;
prespecified adverse effects
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
18.1 Vertigo 1 746 Risk Ratio (M-H, Random, 95% CI) 1.13 [0.05, 23.43]
18.2 Nausea 5 56847 Risk Ratio (M-H, Random, 95% CI) 1.42 [0.94, 2.13]
18.3 Vomiting 4 3440 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.55, 1.42]
18.4 Abdominal pain 3 3303 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.74, 1.30]
18.5 Diarrhoea 4 3440 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.57, 2.64]
18.6 Headache 5 54861 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.48, 2.65]
18.7 Dizziness 4 56710 Risk Ratio (M-H, Random, 95% CI) 1.52 [1.10, 2.10]
18.8 Abnormal dreams 3 708 Risk Ratio (M-H, Random, 95% CI) 4.21 [0.57, 31.33]
18.9 Insomnia 4 54815 Risk Ratio (M-H, Random, 95% CI) 1.56 [0.40, 6.10]
18.10 Anxiety 2 1271 Risk Ratio (M-H, Random, 95% CI) 3.94 [0.53, 29.48]
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18.11 Depressed mood 4 56710 Risk Ratio (M-H, Random, 95% CI) 2.49 [0.75, 8.31]
18.12 Abnormal thoughts or
perceptions
3 2694 Risk Ratio (M-H, Random, 95% CI) 4.42 [1.58, 12.40]
18.13 Pruritis 1 53407 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.94, 1.48]
18.14 Visual impairment 4 56710 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.55, 0.79]
19 Other adverse effects (cohort
studies)
5 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Altered spatial perception 1 2032 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [1.55, 6.45]
19.2 Alopecia 1 2137 Risk Ratio (M-H, Fixed, 95% CI) 1.69 [1.27, 2.25]
19.3 Asthenia 3 3408 Risk Ratio (M-H, Fixed, 95% CI) 1.52 [0.97, 2.40]
19.4 Balance disorder 1 2137 Risk Ratio (M-H, Fixed, 95% CI) 3.59 [2.15, 6.00]
19.5 Confusion 1 525 Risk Ratio (M-H, Fixed, 95% CI) 2.03 [0.11, 36.31]
19.6 Decreased appetite 1 2032 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.87, 1.57]
19.7 Fatigue 1 525 Risk Ratio (M-H, Fixed, 95% CI) 2.37 [0.57, 9.80]
19.8 Hypoaesthesia 1 2137 Risk Ratio (M-H, Fixed, 95% CI) 20.26 [1.23, 333.93]
19.9 Irritability 1 746 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [0.28, 80.59]
19.10 Mouth ulcers 2 55439 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.01, 1.87]
19.11 Paraesthesia 2 2778 Risk Ratio (M-H, Fixed, 95% CI) 2.22 [1.27, 3.89]
19.12 Palpitations 3 3408 Risk Ratio (M-H, Fixed, 95% CI) 4.71 [0.91, 24.26]
19.13 Photosensitization 2 2662 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.52, 1.53]
19.14 Restlessness 1 525 Risk Ratio (M-H, Fixed, 95% CI) 4.74 [0.65, 34.46]
19.15 Slight illness 1 525 Risk Ratio (M-H, Fixed, 95% CI) 2.65 [0.64, 10.87]
19.16 Somnolence 1 525 Risk Ratio (M-H, Fixed, 95% CI) 6.08 [0.37, 100.36]
19.17 Yeast infection 1 2137 Risk Ratio (M-H, Fixed, 95% CI) 1.15 [0.53, 2.49]
20 Other adverse events (RCTs) 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
20.1 Abdominal distension 1 359 Risk Ratio (M-H, Fixed, 95% CI) 3.13 [0.64, 15.27]
20.2 Anger 1 359 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.07, 1.55]
20.3 Disturbance in attention 1 359 Risk Ratio (M-H, Fixed, 95% CI) 3.16 [0.61, 16.47]
20.4 Irritability 1 359 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.45, 2.64]
20.5 Loss of appetite 1 359 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.35, 3.25]
20.6 Malaise 1 203 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.85]
20.7 Mood altered 1 359 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.29, 4.34]
21 Pregnancy related outcomes
(RCTs)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
21.1 Spontaneous abortions 1 2334 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.36, 1.79]
21.2 Still births 1 2334 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.67, 1.52]
21.3 Congenital
malformations
1 2334 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 Adherence (cohort studies) 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
22.1 Short-term travellers 3 852 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.90, 1.13]
22.2 Short-term travellers:
after return
1 46 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.54, 1.87]
22.3 Longer-term
occupational travellers
2 5777 Risk Ratio (M-H, Random, 95% CI) 2.02 [1.80, 2.26]
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Comparison 5. Mefloquine versus currently used regimens; by study design
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Nausea; effects 12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 2.72 [1.52, 4.86]
1.2 Cohort studies 11 5973 Risk Ratio (M-H, Random, 95% CI) 1.72 [0.78, 3.77]
2 Abdominal pain; effects 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
2.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.52, 1.56]
2.2 Cohort studies 9 4494 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.27, 0.87]
3 Diarrhoea; effects 11 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.60, 1.47]
3.2 Cohort studies 10 7648 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.28, 1.34]
4 Headache; effects 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 1.72 [0.99, 2.99]
4.2 Cohort studies 9 5592 Risk Ratio (M-H, Random, 95% CI) 2.19 [1.22, 3.93]
5 Dizziness; effects 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 3.99 [2.08, 7.64]
5.2 Cohort studies 9 4606 Risk Ratio (M-H, Random, 95% CI) 3.17 [1.58, 6.35]
6 Abnormal dreams; effects 8 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 2.04 [1.37, 3.04]
6.2 Cohort studies 7 4543 Risk Ratio (M-H, Random, 95% CI) 7.30 [2.51, 21.18]
7 Insomnia; effects 10 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 4.42 [2.56, 7.64]
7.2 Cohort studies 9 5299 Risk Ratio (M-H, Random, 95% CI) 5.70 [2.83, 11.47]
8 Anxiety; effects 5 Risk Ratio (M-H, Random, 95% CI) Subtotals only
8.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 6.12 [1.82, 20.66]
8.2 Cohort studies 4 3390 Risk Ratio (M-H, Random, 95% CI) 15.26 [8.66, 26.89]
9 Depressed mood; effects 7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
9.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 5.78 [1.71, 19.61]
9.2 Cohort studies 6 4236 Risk Ratio (M-H, Random, 95% CI) 7.82 [3.79, 16.12]
10 Abnormal thoughts or
perceptions; effects
3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Cohort studies 3 3045 Risk Ratio (M-H, Random, 95% CI) 4.20 [0.81, 21.87]
11 Pruritis; effects 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
11.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.60, 2.70]
11.2 Cohort studies 3 2034 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.16, 4.76]
12 Visual impairment; effects 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 RCTs 1 976 Risk Ratio (M-H, Random, 95% CI) 2.04 [0.88, 4.73]
12.2 Cohort studies 3 2560 Risk Ratio (M-H, Random, 95% CI) 2.06 [1.05, 4.02]
13 Adherence; during travel 12 Risk Ratio (M-H, Random, 95% CI) Subtotals only
13.1 RCTs 1 119 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.88, 1.02]
13.2 Cohort studies 11 12131 Risk Ratio (M-H, Random, 95% CI) 1.16 [1.03, 1.30]
14 Adherence; after return 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Cohort studies 4 1221 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.92, 1.17]
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A D D I T I O N A L T A B L E S
Table 1. Risk of bias assessment methods for cohort studies
Bias Authors’ judgement Support for judgement
Confounding Low risk
Moderate risk
Serious risk
Critical risk
No information
We used the following criteria:
Low risk: identified confounders were mea-
sured and were balanced across groups (age,
sex, destination and duration of travel)
Moderate risk: identified confounders were
measured andnot balanced across groups, or
several confounders had not been measured
or not reported across groups
Serious risk: a critical confounder has been
measured and is not balanced across groups
Selection of participants into the study Low risk
Moderate risk
Serious risk
Critical risk
No information
We assessedwhether selection into the study
was unrelated to intervention or unrelated
to outcome, and whether start of interven-
tion and start of follow up coincided for
most subjects. Non-responder bias at the
point of selection was considered here for
cohort studies. We used the following cut
offs for non-response rate: low risk < 10%,
moderate risk 10% to 20%, serious risk >
20%
Measurement of interventions Low risk
Moderate risk
Serious risk
Critical risk
No information
We used the following criteria:
Low risk: the prescription was provided by a
travel clinic which also performed the study,
and discontinuations were recorded and re-
ported, or all participants were issued with
their medication e.g. soldiers or participants
were asked to self-report which medication
they took whilst they were taking it
Moderate risk: the prescription was pro-
vided by a travel clinic which also per-
formed the study but no information re-
garding switches and discontinuations was
available or patients are asked to self-report
which prophylaxis they took shortly after
they finished taking it
Serious risk: Participants were asked to self-
report which prophylaxis they took a long
time after they finished taking it
Departures from intended interventions Low risk
Moderate risk
Serious risk
Critical risk
No information
We assessed whether switches between
interventions of interest were available.
We assessed whether discontinuations and
switches betweenprophylactic regimens had
been recorded and reported
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Table 1. Risk of bias assessment methods for cohort studies (Continued)
Missing data Low risk
Moderate risk
Serious risk
Critical risk
No information
We assessed whether outcome data was rea-
sonably complete for most participants. We
recorded missing data for included partici-
pants e.g. loss to follow up rates and treat-
ment withdrawals
Measurement of outcomes Low risk
Moderate risk
Serious risk
Critical risk
No information
We assessed whether the outcome mea-
sure was objective or subjective. We as-
sessed whether participants or study per-
sonnel were blinded to the intervention re-
ceived. We assessed whether the methods of
outcome assessment were comparable across
intervention groups
Selection of the reported result Low risk
Moderate risk
Serious risk
Critical risk
No information
We used the following criteria:
Low risk: If the questionnaire was provided
in full, or it was clear what was asked within
it
Moderate risk: If it is unclear which ques-
tions are asked, or informationwas provided
on aggregate
Serious risk: If data captured within the
questionnaire was clearly missing
Other Low risk
Moderate risk
Serious risk
Critical risk
No information
We reported the study sponsor.We classified
the analysis of studies sponsored by phar-
maceutical companies as independent of the
sponsor when it was clearly stated that the
sponsor had no input to the trial analysis
Adapted from Higgins 2011 and ACROBAT-NSRI tool
Table 2. Adverse events and adverse effects risk of bias assessment methods
Criterion Assessment Explanation
On conduct
Were harms pre-defined using standardised
or precise definitions?
Adequate
Inadequate
Unclear
We classified as ’adequate’ if the study reported ex-
plicit definitions for adverse events and effects that
allow for reproducible ascertainment e.g. what ad-
verse events were being investigated and what con-
stituted an “event”, what was defined as a serious
or severe adverse event
Was ascertainment technique adequately
described?
Adequate
Inadequate
Unclear
We classified as ’adequate’ if the study reported
methods used to ascertain complications, includ-
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Table 2. Adverse events and adverse effects risk of bias assessment methods (Continued)
ing who ascertained, timing, and methods used
Was monitoring active or passive? Active
Passive
Unclear
We classified monitoring as ’active’ when authors
reviewed participants at set time points during
treatment and enquired about symptoms
Was data collection prospective or retro-
spective?
Prospective
Retrospective
Unclear
We classified as ‘prospective’ if data collection oc-
curred during treatment, or ‘retrospective’ if data
collection occurred following treatment
For laboratory investigations or other tests
Was the number and timing of tests ade-
quate?
Adequate
Inadequate
Unclear
We classified the number and timing of tests as
’adequate’, when tests were taken at baseline and at
least one time point during prophylaxis
Adapted from Bukiwra 2014
Table 3. Characteristics of included studies for efficacy
Study ID Participants
(immune sta-
tus)
Num-
ber of ran-
domised par-
ticipants
Mefloquine
dose
Drug
comparisons
of interest
Duration of
exposure to
malaria
Coun-
try of malaria
exposure
Local drug
resistance
Bunnag 1992 Thai male
adults (pre-
sumed semi-
immune)
605 250
mg weekly for
first 4 weeks,
then 125 mg
weekly
Placebo 24 weeks (trial
duration)
Thailand Chloroquine,
sulphadoxine-
pyrimethamine
and quinine
resistance
Nosten 1994 Preg-
nant women
from theThai-
Burma bor-
der (presumed
semi-
immune)
339 250 mg
weekly for first
4 weeks, then
125
mg weekly un-
til delivery
Placebo Various in en-
demic area
(monitored
until delivery)
Thai-Burma
border
Not
mentioned
Pearlman
1980
Thai residents
aged 10 to 60
years (semi-
immune)
990 180 mg tablet
weekly,
360 mg tablet
weekly, 360
mg every 2
weekswith ap-
propriate ad-
justments for
Placebo 26 weeks Thailand Chloroquine
resistant Plas-
modium falci-
parum
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Table 3. Characteristics of included studies for efficacy (Continued)
children
Santos 1993 Brazilian civil-
ians and sol-
diers aged 12
to 55 years
(semi-
immune)
128 500 mg ev-
ery 4 weeks,
250mg every 2
weeks
Placebo 17 weeks Brazil P fal-
ciparum resis-
tant to chloro-
quine and
“high preva-
lence of mul-
tiresis-
tant Plasmod-
ium fal-
ciparum trans-
mission”
Sos-
souhounto
1995
Ivory Coast
adult males
(semi-
immune)
500 250
mg weekly for
first 4 weeks,
then 125 mg
weekly
Placebo 20 weeks Ivory C oast Not
mentioned
Ohrt 1997 In-
donesian sol-
diers (’largely’
non-immune)
204 250 mg
weekly
Placebo, doxy-
cycline
’approxi-
mately 13
weeks’
Indonesia Sulfadoxine-
pyrimethamine
and chloro-
quine resis-
tance
Weiss 1995 Kenyan chil-
dren (semi-
immune)
169 125 mg
weekly
Placebo (mul-
tivitamin)
, doxycycline,
primaquine
11 weeks Kenya Not
mentioned
Salako 1992 Nigerian adult
males (semi-
immune)
567 250
mg weekly for
first 4 weeks,
then 125 mg
weekly
Placebo,
chloroquine
24 weeks (trial
duration)
Nigeria “...at the time
of the trial,
chloroquine
resistance was
not a prob-
lem”
Hale 2003 Ghanain
adults (semi-
immune)
530 250 mg
weekly
Placebo 12 weeks Ghana Not
mentioned
Arthur 1990 USA sol-
diers (non-im-
mune)
270 250 mg
weekly
Doxycycline 8 weeks Thailand Local chloro-
quine
resistance
Boudreau
1991
Thai adult
males (semi-
immune)
501 500 mg fort-
nightly
Chloroquine 14 weeks (trial
duration)
Cambodia Local chloro-
quine
resistance
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Table 3. Characteristics of included studies for efficacy (Continued)
Steketee
1996
Pregnant
Malawian res-
idents (semi-
immune)
4220 250 mg
weekly
Chloroquine Various in en-
demic area
(monitored
until delivery)
Malawi P fal-
ciparum resis-
tant to chloro-
quine, doc-
umented sen-
sitivity of P
falciparum to
mefloquine
Table 4. Mefloquine versus placebo/no treatment; characteristics of included studies for safety
Study ID Participants Number
enrolled
Method
of adverse event
monitoring
Exclusions for
psychiatric ad-
verse effects
Trial duration Source of fund-
ing
RCTs
Bunnag 1992 Thai male adults 605 Interview with
study personnel
None 24 weeks Roche
Davis 1996 Australian adults
who did not
travel
106 Daily self-
reported diary
Past history of
psychiatric con-
ditions
7 weeks Roche
Hale 2003 Ghanain adults 530 Interview with
study personnel
History of neu-
ropsychiatric ill-
ness
12 weeks USA Army
Nosten 1994 Pregnant
women, Thai-
Burma border
339 Phase 1: weekly
symptom ques-
tionnaire. Babies
were assessed at
birth and at 3,
6, 12, and 24
months
Phase 2: weekly
symptom ques-
tionnaire. Babies
were assessed at
birth and at 2
and 9 months
None Various Government
funding
Ohrt 1997 Indonesian sol-
diers
204 Two symptom
questionnaires.
Daily interview
with study per-
sonnel
History of un-
derlying illness
13 weeks Roche, Pfizer,
USA Army
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Table 4. Mefloquine versus placebo/no treatment; characteristics of included studies for safety (Continued)
Pearlman 1980 Thai
residents aged 10
to 60 years
990 Weekly sick call
by study person-
nel
None 26 weeks Not mentioned
Potasman 2002 Is-
raeli adults who
did not travel
90 Self-reporting
diary
History of de-
pression
48 hours Mepha Ltd
Salako 1992 Nigerian adult
males
567 Interview with
study personnel
None 24 weeks Not mentioned
Santos 1993 Brazilian civil-
ians and soldiers
aged 12 to 55
128 Interview w ith
study personnel
None 17 weeks Roche
Schlagenhauf
1997
Swissair trainee
pilots who did
not travel
23 Interview with
study personnel
Psychosis or se-
vere depression
4 weeks Roche
Sossouhounto
1995
Ivory C oast
adult males
500 Access to the vil-
lage health cen-
tre
None 20 weeks Not mentioned
Vuurman 1996 Dutch adult who
did not travel
42 Interview with
study personnel
H istory of
any serious psy-
chiatric disorder;
evidence of drug
or alcohol abuse
30 days Roche
Weiss 1995 Kenyan children 169 Interview with
study personnel
None 4 months USA Army
Cohort studies
Participants Number
enrolled
Method
of adverse event
monitoring
Fac-
tors influencing
drug allocation
Duration of
travel
Source of fund-
ing
Hoebe 1997 Danish travellers 300 Telephone inter-
view
Allocation based
on guide-
lines and patient
preference
Mean 3 weeks,
range 1 to 9
weeks
Not mentioned
Petersen 2000 Danish travellers 4154 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and patient
preference
Various, not
specified
Not mentioned
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Table 4. Mefloquine versus placebo/no treatment; characteristics of included studies for safety (Continued)
Rietz 2002 Swedish
travellers
491 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and patient
preference
“ Most”, range 2
to 4 weeks
Not mentioned
van Riemsdijk
1997
Danish travellers 1501 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and patient
preference
Mean = 23 days Not mentioned
Wells 2006 USA soldiers 397,442 Restrospective
analysis of hospi-
tal records
No information
available
Minimum 1
month
Government
funding
Table 5. Mefloquine versus placebo/no treatment; quality of adverse events reporting
Study ID Description of how ad-
verse outcomes were de-
fined and recorded¹
Description of ascer-
tainment technique²
Active or passive moni-
toring?
Prospective or retro-
spective data collection?
Bunnag 1992 Inadequate
Comment: No definition
of adverse events or ef-
fects was provided, it is
unclear whether or how
causality was assessed
Adequate Active Prospective
Davis 1996 Adequate Adequate Active Prospective
Hale 2003 Inadequate
Comment: ‘serious’ ad-
verse events were not de-
fined, and methods for
determining causality not
described
Adequate Active Prospective
Nosten 1994 Inadequate
Comment: It is unclear
what questions were in-
cluded within the ques-
tionnaire and whether
and how causality was as-
sessed. ‘Serious’ adverse
effects not defined
Adequate Active Prospective
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Table 5. Mefloquine versus placebo/no treatment; quality of adverse events reporting (Continued)
Ohrt 1997 Inadequate
Comment: No definition
of adverse events or ef-
fects provided, it was un-
clear whether or how
causality was assessed
Adequate Active Prospective
Pearlman 1980 Inadequate
Comment: No definition
of adverse events or ef-
fects was provided, it was
unclear whether or how
causality was assessed
Inadequate
Comment: Weekly sick
call for all villagers
Passive Prospective
Potasman 2002 Inadequate
Comment: No definition
of adverse events or ef-
fects was provided, it was
unclear whether or how
causality was assessed
Adequate Active Prospective
Salako 1992 Inadequate
Comment: No definition
of adverse events or ef-
fects was provided, it was
unclear whether or how
causality was assessed
Adequate Active Prospective
Santos 1993 Inadequate
Comment: No informa-
tion given in the meth-
ods section on definition
of adverse outcomes
Inadequate
Com-
ment: No description of
ascertainment method
Active Prospective
Schlagenhauf 1997 Inadequate
Comment: No definition
of adverse events or ef-
fects was provided, it was
unclear whether or how
causality was assessed
Adequate Active Prospective
Sossouhounto 1995 Inadequate
Comment: No defini-
tions of adverse events
or effects were provided,
it was unclear whether
or how causality was as-
sessed
Unclear Passive Prospective
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Table 5. Mefloquine versus placebo/no treatment; quality of adverse events reporting (Continued)
Vuurman 1996 Adequate Unclear Active Prospective
Weiss 1995 Inadequate
Comment: No defini-
tions of adverse events
or effects were provided,
it was unclear whether
or how causality was as-
sessed
Adequate Active Prospective
Cohort studies
Hoebe 1997 Adequate Adequate Active Retrospective
Petersen 2000 Adequate Adequate Active Retrospective
Rietz 2002 Adequate Adequate Active Unclear
’Filled in after their re-
turn’
Steffen 1993 Adequate Adequate Passive Unclear
Comment: information
was collected during the
flight home, when trav-
ellers should still have
been taking their prophy-
lactic regimen
van Riemsdijk 1997 Adequate Adequate Active Prospective
Wells 2006 Adequate Adequate Passive Retrospective
1. Were harms pre-defined using standardised or precise definitions?
2. Was ascertainment technique adequately described?
Table 6. Serious adverse events; mefloquine versus comparators
Study ID Study design Mefloquine users Drug comparators
Events/ partici-
pants
Description Drug Events/ partici-
pants
Description
Events (not attributed by study authors or participants to the drug regimen)
Bunnag 1992 RCT 0/116 - Placebo 1/121 None provided
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Table 6. Serious adverse events; mefloquine versus comparators (Continued)
Nosten 1994 RCT 1/159 (women) One death
• Septic
shock after an
emergency
caesarean section
Four congenital
malformations:
• Limb
dysplasia (1 case)
, ventricular
septal defect (2
cases), amniotic
bands (1 case)
Placebo 0/152 (women) One congenital
malformation:
• anencephaly
Sossouhounto
1995
RCT 0/103 - Placebo 1/96 One death (not
described)
Ohrt 1997 RCT 0/61 - Placebo 0/65 -
Doxycycline 1/62 Acute hysteria¹
Lobel 2001 Cohort study 8/3703 8 hospitalisations
• for
“fainting,
gastrointestinal
symptoms,
rashes,
headaches,
ophthalmologic
symptoms, and
fever”
Doxycycline 0/69 -
Chloroquine 0/119 -
Overbosch
2001
RCT 10/483 “...infectious ill-
nesses in 7 sub-
jects and breast
cancer, anaphy-
laxis, or fractured
femur in 1 sub-
ject each”
Atovaquone-
proguanil
4/493 “...infectious ill-
nesses in 3 sub-
jects and cere-
bral ischemia in 1
subject”
Studies reporting no serious events or effects
Salako 1992 RCT 0/107 “Ad-
verse events were
all mild and there
were no deaths”
Placebo
Chloroquine
0/101
0/103
-
-
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Table 6. Serious adverse events; mefloquine versus comparators (Continued)
Arthur 1990 RCT 0/134 “No serious side
effects occurred
with either drug
regimen”
Doxycycline 0/119 -
Schlagenhauf
2003
RCT 0/153 “Although a large
number of ad-
verse events were
reported, none
were serious”
Doxycycline
Atovaquone-
proguanil
0/153
0/164
-
-
Sonmez 2005 Cohort study 0/228 “No drug in-
duced side effects
ne-
cessitating emer-
gency care were
observed”
Doxycycline 0/506 -
Andersson
2008
Cohort study 0/491 “No serious ad-
verse events were
recorded”
Atovaquone-
proguanil
0/161 -
Napoletano
2007
Cohort study 0/548 Records hospital-
isations, and re-
ports that none
occurred in either
group of partici-
pants
Atovaquone-
proguanil
Chloroquine
0/707
0/37
-
-
Sossouhounto
1995
RCT 0/103 “All
side effects were
transient (and)...
mild”
Chloroquine 0/100 -
1 This trial described a potentially serious adverse event, but did not provide enough detail to meet our definition.
Table 7. Serious adverse effects; mefloquine versus comparators
Study ID Study design Mefloquine users Drug comparators
Events/ partici-
pants
Description Drug Events/ partici-
pants
Description
Effects (attributed by study authors or participants to the drug regimen)
Hoebe 1997 Cohort study 2/104 Two “seri-
ous acute adverse
No treatment 0/93 -
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Table 7. Serious adverse effects; mefloquine versus comparators (Continued)
reactions”¹
• Depressed
mood
• Dizziness
Petersen 2000 Cohort study 5/809 5
hospitalisations:
• Depressed
mood
• Depressed
mood
• Depressed
mood, “strange
thoughts”
• Depressed
mood, “strange
thoughts”,
itching, vertigo
• Vertigo,
fever, mouth
ulcers, diarrhoea
Chloroquine 6/1223 2
hospitalisations:
• Blurred
vision, nausea,
headache,
general skin
itching,
paraesthesia
• Depressed
mood
No treatment 0/161 -
Korhonen 2007 Cohort study 15/1612 15
hospitalisations:
• Dizziness
(3)
• Heart
palpitations (2)
• Limb
numbness (1)
• Abdominal
pain (1)
• Yeast
infection (1)
• Anxiety and
depression (1)
• Visual
disturbance,
photosensitivity
(1)
• Passing out,
extreme fatigue
(1)
• “Went
crazy”, anxiety,
nausea, vomiting
(1)
• “Psychotic
Doxycycline 9/708 9
hospitalisations:
• Gastrointestinal
disturbance (6)
• Photosensitivity
(1),
• Coughing
(1)
• Anaemia
(1)
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Table 7. Serious adverse effects; mefloquine versus comparators (Continued)
reaction”,
anxiety,
abnormal dreams
(1)
• Anxiety,
abnormal
dreams,
insomnia,
unsteadiness (1)
• Nausea,
dizziness,
blackout (1)
Atovaquone-
proguanil
0/72 -
Chloroquine 4/832 4
hospitalisations:
• Nausea,
dizziness, visual
disturbance,
insomnia,
abnormal
dreams,
unsteadiness,
weakness
• Abnormal
dreams
• Seizures
• Abdominal
pain, diarrhoea
Philips 1996 Cohortstudy 4/285 3 hospitalisations
with “either gas-
troin-
testinal or neuro-
logic symptoms”
and one seizure
Doxycycline 1/383 Severe
oesophagitis
Steketee 1996 RCT 1/? One “neuropsy-
chiatric side ef-
fect”
• Disorientation to
time and place¹
Chloroquine 0/? -
Albright 2002 Cohort study 1/115 One “serious side
effect”¹
Chloroquine 0/22 -
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Table 7. Serious adverse effects; mefloquine versus comparators (Continued)
• Hallucinations
Corominas
1997
Cohort study 1/609 One hospitalisa-
tion:
• Heart
palpitations,
convulsions,
paraesthesia and
vertigo
Chloroquine 0/137 -
Steffen 1993 Cohort study 7/52981 7 hospitalisa-
tions, including:
• Seizures (2)
• Psychosis
(2)
• Vertigo (1)
• 2 not
characterised
Chloroquine 7/20332 7 hospitalisa-
tions. ’Includes’:
• Seizures (2)
• Psychosis
(1)
• 4 not
characterised
Studies reporting no serious events or effects
Hale 2003 RCT 0/46 Nine serious ad-
verse events in the
trial (trial armnot
specified)
“none of which
were considered
by study physi-
cians to be re-
lated to the study
drug”
Placebo 0/94 -
Salako 1992 RCT 0/107 “Ad-
verse events were
all mild and there
were no deaths”
Placebo
Chloroquine
0/101
0/103
-
-
Arthur 1990 RCT 0/134 “No serious side
effects occurred
with either drug
regimen”
Doxycycline 0/119 -
Schlagenhauf
2003
RCT 0/153 “Although a large
number of ad-
verse events were
reported, none
were serious”
Doxycycline
Atovaquone-
proguanil
0/153
0/164
-
-
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Table 7. Serious adverse effects; mefloquine versus comparators (Continued)
Sonmez 2005 Cohort study 0/228 “No drug in-
duced side effects
ne-
cessitating emer-
gency care were
observed”
Doxycycline 0/506 -
Andersson
2008
Cohort study 0/491 “No serious ad-
verse events were
recorded”
Atovaquone-
proguanil
0/161 -
Napoletano
2007
Cohort study 0/548 Records hospital-
isations, and re-
ports that none
occurred in either
group of partici-
pants
Atovaquone-
proguanil
Chloroquine
0/707
0/37
-
-
Sossouhounto
1995
RCT 0/103 “All
side effects were
transient (and)...
mild”
Chloroquine 0/100 -
¹ This trial described a potentially serious adverse effect, but did not provide enough detail to meet our strict definition.
Table 8. Mefloquine versus doxycycline; characteristics of included studies for safety
Study ID Participants Number
enrolled
Method
of adverse event
monitoring
Signif-
icant exclusions
for psychiatric
adverse effects
Duration of
travel
Source of fund-
ing
Randomized controlled trials
Arthur 1990 USA soldiers 270 Blood tests, stool
samples. Inter-
view with study
personnel
None 5 weeks Not mentioned
Ohrt 1997 Indonesian sol-
diers
204 Inter-
view with study
personnel. Exit
questionnaire
“ History of un-
derlying illness”
13 weeks Pfizer and Roche
Schlagenhauf
2003
Non-immune
adult short-term
travellers
674 Participant self-
reported
questionnaire
History of
seizures or psy-
chiatric disorders
4 to 6 weeks GlaxoSmithK-
line and Roche
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Table 8. Mefloquine versus doxycycline; characteristics of included studies for safety (Continued)
Weiss 1995 Kenyan children 169 Interview with
study personnel
None 4 months Government
funding
Non-randomized studies
Participants Number
enrolled
Method
of adverse event
monitoring
Fac-
tors influencing
drug allocation
Duration of
travel
Source of fund-
ing
Cunningham
2014
UK Foreign and
Commonwealth
Office staff
327 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
0 to 36 months Not mentioned
Eick-Cost 2017 USA s oldiers 367,840 Data from the
Defense Medical
Surveillance Sys-
tem, the Phar-
macy Data
Transaction Ser-
vice and the
Theater Medical
Data Store
No information
available
Various, not
specified
Not mentioned
Goodyer 2011 UK adult short-
term travellers
185 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
< 28 days GlaxoSmithK-
line
Korhonen 2007 Peace Corps vol-
unteers
2701 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pan t preference
≥ 6 months Two staff em-
ployed by Peace
Corps
Landman 2015 Peace Corps vol-
unteers
1184 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, not
specified
Not mentioned
Laver 2001 Adult short-term
travellers
660 Participant self-
reported
questionnaire
No information
available
93% < 4 weeks “ No financial
interests to dis-
close”
Lobel 2001 Adult short-term
travellers
5626 Participant self-
reported
questionnaire
No information
available
< 5 weeks “ No financial
interests to dis-
close”
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Table 8. Mefloquine versus doxycycline; characteristics of included studies for safety (Continued)
Meier 2004 UK adults en-
rolled in UK g
eneral p ractice
research database
35,370 Incident cases of
depression, psy-
choses and panic
attacks within
the UK general
practice research
database
No information
available
Various, not
specified
Roche
Napoletano
2007
Italian short-
term travellers
1906 Telephone inter-
view
Allocation based
on guide-
lines and partici-
pant preference
Mean 2 weeks,
range 0 to > 35
days
Not mentioned
Philips 1996 Australian short-
term travellers
741 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, mean 3
weeks, maxi-
mum 3 months
Roche and Pfizer
Saunders 2015 USA soldiers 2351 Participant self-
reported
questionnaire
Primarily doxy-
cycline, soldiers
with contra-in-
di-
cations received
mefloquine
> 90% for 10
months or more
Not mentioned
Schwartz 1999 Israeli short-
term travellers
158 Participant self-
reported
questionnaire
“... daily doxycy-
cline or daily pri-
maquine... was
recommended”
14 to 20 days Not mentioned
Shamiss 1996 Israeli soldiers 45 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
“... an average
of 4 hours stay
in the field over
a period of 2
months”
Not mentioned
Sharafeldin
2010
Dutch medical
students
180 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Mean 74 days
(range 10 to 224
days)
No dedicated
funding
Sonmez 2005 Turkish soldiers 1400 Participant self-
reported
questionnaire
Prior
to March 2002:
doxycyline
After July 2002:
mefloquine
A pprox. 6
months
Not mentioned
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Table 8. Mefloquine versus doxycycline; characteristics of included studies for safety (Continued)
Stoney 2016 USA short-term
travellers
370 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Median duration
13 days
Government
funding
Tan 2017 Peace Corps vol-
unteers
8931 Participant self-
reported
questionnaire
No information
available
Various, not
specified
No dedicated
funding
Terrell 2015 UK soldiers 2032 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Median duration
13 days
“... not funded
by an external
body”
Tuck 2016 UK soldiers 151 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, not
specified
No dedicated
funding
Waner 1999 Adult short-term
travellers
3051 Participant self-
reported
questionnaire
No information
available
A pprox. 6 weeks Not mentioned
Table 9. Mefloquine versus doxycycline; quality of adverse event reporting
Study ID Harms predefined¹ Description of ascer-
tainment technique²
Active or passive moni-
toring?³
Prospective or retro-
spective data collection?
RCTs
Arthur 1990 Inadequate:
No definitions provided
for serious side effects
Unclear: it is not reported
who conducted the inter-
views
Active Prospective
Ohrt 1997 Inadequate
Comment: No defini-
tions of adverse events or
effects were provided, it
wa s unclear whether or
howcausalitywas assessed
Adequate Active Prospective
Schlagenhauf 2003 Adequate Adequate Active Prospective
Weiss 1995 Inadequate
“ Each subject was visited
daily at home by an as-
signed field worker, who
Adequate Active Prospective
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Table 9. Mefloquine versus doxycycline; quality of adverse event reporting (Continued)
asked about symptoms of
malaria or drug side ef-
fects”
Cohort studies
Cunningham 2014 Inadequate
Comment: questionnaire
included a targeted list of
side effects, including “
other psychological prob-
lems” . What was in-
cludedwithin thiswas not
defined
Adequate Passive Unclear
Comment: questionnaire
was performed while par-
ticipants were still taking
chemoprophylaxis med-
ication, although 75%
were non-compliant
Eick-Cost 2017 Adequate Adequate Passive Prospective
Goodyer 2011 Inadequate
“ Also included on the
questionnaire was a single
free-text question asking
travellers to describe any
side effects of antimalarial
medication”
Adequate Active Retrospective
Korhonen 2007 Adequate Adequate Passive Unclear
Comment: n o informa-
tion wa s provided re-
garding the timing of
the questionnaire during
treatment
Landman 2015 Adequate Adequate Passive Unclear
Comment: all partici-
pants were emailed the
questionnaire at one time
point, which occurred at
varying points during the
prophylactic regimen
Lobel 2001 Inadequate
“Travellers… were given
a questionnaire that asked
for... adverse health events
attributed to those drugs”
Adequate Passive Unclear
Comment: informa-
tion was collected at the
airport, when travellers
should still have been tak-
ing the prophylactic regi-
men
Meier 2004 Adequate Adequate Passive Retrospective
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Table 9. Mefloquine versus doxycycline; quality of adverse event reporting (Continued)
Napoletano 2007 Unclear
Comment: adverse events
were categorised on a
scale of one to four, but
it is unclear whether and
howcausalitywas assessed
Adequate Active Retrospective
Philips 1996 Inadequate
Comment: it wa s unclear
what constituted a seri-
ous or severe event and in-
sufficient information on
the questions that trav-
ellers were asked
Inadequate
“... a mailed question-
naire approximately 2
weeks after their antici-
pated return home date’
‘if a reply had not been
received within 4 weeks
an abbreviated question-
naire was sent out.”
Comment: nodetails pro-
vided regarding abbrevi-
ated questionnaire
Active Retrospective
Saunders 2015 Inadequate
Comment: insufficient
information of the ques-
tions that travellers were
asked
Adequate Passive Retrospective
Schwartz 1999 Inadequate
“... we directly contacted
all travelers for complete
follow-up and assessment
of compliance. Fifty trav-
elers taking primaquine
completed a question-
naire regarding side ef-
fects”
Inadequate
Comment: see
quote. Different methods
of follow up for different
forms of prophylaxis
Unclear Unclear
Shamiss 1996 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Inadequate
“ Questionnaires were
distributed and collected
by the flight surgeon to45
aircrew…questionnaires
were immediately evalu-
ated and further data col-
lection was done by tele-
phone, if necessary”
Passive Unclear
Comment: it wa s unclear
at which time point data
collection occurred
Sharafeldin 2010 Inadequate
Comment: n o informa-
tion wa s provided on
Inadequate
Comment: n o mention
of how adverse events
Passive Retrospective
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Table 9. Mefloquine versus doxycycline; quality of adverse event reporting (Continued)
how information on ad-
verse effects was sought
were recorded in the ques-
tionnaire
Sonmez 2005 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Adequate Active Prospective
Stoney 2016 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Inadequate
Comment: n o informa-
tion is reported on how
adverse events were ascer-
tained
Active Prospective
Tan 2017 Adequate Adequate Active Retrospective
Terrell 2015 Inadequate
“ The questionnaire ap-
proved by theMODREC
included the 19 com-
monest adverse effects de-
scribed in the manufac-
turers’ product documen-
tation”
Comment: Adverse
events listed in the ques-
tionnaire are not reported
Adequate Passive Unclear
Comment: information
obtained during transit
through Nairobi back to
the UK. It wa s unclear
whether participants were
still taking prophylaxis at
this time point
Tuck 2016 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Adequate Active Unclear
Comment: i t wa s
not specified at which
point during treatment
the questionnaire was ad-
ministered
Waner 1999 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Adequate Passive Unclear
Comment: information
was collected during the
flight home, when trav-
ellers should still have
been taking their prophy-
lactic regimen
1. Were harms pre-defined using standardised or precise definitions?
2. Was ascertainment technique adequately described?
3. Monitoring classed as ’active’ if it occurred at set time points during treatment.
For full description of analysis methods, see Table 2.
186Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 10. Mefloquine versus atovaquone-proguanil; characteristics of included studies for safety
Study ID Participants Number
enrolled
Method
of adverse event
monitoring
Signif-
icant exclusions
for psychiatric
adverse effects
Duration of
travel
Source of fund-
ing
Randomized controlled trials
Overbosch
2001
Travellers from
Canada, Ger-
many, Nether-
lands, South
Africa, UK
1013 Interview with
study personnel
“... history of al-
coholism,
seizures or psy-
chiatric or severe
neurological dis-
orders”
Mean 2.5 weeks GlaxoSmithK-
line
Schlagenhauf
2003
Non-immune
adult short-term
travellers
674 Participant self-
reported
questionnaire
“ History of
seizures or psy-
chiatric
disorders”
4 to 6 weeks GlaxoSmithK-
line and Roche
van Riemsdijk
2002
Dutch short-
term travellers
140 Interview
and testing with
study personnel
“H istory of alco-
holism, seizures,
psychiatric
disorders, severe
neurological dis-
orders”
Mean 19 days Government
funding
Non-randomis ed studies
Participants Number
enrolled
Method
of adverse event
monitoring
Fac-
tors influencing
drug allocation
Duration of
travel
Source of fund-
ing
Andersson
2008
Swedish soldiers 609 Participant self-
reported
questionnaire
Mainly
mefloquine, sol-
diers with con-
tra-indi-
cations received
atovaquone-
proguanil
6 months Not mentioned
Belderok 2013 Dutch short-
term travellers
945 Participant self-
re-
ported question-
naire (measured
adherence)
Allocation based
on guide-
lines and partici-
pant preference
84% < 29 days Government
funding
Cunningham
2014
UK Foreign and
Commonwealth
Office staff
327 Participant self-
reported
questionnaire
Allocation based
on
guidelines and p
0-36 months Not mentioned
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Table 10. Mefloquine versus atovaquone-proguanil; characteristics of included studies for safety (Continued)
articipant prefer-
ence
Eick-Cost 2017 USA s oldiers 367,840 Data from the
Defense Medical
Surveillance Sys-
tem, the Phar-
macy Data
Transaction Ser-
vice and the
Theater Medical
Data Store
No information
available
Various, not
specified
Not mentioned
Goodyer 2011 UK adult short-
term travellers
185 Participant self-
reported
questionnaire
Allocation based
on
guidelines and p
articipant prefer-
ence
< 28 days GlaxoSmithK-
line
Kato 2013 Japanese short-
term travellers
316 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Mean 20.0 ± 9.
6 days in the ato-
vaquone-
proguanil group
and 59.0 ± 15.
9 days in the
mefloquine
group
Not mentioned
Korhonen 2007 Peace Corps vol-
unteers
2701 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
≥ 6 months Two staff em-
ployed by Peace
Corps
Kuhner 2005 German short-
term travellers
495 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
A tovaquone-
proguanil mean
2.
6 weeks, meflo-
quine mean 7
weeks
Not mentioned
Landman 2015 Peace Corps vol-
unteers
1184 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, not
specified
Not mentioned
Laverone 2006 Italian short-
term travellers
1176 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
> 90% 0 to 30
days
Not mentioned
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Table 10. Mefloquine versus atovaquone-proguanil; characteristics of included studies for safety (Continued)
Napoletano
2007
Italian short-
term travellers
1906 Telephone inter-
view
Allocation based
on guide-
lines and partici-
pant preference
Mean 2 weeks,
range 0 to > 35
days
Not mentioned
Schneider 2013 UK adults en-
rolled in UK g
eneral p ractice
research database
Not available Incident cases of
a neuropsychi-
atric dis-
orders during or
after antimalarial
drug use
No information
available
Various, not
specified
Roche
Sharafeldin
2010
Dutch medical
students
180 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Mean duration
of stay 74 days
(range 10 to 224
days)
“ N o dedicated
funding for this
project”
Stoney 2016 USA short-term
travellers
370 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Median duration
13 days
Government
funding
Tan 2017 Peace Corps vol-
unteers
8931 Participant self-
reported
questionnaire
No information
available
Various, not
specified
No dedicated
funding
Tuck 2016 UK soldiers 151 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, not
specified
No dedicated
funding
Table 11. Mefloquine versus atovaquone-proguanil; quality of adverse event reporting
Study ID Harms predefined¹ Description of ascer-
tainment technique²
Active or passive moni-
toring?³
Prospective or retro-
spective data collection?
RCTs
Overbosch 2001 Adequate Adequate Active Prospective
Schlagenhauf 2003 Adequate Adequate Active Prospective
van Riemsdijk 2002 Adequate Adequate Active Prospective
Cohort studies
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Table 11. Mefloquine versus atovaquone-proguanil; quality of adverse event reporting (Continued)
Andersson 2008 Inadequate
Comment: insufficient
information provided on
the questions which sol-
diers were asked
Inadequate
Com-
ment: different ascertain-
ment technique used for
one of the three groups,
which is inadequately de-
scribed
Active Unclear
Comment: d ata col-
lection was prospective
for 448/609 participants
(LA04 and LA05), but
retrospective for 161 par-
ticipants (LA02)
Cunningham 2014 Inadequate
Comment: questionnaire
included a targeted list
of side effects, includ-
ing “ other psychologi-
cal problems” . What was
included within this was
not defined
Adequate Passive Unclear
Comment: questionnaire
was performed while par-
ticipants were still taking
chemoprophylaxis med-
ication, although 75%
were non-compliant
Eick-Cost 2017 Adequate Adequate Passive Prospective
Goodyer 2011 Inadequate
“ Also included on the
questionnaire was a single
free-text question asking
travelers to describe any
side effects of antimalar-
ial medication”
Adequate Active Retrospective
Kato 2013 Adequate Adequate Passive Unclear
Comment: the timing of
this questionnaire has not
been made clear
Korhonen 2007 Adequate Adequate Passive Unclear
Comment: n o informa-
tion wa s provided re-
garding the timing of
the questionnaire during
treatment
Kuhner 2005 Inadequate
Comment: insufficient
information provided on
the questions that partic-
ipants were asked
Adequate Active Retrospective
Landman 2015 Adequate Adequate Passive Unclear
Comment: all partici-
pants were emailed the
questionnaire at one time
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Table 11. Mefloquine versus atovaquone-proguanil; quality of adverse event reporting (Continued)
point, which occurred at
varying points during the
prophylactic regimen
Laverone 2006 Adequate Adequate Passive Retrospective
Napoletano 2007 Unclear
Comment:
adverse events were cate-
gorised on a scale of one
to four, but it is unclear
whether and how causal-
ity was assessed
Adequate Active Retrospective
Schneider 2013 Adequate Adequate Passive Retrospective
Sharafeldin 2010 Inadequate
Comment: n o informa-
tion is provided on how
information on adverse
effects was sought
Inadequate
Comment: n o mention
of how adverse events
were recorded in the
questionnaire
Passive Retrospective
Stoney 2016 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Inadequate
Comment: n o informa-
tion is reported on how
adverse events were ascer-
tained
Active Prospective
Tan 2017 Adequate Adequate Active Retrospective
Tuck 2016 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Adequate Active Unclear
Comment: i t wa s
not specified at which
point during treatment
the questionnaire was ad-
ministered
1. Were harms pre-defined using standardised or precise definitions?
2. Was ascertainment technique adequately described?
3. Monitoring classed as ’active’ if it occurred at set time points during treatment.
For full description of analysis methods, see Table 2.
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Table 12. Mefloquine versus chloroquine; characteristics of included studies for safety
Study ID Participants Number
enrolled
Method
of adverse event
monitoring
Signif-
icant exclusions
for psychiatric
side effects
Trial duration Source of fund-
ing
RCT s
Boudreau 1991 Thai gemminers 501 Interview with
study personnel
None 14 weeks USA Army
Boudreau 1993 USA soldiers 359 Interview
with study per-
sonnel and com-
puterised ques-
tionnaire
“M edical his-
tory of psychi-
atric or neuro-
logical problems
within the last 5
years”
13 weeks Not mentioned
Bunnag 1992 Thai adult mal es 605 Interview with
study personnel
None 24 weeks Roche
Salako 1992 Nigerian adult
males
567 Interview with
study personnel
None 24 weeks Not mentioned
Sossouhounto
1995
Ivory C oast
adult males
500 “
Access to the vil-
lage health cen-
tre. Clinical ex-
amination with
study personnel”
None 20 weeks Not mentioned
Steketee 1996 Preg-
nant Malawian
women
4220 Interview with
study personnel
None Monitored from
enrolment to de-
livery
Government
funding
Non-randomised studies
Participants Number
enrolled
Method
of adverse event
monitoring
Fac-
tors influencing
drug allocation
Duration of
travel
Source of fund-
ing
Albright 2002 USA travelling
children aged <
13 years
177 Interview with
study personnel
Allocation based
on guide-
lines and partici-
pant preference
Various, not
specified
Not mentioned
Corominas
1997
Spanish
short-term adult
travellers
1054 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
Maximum 6
weeks
Not mentioned
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Table 12. Mefloquine versus chloroquine; characteristics of included studies for safety (Continued)
pant preference
Cunningham
2014
UK Foreign and
Commonwealth
Office staff
327 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
0 to 36 months Not mentioned
Hill 2000 USA short-term
travellers
822 Interview with
study personnel
Allocation based
on guide-
lines and partici-
pant preference
Median 19 days,
up to 90 days
Not mentioned
Korhonen 2007 Peace Corps vol-
unteers
2701 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
≥ 6 months Two staff em-
ployed by Peace
Corps
Laver 2001 Adult short-term
travellers
660 Participant self-
reported
questionnaire
No information
available
93% < 4 weeks “ No financial
interests to dis-
close”
Laverone 2006 Italian short-
term travellers
1176 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
> 90% 0 to 30
days
Not mentioned
Lobel 2001 Adult short-term
travellers
5626 Participant self-
reported
questionnaire
No information
available
M ost < 5 weeks “ No financial
interests to dis-
close”
Napoletano
2007
Italian short-
term travellers
1906 Telephone inter-
view
Allocation based
on guide-
lines and partici-
pant preference
Mean 2 weeks,
range 0 to > 35
days
Not mentioned
Petersen 2000 Danish travellers 4154 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Various, 65%<3
weeks
Not mentioned
Rietz 2002 Swedish short-
term travellers
491 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
“ Most” 2 to 4
weeks
Not mentioned
Steffen 1993 Adult short-term
travellers
145,003 Participant self-
reported
questionnaire
No information
available
98% stayed be-
tween 1 and 4
weeks
Roche
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Table 12. Mefloquine versus chloroquine; characteristics of included studies for safety (Continued)
Stoney 2016 USA short-term
travellers
370 Participant self-
reported
questionnaire
Allocation based
on guide-
lines and partici-
pant preference
Median duration
13 days
Government
funding
Tan 2017 Peace Corps vol-
unteers
8931 Participant self-
reported
questionnaire
No information
available
Various, not
specified
No dedicated
funding
Waner 1999 Adult short-term
travellers
3051 Participant self-
reported
questionnaire
No information
available
A pprox. 6 weeks “
not funded by an
external body”
Table 13. Mefloquine versus chloroquine; quality of adverse events reporting
Study ID Harms predefined¹ Description of ascer-
tainment technique²
Active or passive moni-
toring?³
Prospective or retro-
spective data collection?
RCTs
Boudreau 1991 Adequate Adequate Active Prospective
Boudreau 1993 Adequate Adequate Active Prospective
Bunnag 1992 Inadequate
“ Adverse events were
defined clinically, and
starting week 14, vol-
unteers reporting adverse
events were interviewed
by members of the hospi-
tal team”
Adequate Active Prospective
Salako 1992 Inadequate
“ Particular attention was
paid to complaints such
as
fever, chills, malaise, nau-
sea and vomiting, rashes
and other symptoms and
signs that could be re-
garded as adverse events.
”
Comment: no clear def-
inition of adverse events
wa s provided
Adequate Active Prospective
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Table 13. Mefloquine versus chloroquine; quality of adverse events reporting (Continued)
Sossouhounto 1995 Inadequate
“ Participants had access
to a village health center,
where they could notify
personnel of any malaise
or side effects”
Unclear
“ Clinical examinations
and parasitologic tests
were performed every 4
weeks”
Passive Prospective
Steketee 1996 Adequate Adequate Active Prospective
Cohort studies
Albright 2002 Adequate Adequate Passive Retrospective
Corominas 1997 Inadequate
Comment: insuf-
ficient information wa s
provided about the ques-
tions that travellers were
asked
Adequate Active Retrospective
Cunningham 2014 Inadequate
Comment: questionnaire
included a targeted list
of side effects, includ-
ing “ other psychologi-
cal problems” . What was
included within this was
not defined
Adequate Passive Unclear
Comment: questionnaire
was performed while par-
ticipants were still taking
chemoprophylaxis med-
ication, although 75%
were non-compliant
Hill 2000 Inadequate
Comment: insuf-
ficient information wa s
provided about the ques-
tions that travellers were
asked
Adequate Active Retrospective
Korhonen 2007 Adequate Adequate Passive Unclear
Comment: No informa-
tion wa s provided re-
garding the timing of
the questionnaire during
treatment
Laverone 2006 Adequate Adequate Passive Retrospective
Lobel 2001 Inadequate
“Travellers… were
given a questionnaire that
asked for... adverse health
Adequate Passive Unclear
Comment: informa-
tion was collected at the
airport, when travellers
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Table 13. Mefloquine versus chloroquine; quality of adverse events reporting (Continued)
events attributed to those
drugs”
should still have been tak-
ing the prophylactic regi-
men
Napoletano 2007 Unclear
Comment: adverse events
were categorised on a
scale of one to four, but
it is unclear whether and
how causality was as-
sessed
Adequate Active Retrospective
Petersen 2000 Inadequate
Comment: i t wa s un-
clear whether the ques-
tionnaire implied causal-
ity to the drug regimen
Adequate Active Retrospective
Rietz 2002 Adequate Adequate Active Retrospective
Steffen 1993 Adequate Adequate Passive Unclear
Comment: information
was collected during the
flight home, when trav-
ellers should still have
been taking the prophy-
lactic regimen
Stoney 2016 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Inadequate
Comment: n o informa-
tionwa s reported on how
adverse events were ascer-
tained
Active Prospective
Tan 2017 Adequate Adequate Active Retrospective
Waner 1999 Inadequate
Comment: insufficient
information provided on
the questions that trav-
ellers were asked
Adequate Passive Unclear
Comment: information
was collected during the
flight home, when trav-
ellers should still have
been taking the prophy-
lactic regimen
1. Were harms pre-defined using standardised or precise definitions?
2. Was ascertainment technique adequately described?
3. Monitoring classed as ’active’ if it occurred at set time points during treatment.
For full description of analysis methods, see Table 2.
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Table 14. Mefloquine versus currently used regimens; by duration of travel
Mefloquine versus atovaquone-proguanil and doxycycline
Outcome Short- term travellers¹ Longer- term travellers² Test for subgroup
differences
Relative effect (RR)
(95% CI)
Studies (participants)
Relative effect (RR)
(95% CI)
Studies (participants)
Serious adverse effects RR 5.38
(0.60 to 47.84)
3 cohort studies (2657)
RR 0.93
(0.43 to 2.01)
3 cohort studies (3147)
P = 0.14
Discontinuations due to ad-
verse effects (RCTs)
RR 2.64
(1.51 to 4.62)
5 RCTs (2048)
- -
Discontinuations due to ad-
verse effects (cohort studies)
RR 1.81
(0.86 to 3.80)
7 cohort studies (2907)
RR 1.19
(0.45 to 3.17)
4 cohort studies (5711)
P = 0.50
Nausea RR 2.02
(0.87 to 4.68)
6 cohort studies (2469)
RR 0.96
(0.22 to 4.18)
3 cohort studies (2725)
P = 0.39
Abdominal pain RR 0.66
(0.22 to 1.98)
5 cohort studies (1801)
RR 0.30
(0.22 to 0.42)
3 cohort studies (2725)
P = 0.18
Diarrhoea RR 0.64
(0.15 to 2.71)
5 cohort studies (2428)
RR 0.57
(0.22 to 1.49)
4 cohort studies (5187)
P = 0.89
Headache RR 2.39
(0.69 to 8.22)
5 cohort studies (2086)
RR 2.09
(1.10 to 3.95)
4 cohort studies (3506)
P = 0.85
Dizziness RR 3.05
(1.15 to 8.12)
4 cohort studies (1067)
RR 3.84
(1.34 to 11.00)
4 cohort studies (3506)
P = 0.76
Abnormal dreams RR 6.25
(1.16 to 33.67)
3 cohort studies (1037)
RR 7.62
(2.06 to 28.18)
4 cohort studies (3506)
P = 0.86
Insomnia RR 3.09
(0.30 to 32.21)
4 cohort studies (1760)
RR 8.67
(4.73 to 15.89)
4 cohort studies (3506)
P = 0.40
197Mefloquine for preventing malaria during travel to endemic areas (Review)
Copyright © 2017 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Table 14. Mefloquine versus currently used regimens; by duration of travel (Continued)
Anxiety RR 3.26
(0.20 to 53.46)
1 cohort study (487)
RR 18.05
(9.75 to 33.42)
3 cohort studies (2854)
P = 0.24
Depressed mood RR 2.52
(0.76 to 8.29)
3 cohort studies (1026)
RR 12.59
(6.47 to 24.49)
3 cohort studies (3210)
P = 0.02
Abnormal thoughts and be-
haviours
RR 1.29
(0.07 to 22.44)
1 cohort study (487)
RR 7.78
(1.12 to 54.06)
2 cohort studies (2558)
P = 0.31
Adherence: during travel RR 1.10
(1.03 to 1.18)
7 cohort studies (7241)
RR 1.20
(0.88 to 1.62)
4 cohort studies (4890)
P = 0.61
Adherence: after return RR 1.04
(0.92 to 1.17)
4 cohort studies (1221)
- -
1 Short-term travellers: Approximately 3 weeks (range 1 day to 3 months). References: Goodyer 2011; Kato 2013; Kuhner 2005;
Napoletano 2007; Laver 2001; Laverone 2006; Lobel 2001; Philips 1996; Schwartz 1999; Shamiss 1996; Sonmez 2005; Stoney
2016; Terrell 2015
2 Longer-term travellers: Approximately 6 months (range 0 to 36 months in Cunningham 2014. Otherwise 3 months or longer).
References Andersson 2008; Cunningham 2014; Korhonen 2007; Landman 2015; Saunders 2015; Sharafeldin 2010
Table 15. Mefloquine versus currently used regimens; by military or non-military participants
Mefloquine versus atovaquone-proguanil and doxycycline
Outcome Military¹ Non-military² Test for subgroup
differences
Relative effect (RR)
(95% CI)
Studies (participants)
Relative effect (RR)
(95% CI)
Studies (participants)
Serious adverse effects 0 events in 1386 participants RR 1.21
(0.60 to 2.44)
4 cohort studies (4418)
-
Discontinuations due to ad-
verse effects (RCTs)
RR 2.08
(0.13 to 32.73)
2 RCTs (441)
RR 2.22
(1.17 to 4.21)
4 RCTs (1669)
P = 0.96
Discontinuations due to ad-
verse effects (cohorts)
RR 1.24
(0.32 to 4.88)
4 cohort studies (3408)
RR 1.89
(1.35 to 2.64)
8 cohort studies (8938)
P = 0.56
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Table 15. Mefloquine versus currently used regimens; by military or non-military participants (Continued)
Nausea RR 1.39
(0.36 to 5.36)
4 cohort studies (1578)
RR 1.70
(0.60 to 4.81)
6 cohort studies (3767)
P = 0.26
Abdominal pain RR 0.43
(0.14 to 1.29)
4 cohort studies (1578)
RR 0.56
(0.23 to 1.35)
5 cohort studies (3099)
P = 0.72
Diarrhoea RR 0.30
(0.09 to 0.96)
4 cohort studies (3999)
RR 1.05
(0.54 to 2.06)
6 cohort studies (3767)
P = 0.07
Headache RR 1.19
(0.14 to 9.79)
2 cohort studies (1386)
RR 2.48
(1.40 to 4.40)
7 cohort studies (4206)
P = 0.51
Dizziness RR 2.95
(1.37 to 6.36)
3 cohort studies (844)
RR 3.58
(1.39 to 9.25)
6 cohort studies (3880)
P = 0.76
Abnormal dreams RR 11.02
(4.61 to 26.34)
1 cohort study (652)
RR 6.59
(1.74 to 25.00)
6 cohort studies (3891)
P = 0.53
Insomnia RR 2.34
(0.41 to 13.35)
3 cohort studies (1537)
RR 10.24
(6.26 to 16.76)
6 cohort studies (3880)
P = 0.11
Anxiety - RR 16.94
(9.36 to 30.64)
4 cohort studies (3390)
-
Depressed mood RR 13.44
(3.34 to 54.05)
1 cohort study (652)
RR 6.49
(2.66 to 15.85)
5 cohort studies (3584)
P = 0.39
Abnormal thoughts and be-
haviours
- RR 5.11
(1.11 to 23.53)
3 cohort studies (3045)
-
Adherence: during travel RR 1.18
(1.00 to 1.40)
5 cohort studies (4652)
RR 1.16
(0.99 to 1.35)
8 cohort studies (10785)
P = 0.85
Adherence: after return RR 1.16
(0.86 to 1.55)
1 cohort study (43)
RR 1.02
(0.89 to 1.16)
3 cohort studies (1178)
P = 0.44
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1 Military participants: References: RCTs: Arthur 1990; Ohrt 1997. Cohort studies: Andersson 2008, Saunders 2015; Shamiss 1996;
Sonmez 2005; Terrell 2015; Tuck 2016
2 Non-military participants: References: RCTs: Overbosch 2001; Schlagenhauf 2003; van Riemsdijk 2002;Weiss 1995. Cohort studies:
Cunningham 2014; Goodyer 2011; Kato 2013; Kuhner 2005; Korhonen 2007; Landman 2015; Laver 2001; Laverone 2006; Lobel
2001; Napoletano 2007; Philips 1996; Schwartz 1999; Sharafeldin 2010; Stoney 2016
WH A T ’ S N E W
Last assessed as up-to-date: 22 June 2017.
Date Event Description
20 October 2017 New search has been performed New author team appointed.
Protocol rewritten. Criteria for included studies, meth-
ods, and outcomes revised. Protocol checked and agreed
by two editors. Modifications included:
• Scope of protocol changed to cover only efficacy
and safety of mefloquine.
• Updated search.
• Types of studies changed to include non-
randomized controlled trials/cohort studies for analysis
of safety.
• Control changed to include placebo or no
intervention.
• Types of participants changed to include all adults
and children, including pregnant women (now includes
immune and partially-immune participants).
• Adverse outcomes altered, added adverse events
and adverse effects monitoring, measures of adherence
and adverse pregnancy outcomes.
• ’Risk of bias’ assessment modified to include
methods of assessment for non-randomized trials and
risk of bias in conduct and reporting of adverse events
and adverse effects.
• We did not include any analysis of deaths,
suicides, or parasuicides attributable to mefloquine
prophylaxis; these are addressed in a separate review
(Tickell-Painter 2017).
• Review title modified to reflect the change in the
protocol to evaluate mefloquine against alternatives
20 October 2017 New citation required and conclusions have changed The previous version of this review, ’Drugs for prevent-
ing malaria in travellers’, was withdrawn. The reason for
this was the editorial team detected several errors in a
subsidiary analysis of case reports described in the dis-
cussion and in appendix 9 of the withdrawn review
This new edition covers only mefloquine and compar-
isons with alternative drugs. The case reports analysis
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(Continued)
has been removed entirely. A separate team, including
the lead author of this review, carried out a new review
of case reports of death and parasuicide associated with
mefloquine, published in the journal, ’Travel Medicine
and Infectious Disease’
H I S T O R Y
Protocol first published: Issue 2, 2007
Review first published: Issue 4, 2009
Date Event Description
29 September 2015 Amended This review has been withdrawn. Please see Published notes section for explanation.
16 June 2010 Amended In-text links to appendices corrected.
9 November 2009 Amended Tables moved to appendices in order to enhance readability.
C O N T R I B U T I O N S O F A U T H O R S
Maya Tickell-Painter (MTP) and David Sinclair (DS) performed title and abstract and full text screening of the search results. MTP
and Nicola Mayaan assessed the methodological quality of trials and extracted and analysed data. MTP completed the first draft of the
review. DS, Cheryl Pace and Rachel Saunders provided advice on content and methodology. All authors approved the final version for
publication.
D E C L A R A T I O N S O F I N T E R E S T
NMwas contracted by the Cochrane Infectious Diseases Group (CIDG) as a freelance consultant to work on this review and previously
worked for Enhanced Reviews Ltd, a company that conducts systematic reviews mostly for the public sector. NM is currently employed
by Cochrane Response, an evidence services unit operated by Cochrane.
CP has been involved in aspects of clinical trial management for trials of antimalarials (other than mefloquine) where the study drug
has been supplied free of charge by the manufacturer.
David Sinclair was employed at Liverpool School of Tropical Medicine as an author and editor with the CIDG, funded through a grant
from the UK Department for International Development.
RS was employed at Liverpool School of Tropical Medicine as an author with the CIDG, funded through a grant from the UK
Department for International Development.
MTP was employed at Liverpool School of Tropical Medicine as an author with the CIDG, funded through a grant from the UK
Department for International Development.
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S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Grant: 5242
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the protocol we planned to use a modified version of the ACROBAT-NRSI tool (now referred to as ROBINS-I) (ACROBAT-NSRI
tool). In the full review we used the original version.
In the protocol we stated that we would include “clinical cases of malaria, diagnosed by PCR or microscopy”. In the full review we
included trials in which the methods of detection for malaria were unclear, or different (one RCT which tested for antibodies to a
circumsporozoite protein four weeks after travel). This change occurred due to difficulties in establishing diagnoses of malaria in short-
term travellers. No cases of malaria occurred in any study arm in any of these additionally included studies.
In the full review we did not include comparisons with regimens that are currently not routinely used or single-arm cohort studies.
These are planned to be analysed in separate systematic reviews (Rodrigo 2016; Tickell-Painter 2017).
Differences between 2015 review and this review update
We amended the review title from ’Drugs for preventing malaria in travellers’ to ’Mefloquine for preventing malaria during travel to
endemic areas.
We rewrote the protocol. Criteria for included studies, methods, and outcomes were revised. The was externally peer refereed by two
editors.
The scope of the review changed to cover only efficacy and safety of mefloquine. The search was updated. The types of studies were
changed to include non-RCTs/cohort studies for analysis of safety. The control arm was changed to include placebo or no intervention,
as well as the commonly used alternatives of atovaquone-proguanil, doxycycline, and chloroquine. Types of participants were changed to
include all adults and children, including pregnant women (now includes immune and partially- immune participants). We altered the
inclusion of adverse outcomes; we included measures of adherence to the drug regime and adverse pregnancy outcomes. We modified
the ’Risk of bias’ assessment to include methods of assessment for non-randomized trials and risk of bias in conduct and reporting of
adverse events and adverse effects.
We did not include any analysis of deaths, suicides, or parasuicides attributable to mefloquine prophylaxis; these are addressed in a
separate review (Tickell-Painter 2017).
The author team changed from Jacquerioz FA and Croft AM to Tickell-Painter M, Mayaan N, Saunders R, Pace C, and Sinclair D.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Travel; Antimalarials [adverse effects; ∗therapeutic use]; Atovaquone [adverse effects; therapeutic use]; Chloroquine [adverse effects;
therapeutic use]; Doxycycline [adverse effects; therapeutic use]; Drug Combinations; Drug Resistance; Drug Therapy, Combination
[methods]; Malaria, Falciparum [∗prevention & control]; Mefloquine [adverse effects; therapeutic use]; Primaquine [adverse effects;
therapeutic use]; Proguanil [adverse effects; therapeutic use]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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